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Abstract 
Myeloperoxidase (MPO) is an enzyme released by activated neutrophils, monocytes, and 
some tissue macrophages as part of the inflammatory response at sites of inflammation. 
Thiocyanate anions are a major and preferred substrate for MPO, with oxidation giving rise 
to increased concentrations of hypothiocyanous acid (HOSCN) at the expense of 
hypochlorous acid (HOCl) which is generated from chloride ions. There is considerable 
evidence that these oxidants contribute to damage at sites of inflammation and contribute to 
the pathophysiology of cardiovascular diseases. HOSCN is much less reactive and more 
selective than HOCl, and the damage induced by HOSCN, which occurs primarily at Cys 
residues is generally reversible. Therefore, increased formation of HOSCN, at the expense of 
HOCl, driven by increasing thiocyanate levels, has been hypothesised to be protective against 
inflammation-induced damage.  
In the first study, Sprague-Dawley rats were pre-treated with oral sodium thiocyanate 
(10 mM) for one week to raise plasma thiocyanate (SCN-) levels. After this period, the rats 
underwent transient ligation of the left anterior descending (LAD) coronary artery for 30 
minutes to simulate a myocardial infarction and ensuing ischemia-reperfusion (IR) injury. 
Rats were then allowed to recover for 24 hours or 4 weeks before sacrifice and analysis by 
MRI and echocardiography. Pre-treatment with sodium thiocyanate (NaSCN) significantly 
increased the plasma SCN- concentrations compared to controls. MRI analysis indicates that 
the supplemented rats have a significantly reduced infarct area compared to controls after 24 
hours (the percent infarct of the total reperfused area was 73% in controls vs. 54% in SCN- 
treated animals). Echocardiography data indicates a statistically-significant increase in the 
left ventricular end systolic and diastolic areas in the control IR group which is not seen in 
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the treatment IR group over a 4-week period following surgery. This data supports the 
hypothesis that elevated levels of SCN- protect against myocardial ischemia-reperfusion 
injury, and may represent a potential protective treatment against acute cardiovascular disease 
(CVD).   
In the second study, high-fat diet fed ApoE-/- mice were treated with oral NaSCN (2.5 
mM or 10 mM) for 4, 8 and 18 weeks, representing early, mid and late-stage plaques, 
respectively. After this period, mice were sacrificed and changes in atherosclerotic plaque 
area and markers of plaque stability were determined. Treatment with NaSCN resulted in a 
significant and dose-dependent increase in plasma SCN- concentrations compared to controls. 
The 2.5 mM NaSCN treatment was shown to significantly reduce plaque size at 4 weeks, and 
resulted in an increase in collagen content of the atherosclerotic lesions over the 18-week 
time course, suggesting that the 2.5 mM concentration promotes a more stable plaque 
phenotype. With the higher concentration of SCN- (10 mM) there was no significant change 
in plaque size compared to the control (no SCN- supplementation) high-fat diet fed ApoE-/- 
mice, and at the 18 week time point the lesions of the 10 mM SCN- mice had reduced 
collagen content and increased cholesterol levels. Plaques from the 10 mM SCN--treated 
mice also showed significant increases in macrophage cell numbers at 8 weeks, and MPO at 
18 weeks, suggesting that the 10 mM NaSCN treatment increases plaque instability. However, 
no changes in macrophages or MPO were detected in the 2.5 mM treated animals. These data 
support the hypothesis that elevated levels of SCN- can protect against atherosclerosis in this 
mouse model of the disease, but this is dependent on the dose and the length of the treatment 
period.   
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Finally, two pilot clinical studies were also implemented to investigate the role of 
SCN- and the MPO system in the context of asymptomatic vs. symptomatic CVD, and also in 
sepsis. In the asymptomatic vs. symptomatic CVD pilot study, plasma derived from the 
carotid artery was analysed for MPO concentration, thiocyanate ions and levels of protein 
oxidation in a cohort of 73 patients exhibiting either asymptomatic (n = 49) or symptomatic 
(n = 24) CVD, as well as 43 subjects who provided femoral artery derived plasma samples 
who acted as controls. The total amount of plasma MPO protein was found to be significantly 
increased in the carotid samples of both asymptomatic (average of 123 ng/mL) and 
symptomatic (average of 145 ng/mL) CVD patients compared to the femoral samples 
(average of 104 ng/mL). The concentration of SCN- in plasma was also observed to be 
significantly decreased in the carotid samples of both asymptomatic (average of 36 µM) and 
symptomatic (average of 34 µM) CVD patients compared to the femoral samples (average of 
55 µM). The levels of total thiols on plasma protein was also observed to be significantly 
decreased only in the carotid artery plasma samples of symptomatic (average of 448 µM) 
CVD patients compared to the femoral artery plasma samples (average of 493 µM). This pilot 
study demonstrates that changes in the MPO system occur with CVD severity. 
In the sepsis pilot study the same parameters were examined in a cohort of 38 patients 
admitted to the intensive care unit (ICU) at Aberdeen Royal Infirmary, including both sepsis 
(n = 20) and non-infected (n = 18) critically ill patients. At the time of admission, plasma 
MPO levels were found to be significantly elevated in the sepsis patients compared to 
controls (210 vs 130 ng/mL respectively) while no difference in total protein concentration 
was detected. Multiple markers of oxidative damage were observed in the sepsis patients, 
including decreased plasma protein thiols (10 nM versus 14 nM), decreased methionine 
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residues (0.00705 versus 0.00831 pmol/Ile/mg protein/ml), and elevated methionine 
sulphoxide residues (0.00785 versus 0.00584 pmol/Ile/mg protein/ml). 24 hours after 
admission to the intensive care unit, these altered parameters were normalised, and no 
significant differences were detected between the sepsis and control subjects. This pilot study 
demonstrates that acute sepsis results in both increased plasma MPO levels, and MPO-
mediated damage, with these parameters normalised after 24 hours of hospital treatment. 
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Chapter 1 
Introduction 
This chapter presents a general overview of myeloperoxidase (MPO), its enzymology, and its 
roles in the immune response. A review of the current literature on the roles of mammalian 
heme peroxidases is also provided, with particular emphasis on the postulated involvement of 
MPO in a number of disease states, focusing on atherosclerosis and cardiovascular disease. 
The chapter will conclude with the project’s proposed hypothesis.  
 
1.1. The ‘Western Disease’ paradigm 
The ‘Western Disease’ paradigm, or ‘diseases of affluence’, is a term given to selected non-
communicable diseases (NCDs), and their associated health conditions, which are commonly 
thought to be a result of increasing wealth in a society [1]. While already well-established in 
the ‘West’, the occurrence of these disorders is also rapidly rising in the developing world, 
distinguishing this epidemic as a truly global issue.  
 Paradoxically, factors associated with the increasing global prevalence of the 
‘Western Disease’ paradigm appear to be factors which many people would regard as 
improvements in their lives: a reduction in menial physical activity, easy accessibility to low-
cost foods, and a longer life-span. By eliminating manual tasks, people exert less energy in 
their everyday lives. This is accompanied by a ‘Western’ diet, which is food that is low-cost 
and readily accessible, with high-fat and sugar contents, resulting in hugely excessive 
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influxes of energy. This results in an energy imbalance as individuals expend less energy than 
is consumed. Due to the greater human longevity connected with the ‘Western’ lifestyle, 
associated problems have a much greater period of time to accumulate and exert their effects 
[2].  
 According to the most recent data from the World Health Organisation (WHO), 36 
million of the 57 million global deaths in 2008 were due to NCDs. Cardiovascular diseases 
(CVDs) account for most NCD deaths (17.3 million people, globally, in 2008). Of these 
deaths, an estimated 7.3 million were due to coronary heart disease and 6.2 million were due 
to stroke. Besides CVDs, the most common NCD deaths are a result of cancers (7.6 million), 
respiratory diseases (4.2 million), and diabetes (1.3 million). In Australia alone, NCDs 
resulted in over 125,000 deaths, contributing to approximately 90% of the year’s mortality 
[3]. 
 
1.2. Cardiovascular disease 
CVD is a class of diseases that involve the heart, the blood vessels (arteries, capillaries, and 
veins), or both. Such conditions include coronary heart disease, ischemic heart disease, 
rheumatic heart disease, hypertensive heart disease, congenital heart disease, heart failure, 
cardiomyopathy, endocarditis, myocarditis, cerebrovascular disease, peripheral arterial 
disease, and deep vein thrombosis [4]. It is also a collective term for both microvascular and 
macrovascular diseases. Microvascular diseases include various neuropathies, end-stage renal 
disease, and blindness; while macrovascular diseases refer to atherosclerotic events such as 
stroke, myocardial infarction, and limb amputation [5]. 
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 The most important behavioural risk factors for heart disease and stroke are unhealthy 
diet, physical inactivity, tobacco use, and harmful use of alcohol. Behavioural risk factors are 
responsible for approximately 80% of coronary heart disease and cerebrovascular disease. 
The effects of unhealthy diet and physical inactivity may present themselves in individuals as 
raised blood pressure, raised blood glucose (hyperglycaemia), raised blood lipids 
(hyperlipidaemia), insulin resistance, and obesity [6]. These “intermediate risks factors”, 
which can be measured in primary care facilities, are indicative of an increased risk of 
developing a heart attack, stroke, heart failure and other complications [3]. 
 More people die annually from CVDs than from any other cause, with worldwide 
mortality approaching 17.5 million per year [3]. The global number of annual CVD related 
deaths has been projected to reach 23.3 million by 2030, with CVDs likely to remain the 
greatest cause of mortality for the foreseeable future [7]. 
  CVDs are the leading cause of death in Australia, accounting for an estimated 35% of 
annual mortality [3]. As a result, CVDs are a heavy burden on the health care system. In 
2004-2005, CVDs were the single most expensive disease sector, requiring 6 billion dollars 
and encompassing 11% of total health care expenditure [8,9]. The cost of CVDs in Australia 
is expected to rise to $16.2 billion by 2032-2033 as the population ages [10]. This is due to 
the increasing prevalence of CVD onset with age. Strikingly, 13% of individuals aged 34 – 
44 years, 23% of individuals aged 45 – 54 years, and 63% of individuals aged 75 years or 
over have been reported to have developed at least one form of cardiovascular condition [11]. 
The most common form of CVD is atherosclerosis. Its nature, pathogenesis and 
classifications are discussed in the following sections.   
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1.3. Atherosclerosis 
The thickening and hardening of arteries is known arteriosclerosis [12]. Atherosclerosis is a 
particular form of arteriosclerosis where the artery wall thickens and loses elasticity due to 
the aggregation and accumulation of fatty materials in the artery wall. The accumulation of 
fatty materials, such as cholesterol, cholesteryl esters and triglycerides from apolipoprotein 
B-100 (ApoB-100) containing lipid-protein particles, combined with vascular inflammation 
gives rise to atherosclerotic lesion development in the vessel intima [13]. These lesions are 
also referred to as plaques or atheromas, and the process in which they are formed is called 
atherogenesis [13]. The narrowing and constriction of affected blood vessels can result in 
serious complications including myocardial infarction, stroke, and limb amputation [5]. An 
atheroma is characterised by three main compartments: the nodular build-up of lipid-laden 
macrophages, cholesterol crystals, and, in the case of chronic and advanced lesions, 
calcification [14]. Sclerosis occurs as the fibrotic changes in the connective tissues of the 
vascular wall harden the artery.  
Atherosclerosis often culminates in one of two critical complications. Firstly, if the 
integrity of the fibrous cap is compromised, the plaque may rupture, exposing thrombogenic 
material to the blood stream. This may result in a thromboembolism, where the thrombus 
may become lodged in and occlude smaller blood vessels resulting in ischemic damage. Even 
if the clot is able to be healed and contracts, stenosis may ensue, narrowing the artery and 
reducing blood supply to any downstream tissues and organs [13,15]. Secondly, after 
sustained periods of inflammation the structural integrity of the vessel wall itself may become 
compromised and therefore susceptible to an aneurysm. This increases the risk of vessel 
rupture, which may lead to a potentially life threatening internal hemorrhage [16].  
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1.3.1. Risk factors for atherosclerosis 
1.3.1.1. Hypertension 
It is universally accepted that endothelial cell damage occurs during hypertension; however, 
it remains unclear whether hypertension is the cause or effect. It may well be both [17]. 
Arterial hypertensive states are associated with increased oxidative stress and endothelial 
dysfunction, primarily represented by impaired endothelium-dependent vasodilation resulting 
from reduced nitric oxide (NO·) bioavailability [18]. This endothelial dysfunction is a key 
and defining feature of early atherosclerosis, and the mechanisms of which will be discussed 
in greater detail later in this chapter.  
1.3.1.2. Diabetes mellitus 
Diabetes is associated with a significantly increased cardiovascular risk. This applies to both 
type I and type II diabetes [5]. The chronic and sustained hyperglycaemia and elevated levels 
of free fatty acids that characterise diabetes cause mitochondrial dysfunction, resulting in 
superoxide radical (O2·
-) overproduction from the mitochondrial electron transport chain. 
Thus, diabetes is also associated with increased oxidative stress [19]. The increased levels of 
O2·
- activate a number of pathways involved in the pathogenesis of diabetic atherosclerosis 
including polyol pathway flux, generation of advanced glycation end products (AGEs), 
increased AGE receptor expression, protein kinase C activation, and stimulation of the 
hexosamine pathway [20]. Increased levels of O2·
- also interferes with endothelial 
NO· production, which will be discussed in a later section.  
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1.3.1.3. Smoking 
Cigarette smoke is one of the major risk factors for CVD [21]. Numerous toxins found in 
cigarette smoke contribute to endothelial cell damage [22]. Cigarette smoking has been 
shown to be associated with endothelial inflammation and the subsequent release of pro-
inflammatory factors [23]. Chronic exposure results in oxidative stress and also impairs 
endothelium-dependent vasodilation, whilst acute exposure has less pronounced effects [24]. 
Passive exposure to cigarette smoke also correlates with an increased occurrence of CVDs 
[25], as well as in experimental studies of atherosclerosis [26]. Even the offspring of female 
rats exposed to second hand smoke during pregnancy have been shown to exhibit 
atherosclerotic precursor lesion formation [27]. 
1.3.1.4. Cholesterol and lipoproteins 
Cholesterol in plasma is transported in protein-lipid particles called lipoproteins. Various 
classes of lipoproteins exist, including very-low density lipoprotein (VLDL), low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL). They are classified based on their 
size, density, composition, and atherogenicity [6]. Elevated levels of circulating LDL, VDL, 
and remnant intermediate-density lipoprotein (IDL), are known to promote atherosclerosis. 
Therefore, high concentrations of these lipoproteins in the blood strongly correlate with 
human coronary heart disease [28].  
 LDL is a spherical-shaped particle with a molecular weight of approximately 2.5 
MDa, density of 1.02-1.06 g/mL, and diameter of 180-250 Ǻ. It is the primary transporter of 
cholesterol to cells. LDL is composed of approximately 22% protein, with the remainder lipid. 
A single molecule of ApoB-100 consists of 42% cholesteryl esters, 22% phospholipid, 8% 
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cholesterol, and 6% triglycerides [29]. LDL comprises of 3 subclasses that differ based on 
lipid composition, chemical composition, size, density, and ApoB-100 structural differences. 
These subclasses are L1, L2, and L3, with L1 representing the smallest subclass and L3 the 
most dense. LDL particles have been strongly associated with the development of coronary 
artery disease [30]. A number of mechanisms for the pro-atherogenic effect of LDL have 
been postulated. These include greater subendothelial space penetration and retention, a 
greater affinity for proteoglycans, and a greater susceptibility to oxidation [6]. This latter 
point has been a focus of particular attention as the oxidatively modified form of LDL (ox-
LDL) has been suggested to be of greater importance than native LDL in atherogenesis [31].  
 HDL has a molecular weight of between 1.75-3.60 x 105 Da and density of 1.06-1.21 
g/mL. The total protein content of HDL is 45-55%, with lipids making up the remainder [32]. 
Like LDL, HDL comprises of several heterogeneous subclasses. They are distinguished by 
their apolipoprotein composition: only ApoA-I (LP-A-I), both ApoA-I and ApoA-II (LP-A-I: 
A-II), both ApoA-I and ApoA-IV (LP-A-I: A-IV), and both ApoA-I and ApoE (LP-A-I: E). 
ApoA-I is three times more abundant by mass than ApoA-II, with the pair making up 
approximately 90% of protein content [33]. When evaluated by nuclear magnetic resonance, 
HDL can be subdivided into classes H5 to H1, in order of diminishing size [30]. HDL may 
also be classed in two separate categories in accordance with its roles in protecting against 
atherosclerosis. The larger ApoA-I containing HDL particles with densities between 1.063 
and 1.125 g/mL (H5, H4, and H3) have been found to negatively correlate with coronary 
heart disease. In contrast, the smaller ApoA-I lacking HDL particles with densities between 
1.125 and 1.21 g/mL (H2 and H1) have been found to positively correlate with coronary heart 
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disease. ApoA-I containing HDL particles therefore appear to decrease or prevent 
atherogenesis [34,35] 
1.3.2. The pathogenesis of atherosclerosis 
1.3.2.1. Endothelial dysfunction 
Before structural changes occur to the vasculature, the impairment of endothelium-dependent 
relaxation is the hallmark of atherosclerotic vessels [18,36]. This impairment is due to the 
reduced bioavailability of NO· produced from local NO· synthases (NOSs) [37]. In human 
tissue, NO· is generated by NOS complexes from the conversion of L-arginine to L-citrulline 
at the expense of NADPH. The required cofactors of NOSs include Ca2+/calmodulin, flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN), and tetrahydropterin (BH4) 
[38,39]. In the vascular wall, NO· is produced in the endothelium by the constitutively 
expressed endothelial NOS isoform (eNOS). Whilst the eNOS monomers are inactive, the 
homodimer is active, and may be activated in both receptor-independent and –dependent 
manners, such as blood shear-stress and acetylcholine stimulation respectively [40]. The 
primary role of NO· produced by eNOS is to maintain vascular homeostasis by triggering 
vessel dilation under necessary conditions [41]. The perturbation of this function is a key step 
in the initiation of atherogenesis.  
 Dysfunction of the eNOS/NO· pathway can result from a number of factors. These 
include a reduction in eNOS activity, a decreased sensitivity of the endothelium to NO·, and 
accelerated degradation of NO· [42].  
 The constitutive expression of eNOS is regulated by many factors including 
hemodynamic forces, cytokines, modified LDL, hypoxia, and sex hormones [43,44]. In the 
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setting of atherosclerosis, turbulent shear stress at sites of lesion development, along with 
elevated levels of various cytokines as well as oxidised LDL (ox-LDL), are believed to be the 
greatest drivers of eNOS expression [45]. However, conflicting evidence surrounds whether 
eNOS expression is reduced or enhanced in atherosclerosis [45,46]. In advanced lesions, 
elevated cytokines have been postulated to promote a decrease in eNOS mRNA stability, 
contributing to a potential decrease in eNOS expression [47].  
 While changes to eNOS expression in atherosclerosis is somewhat controversial, it is 
well established that its activity is reduced. Both ox-LDL and lysophosphatidylcholine, 
lipoproteins associated with atherosclerosis, inhibit the signal transduction cascade from the 
activated eNOS receptor [48,49]. By reducing the expression of upstream regulators, 
including Akt and heat shock protein (HSP) 90, these lipids inhibit eNOS activity. Ox-LDL 
also results in caveolin-1 (Cav-1) upregulation and endothelial arginase II (Arg II) activation, 
also contributing to reduced eNOS activity [50]. 
 The inflammatory nature of atherosclerosis promotes oxidation of many compounds. 
In the case of eNOS, O2·
- that results from increased oxidative stress react with NO· to 
produce peroxynitrite (ONOO-). Both O2·
-, and to a greater extent ONOO-, reacts with 
eNOS’s essential cofactor BH4 to generate its partially oxidised analogue 7,8-
dihydrobiopterin (BH2). BH2 does not retain the ability to act as a cofactor with eNOS [51], 
and NO· production by eNOS has been shown to closely correlate with the intracellular 
concentration of BH4 [52]. These oxidants may also damage the zinc-thiolate clusters of 
eNOS, which are critical for BH4 and L-arginine binding [53]. Destruction of the zinc-
thiolate clusters can also lead to dissociation of the eNOS homodimer, resulting in a loss of 
activity [54]. During these conditions when there is depleted BH4, eNOS becomes 
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‘uncoupled’. In the uncoupled eNOS system, the electrons from the NADPH are diverted to 
molecular oxygen (O2), rather than L-arginine, resulting in O2·
- generation rather than 
NO· [50,55]. This phenomenon of O2·
- production was first observed with neuronal NOS 
(nNOS), and subsequently with eNOS [56]. Other potential causes of eNOS dysfunction are 
arginine depletion [57], asymmetric dimethyl-L-arginine (ADMA) competition [58], and S-
glutathionylation of eNOS [59].  
1.3.2.2. Lesion initiation 
The developmental process of atheromatous lesions is referred to as atherogenesis. It is 
characterised by angiogenesis and remodelling of arteries leading to subendothelial 
accumulation of fatty substances, resulting in the formation of a plaque. The exact cause of 
initiation of atherogenesis remains somewhat elusive, although a pivotal role for endothelial 
dysfunction is likely, as previously mentioned. The early stages of atherogenesis are known 
to require recruitment of monocytes, and their ultimate differentiation into macrophages 
[60,61].  
Monocytes are required to cross the vascular endothelium for routine immunological 
surveillance of tissues, and their entry into inflamed sites [60]. This process of 
transendothelial migration, or diapedesis, initially involves tethering of monocytes to the 
endothelium, followed by loose rolling along the vascular surface. Firm adhesion to the 
endothelium is then established via interactions between the monocyte and a number of 
cellular adhesion proteins expressed on the endothelial cell surface. These adhesion proteins 
include vascular cell adhesion molecule-1 (VCAM-1), integrins, and clusters of 
differentiation (CD) molecule receptors, occurring at different steps along the migration. A 
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gradient of chemoattractants is responsible for driving the subsequent monocyte migration 
into the endothelial intima. One of the major chemokines responsible for monocyte migration 
is monocyte chemoattractant protein-1 (MCP-1), which interacts with its C-C chemokine 
receptor type 2 (CCR2), located on the monocyte surface. After penetrating the endothelial 
basement membrane, the monocytes may migrate through the extracellular tissue matrix and 
differentiate into macrophages [60,62,63]. Figure 1.1 depicts the processes that contribute to 
the early stages of atherosclerotic lesion development.  
 
Figure 1.1- Monocytes and macrophages in angiogenesis (adapted from Libby, 2002). 
 The rate at which the endothelial monolayer permits this migration by monocytes is 
fairly low, with the firm adhesion of leukocytes generally resisted. In the setting of 
atherogenesis, however, the degree to which leukocytes may firmly attach is increased, 
allowing greater numbers to migrate through the vascular endothelium. Cell surface 
expression of VCAM-1, and to a lesser extent P- and E-selectin, has been found to be of 
particular significance in this phenomenon for several reasons. Firstly, VCAM-1 binds 
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selectively with monocytes and T lymphocytes; the primary leukocyte classes found in 
nascent atheroma [63]. Also, arterial regions prone to lesion formation are associated with 
greater VCAM-1 expression [64]. The expression of VCAM-1 has also been observed to rise 
in both mouse and rabbit models of cholesterol-induced lesion formation before leukocyte 
recruitment [65]. Knockout of the VCAM-1 gene in mice is lethal; however, introduction of 
hypomorphic VCAM-1 variants to atherosclerosis-susceptible ApoE knockout mice results in 
reduced atheroma development [66].    
 The enforced induction of these adhesion molecules results from the inversed 
expression of pro-inflammatory cytokines. This cytokine release may be a result of a number 
of pathophysiological phenomena including modified LDL, free radicals, hypertension, 
hemodynamic stress, or infectious organisms [63]. In the setting of early atherogenesis, these 
cytokines alter endothelial function, overexpressing adhesion molecules such as VCAM-1 
(see above) and chemokines promoting monocyte and T lymphocyte recruitment, such as 
MCP-1 [67]. 
 Once recruited to the arterial intima, monocytes mature into macrophages. 
Macrophages are known to express a number of scavenger receptors, including scavenger 
receptor A (SRA) and CD36, which bind to modified forms of LDL. Common modifications 
include oxidation and glycation (also referred to as non-enzymatic glycosylation) [68]. The 
modified LDL is then internalised and accumulate intracellularly as cytoplasmic droplets. 
Lipid-laden macrophages undergo several alterations, including taking on a foamy 
appearance when viewed under a microscope, hence the terminology “foam cell”. Foam cells 
amplify the local inflammatory signals of the lesion site through the production of reactive 
oxygen species (ROS), pro-inflammatory cytokines and tissue damaging proteins, including 
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matrix metalloproteinases (MMPs). The latter are of key importance in determining whether 
thrombotic complications occur, as MMPs can degrade the extracellular matrix that maintains 
the integrity of the plaque’s fibrous cap [69]. Clusters of foam cells form fatty streaks and 
represent the next stage in the progression of atherogenesis: the formation of complex 
atherosclerotic lesions [63,68]. 
1.3.2.3. Lesion progression 
The same cytokines that promote the development of atherogenesis are also capable of 
regulating cell death. As a result, in advanced lesions a necrotic core develops within the 
atheroma. This occurs due to a combination of oncosis and apoptosis, the extent of which 
increases with the progression of atherosclerosis [70]. The death of smooth muscle cells 
(SMCs) within the plaque is especially significant as they provide the interstitial collagen that 
strengthens the fibrous cap of the plaque. Therefore, increased apoptosis of SMCs contributes 
to plaque destabilisation [71,72]. 
 In the early lesion, SMCs migrate into the arterial intima. The accumulation of 
collagen-synthesising SMCs leads to the production of extracellular matrix, and subsequent 
fortification of the plaque’s fibrous cap. However, the net setting-down of extracellular 
matrix depends on the balance between SMC extracellular matrix synthesis and extracellular 
matrix degradation by MMPs. In this regard, plaques may be broadly classed by their 
morphology in one of two general categories: ‘stable’ or ‘vulnerable’. The ‘stable’ plaque has 
a greater fibrous component than the unstable ‘vulnerable’ plaque [67]. It should be noted 
that other more complex classification systems exist and these will be discussed in a later 
section.  
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 ‘Stable’ plaques are often benign. Due to the thick fibrous cap of ‘stable’ plaques, 
they are unlikely to rupture. However, chronic symptoms may develop if the plaque grows to 
a size where it occludes the artery significantly. Such symptoms include angina pectoris and 
claudication of the lower extremities, which can occur due to ischemia during times of 
increased metabolic demand. These events are generally not life threatening [68]. 
 ‘Vulnerable’ plaques have a much thinner fibrous cap, making them much more 
susceptible to rupture. They may not cause chronic symptoms, but upon rupture may cause an 
acute thrombotic event. As thrombus spills from the ruptured atheroma into the blood stream, 
the clot may travel to any number of smaller capillaries which it could occlude, resulting in 
an embolism. Depending on the site of blockage, a ruptured atherosclerotic lesion could 
result in myocardial infarction, stroke, or limb amputation [63,68]. 
1.3.2.4. Thrombosis and stenosis 
Figure 1.2 depicts the predominant events of advanced atherosclerotic lesion development. 
Atheroma rupture does not inevitably cause acute complications. Plaque thrombogenicity 
depends on the balance of pro- and anticoagulants present. Thrombogenesis is driven by 
tissue factor-induced activation of the coagulation cascade, while thrombolysis is driven by 
thrombomodulin [73]. The activity of plasminogen activators and their inhibitors can be 
altered by various cytokines found in the atheroma, including interleukin-1 (IL-1) and tumour 
necrosis factor alpha (TNFα). In this way, these inflammatory factors can modulate the 
balance between thrombus formation and dissolution [74]. Rupture of the atheroma cap then 
allows for contact between the blood coagulant proteins and the pro-coagulant factors of the 
plaque, generating thrombus at the site of rupture. If the thrombus detaches, serious 
  
 
15 
 
 
complications may ensue from the resulting embolus, as previously mentioned. If the 
thrombotic event proves to be non-fatal, the plaque rupture may heal. The SMC component 
of the plaque mends the fibrous cap, stabilising the plaque once again. As a result of the 
repair, the endothelial intima becomes more fibrous, and therefore thicker and further 
impinges on the vessel lumen. The plaque may go on to rupture again and, if healed once 
again, further restrict the vessel lumen diameter. The thickening of the vessel wall in this 
successive cycle of rupture and repair is called stenosis, and the plaques that cause it stenotic 
lesions. Stenosis results in the same chronic symptoms as ‘stable’ plaques, namely angina 
pectoris and claudication of the lower extremities. Again, these ischemic symptoms are 
generally not life threatening, but limit the level of exertion an individual is capable of 
[15,75].  
The thrombotic potential of a plaque, its vulnerability to rupture, and the overall 
cardiovascular risk strongly correlate with enhanced cytokine expression within the atheroma. 
That is to say, a greater degree of vascular inflammation is likely to result in a worse 
prognostic outcome [67].   
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Figure 1.2- Schematic of the development of atherosclerosis (adapted from Libby, 2002). 
  
1.3.3. Classifications of atherosclerosis 
Many attempts have been made to establish and unify the classification of the development of 
atherosclerotic lesions, with slight variations between systems. In 1995, the American Heart 
Association’s (AHA’s) Committee on Vascular Lesions compiled much of what was 
currently known about the composition and structure of human atherosclerotic lesions and 
about arterial sites at which they develop, and recommended a numerical classification of 
histologically defined lesion types. According to this classification system, lesions are 
divided into three categories: Early (Type I and II), Intermediate (Type III), and Advanced 
(Type IV-VI) [12,76]. A schematic of this classification system is depicted in Figure 1.3.  
  
 
17 
 
 
   
Figure 1.3- The American Heart Association’s classification system for atherosclerotic 
lesions (adapted from Stary et al., 1995). 
 
 Type I lesions represent the very initial changes in the vascular intima. This early 
lesion contains enough atherogenic lipoprotein to elicit an increase in macrophages and 
formation of scattered foam cells. These changes may be detected microscopically or 
chemically. Type I lesions occur more predominantly at sites of adaptive intimal thickening, 
which occurs at constant locations in all people from birth as a means to cope with local 
mechanical forces [12].  
 Type II lesions include fatty streaks, but not all type II lesions are fatty streaks. These 
lesions consist primarily of stratified layers of macrophage foam cells. Intimal SMCs also 
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become lipid-laden. Type II lesions also see an increase in macrophages without lipid 
droplets, T lymphocytes, and mast cells [12].  
 Type III lesions form the intermediate stage between type II and type IV, where type 
IV is a potentially symptom-producing atheroma. In addition to the lipid-laden cells of type II, 
type III lesions contain scattered collections of extracellular lipid droplets. The lipid droplets 
pool below the stratified layer of foam cell macrophages, replacing matrix proteoglycans and 
fibres and forcing SMCs apart. Thus lipid deposits disrupt SMC coherence. This extracellular 
lipid is the immediate precursor of the larger, confluent, and more disruptive core of 
extracellular lipid that characterises a fully developed atheroma [12].  
 The progression to type IV lesion marks the development of a true atheroma, and the 
classification of advanced lesions. Beginning around the fourth decade of life, these lesions 
have a lipid core that develops from an increase, and the consequent confluence, of the small 
isolated pools of extracellular lipid that characterise type III lesions [76]. 
 The formation of thick layers of fibrous connective tissue denotes the transition to a 
type V lesion. If the lesion goes on to develop a fissure, hematoma, and/or thrombus at the 
fibrous cap, it is then classified as a type VI lesion. Furthermore, if these advanced lesions 
become calcified they are then denoted as type VII lesions. Type VIII lesions are fibrotic 
lesions where the presence of lipids is minimal or even absent. These lesions may also be 
referred to as stenotic lesions [76,77].  
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1.4. Symptoms of atherosclerosis 
1.4.1. Myocardial infarction and ischemia-reperfusion injury 
Acute obstruction of the coronary artery results in the region of myocardium supplied by that 
vessel to experience acute myocardial ischemia, and in so doing determines the salvageable 
area of the MI should the coronary occlusion be over a temporary period of time or 
permanent. If the period of acute myocardial ischemia is sustained for a period of time 
extending beyond roughly 20 minutes, cardiomyocyte death begins. This starts in the 
subendocardium and spreads as a ‘wavefront’ transmurally toward the epicardium [78]. 
 
Figure 1.4- Schematic of ischemia-reperfusion injury (adapted from Hausenly and Yellon, 
2013) 
 The subsequent deprivation of both oxygen and nutrients to the myocardium results in 
a cascade of rapid metabolic and biochemical changes, depicted in Figure 1.4. The absence of 
oxygen brings oxidative phosphorylation to a halt, which leads to depolarisation of the 
mitochondrial membrane, the depletion of ATP, and also inhibition of myocardial 
contractility. These alterations are exaggerated as the F1F0 ATPase functions in reverse, to 
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maintain the mitochondrial membrane potential, which leads to hydrolysis of any remaining 
available ATP [79].  
 The absence of oxygen during ischemia also switches cellular metabolism to 
anaerobic glycolysis, which results in the accumulation of intracellular lactate and a reduction 
in pH. Protons also accumulate intracellularly, activating the Na+-H+ ion exchanger, 
extruding protons from the cell in exchange for Na+. ATP depletion during ischemia also 
deactivates the 3Na+-2K+ ATPase, and therefore exacerbating the intracellular Na+ overload. 
This activates the reverse function of the 2Na+-Ca2+ ion exchanger, as the cell tries to extrude 
Na+ but results in intracellular Ca2+ overload [79]. 
 Following the onset of acute myocardial ischemia, prompt myocardial reperfusion is 
crucial to salvaging viable myocardium, limiting MI size, preserving left-ventricle systolic 
function, and preventing the onset of heart failure. However, while reperfusion represents the 
absolute treatment for acutely ischemic myocardium, it can also independently induce 
cardiomyocyte death [80]. Myocardial reperfusion injury can cause damage in a number of 
ways including reperfusion-induced arrhythmias [81], myocardial stunning [82], 
microvascular obstruction [83], and lethal myocardial reperfusion injury [84]. 
 Neutrophils are the primary responders in IR injury and have been implicated in 
mediating lethal myocardial reperfusion injury, acting in a fashion similar to the bacterial 
invasion of a host [85-87]. Ischemia without reperfusion results in a slow infiltration of 
neutrophils in to the salvageable area over a 12-24 hour period, and is restricted to the border 
of the myocardium’s salvageable area. With reperfusion, however, neutrophil infiltration and 
accumulation is accelerated and increased, with a greater degree of accumulation in the 
subendocardium [86]. This is because myocardial reperfusion injury shares many 
  
 
21 
 
 
characteristics with that of an inflammatory response. The reperfusion component of IR 
injury prompts a release of oxygen free radicals, cytokines, and other pro-inflammatory 
mediators, as well as granting greater access to the ischemic tissue [87]. This results in the 
activation of both neutrophils and the coronary vascular endothelium, the activation of which 
promotes the expression of adhesion molecules. In this way, neutrophils are recruited to the 
surface of the endothelium (within minutes of the onset of reperfusion), and initiate a specific 
cascade of cell-cell interactions. Neutrophils first adhere to the vascular endothelium, before 
undergoing transendothelial migration, and finally directly reacting with myocytes [85].  
 Once in the post-ischemic myocardium, neutrophils may cause damage in several 
ways. Neutrophils are known to release upwards of 20 different proteolytic enzymes, 
including elastase and collagenase, which target extracellular matrix proteins. They also 
release a number of cytokines and lipids which further activate and recruit more neutrophils 
[88]. Another enzyme neutrophils release is the peroxidase enzyme MPO, which will be 
discussed in depth in the following section. 
 
1.5. Mammalian heme peroxidases 
There are two major superfamilies of heme peroxidase enzymes in biological systems. The 
first consists of heme peroxidases found in plants, fungi, and archaea. The origin of this 
superfamily is believed to be the duplication of a single ancestral gene, with three classes 
now recognised within the superfamily based on their sequence alignment [89].   
 The second superfamily comprises the mammalian heme peroxidases, which 
drastically differ from the first superfamily in features including primary sequence, tertiary 
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structure, and prosthetic groups. The three major mammalian heme peroxidases are MPO, 
eosinophil peroxidase (EPO), and lactoperoxidase (LPO) which are discussed in the 
following sections. Other mammalian peroxidase enzymes include human salivary peroxidase 
(SPO), thyroid peroxidase (TPO), gastric peroxidase (GPO), peroxiredoxins (Prx), and 
glutathione peroxidase (GPx). Whilst the first three of these are heme peroxidases, the latter 
pair have cysteine (Cys) and selenocysteine (Sec) active sites. 
 The human MPO, EPO and LPO genes are situated adjacent to each other on 
chromosome 17. Their intron-exon structure is also very similar, indicating that they have 
arisen from a common ancestor through gene amplification [90]. While LPO is not highly 
cationic, both MPO and EPO are. This allows for them to tightly bind to negatively charged 
surfaces, such as that of bacterial cell surfaces [91,92], endothelial cell surfaces [93], and 
extracellular matrix [94]. The crystal structures of a number of MPO and LPO isoforms have 
been solved, and the structure of MPO is depicted in Figure 1.5. 
1.5.1. Myeloperoxidase 
The mature human MPO enzyme is a dimeric, cationic, protein with a molecular weight of 
146 kDa, and plays an important role in the innate immune response. The two 73 kDa 
monomers are linked by a Cys bridge at the Cys153 residue. Each monomer is structurally 
identical and functionally independent, consisting of a 467 amino acid, 58.5 kDa, heavy chain 
and a 106 amino acid, 14.5 kDa light chain [95]. The heavy chain is glycosylated, and houses 
the iron protoporphyrin IX active site. The heme group is situated deep within a cleft in the 
enzyme, restricting access to the iron atom to all but the smallest molecules that can navigate 
the cavity, including hydrogen peroxide (H2O2) [96,97]. The MPO substrate binding site is 
located within a hydrophobic pocket at the entrance to the heme crevice [98]. 
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  The highest abundance of MPO is in neutrophils, where it comprises ~5% of the dry 
mass of the cell. Due to the heme group MPO contains, neutrophil rich secretions such as pus 
and mucus have a green colouration. MPO is specifically situated in the lysosome-like 
azurophil granules produced by promyelocytes. It is compactly stored in these granules, 
binding with a matrix-like network of polyanionic glycosaminoglycans which renders the 
MPO enzyme in an inactive state. In addition to neutrophil granulocyte derived MPO, 
monocyte progenitor cells synthesise the enzyme whilst they mature in the bone marrow [99]. 
MPO synthesis in monocytes ceases upon maturation, so it is not actively produce in 
circulating monocytes. Upon further maturation from monocyte to macrophage, a further loss 
of MPO occurs resulting in no active MPO present in fully matured macrophages. However, 
quiescent macrophages have been documented to re-initiate MPO synthesis under certain 
conditions, such as those in atherosclerotic lesions [100,101].  
Figure 1.5- X-ray crystal structure of human MPO at 1.8 Ǻ resolution 
(adapted from Fiedler et al., 2000). 
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 Neutrophils are the primary effector cell of the innate immune response, providing a 
first line of broad-spectrum defense against invading pathogens. This is achieved through the 
generation of powerful oxidising agents by MPO, depicted in Figure 1.6. When activated, 
neutrophils assemble an NADPH oxidase (NOX)-2 enzyme complex at the cell’s plasma or 
phago lysosomal membranes. This complex undergoes a ‘respiratory burst’ to reduce O2 to 
O2·
- via the oxidation of NADPH [102]. The O2·
- then undergoes rapid spontaneous or 
catalysed dismutation, the latter facilitated by the enzyme superoxide dismutase (SOD). The 
products that result from the dismutation reaction are O2 and hydrogen peroxide (H2O2) [103]. 
While H2O2 has bactericidal and cytotoxic properties at high concentrations, its effect is 
limited at the lower concentrations that are generated via the ‘respiratory burst’ [104]. 
Coinciding with the assembly of the NADPH oxidase complex and subsequent respiratory 
burst, the MPO containing azurophilic granules are secreted from the neutrophil into the 
phagosomal compartment and MPO is released. While most of the MPO remains 
compartmentalised, some MPO is also released extracellularly [99]. While the MPO protein 
is not bactericidal in itself, its enzymatic products are. MPO catalyses a reaction with H2O2, 
from the aforementioned ‘respiratory burst’, and halide (chloride, Cl-; bromide, Br-; iodide, I-) 
or pseudohalide (thiocyanate, SCN-) ions to generate hypohalous acids (hypochlorous acid 
(HOCl); hypobromous acid (HOBr); hypoiodous acid (HOI); hypothiocyanous acid 
(HOSCN)) [99,105]. These oxidants are believed to account for a large portion of the anti-
bacterial activity of neutrophils, in conjunction with other oxidants (such as NO·, ONOO-, 
and H2O2) and enzymes (including proteases, lysozymes, and peptides). It should be noted 
that of the 3 examples given, only SCN- is classed as a pseudohalide as it has similar activity 
to that of the genuine halides, such as Br- and Cl-.   
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 The biological importance of MPO is apparent from studies on MPO deficient 
individuals. Neutrophils from MPO deficient people undergo phagocytosis of foreign 
material normally. They then exhibit a sustained ‘respiratory burst’ to produce O2·- and H2O2. 
However, MPO deficiency ultimately culminates in a greater risk of chronic infection 
[106,107]. While MPO is clearly beneficial in terms of the innate immune response to 
invading pathogens, there is accumulating evidence that inappropriate generation of oxidants 
by MPO (be it the wrong place, the wrong time, or the wrong amount) may result in damage 
to the host’s tissue. Thus host tissue damage at sites of inflammation is associated with a 
number of human pathologies, and has been linked to oxidant generation by MPO [99,108]. 
This evidence will be presented in greater depth in a later section.  
Figure 1.6- Mechanisms resulting in the generation of MPO-derived oxidative products 
(adapted from Talib et al., 2012). 
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1.5.2. Eosinophil peroxidase 
EPO shares 70% amino acid homology with MPO. Like MPO, it is highly cationic and 
contains an iron protoporphyrin IX prosthetic group. It is synthesised as an 80 kDa single-
chain precursor before being processed in to its 69.8 kDa mature form. The mature EPO 
protein consists of a 57.9 kDa heavy chain and an 11.9 kDa light chain, taking much the same 
form as the MPO monomer [89].   
   EPO is the major granule protein of eosinophils, which are specialised human 
leukocytes that target and eliminate parasites and other related organisms as part of the innate 
immune response. Due to the larger size of parasites compared to bacteria, eosinophils are 
unable to endocytose their target organisms. Instead, due to their highly cationic nature, they 
attach to the surface of the parasite and exocytose their granule contents directly onto it. The 
major contents of the secreted granules are EPO, major basic protein, eosinophil cationic 
basic protein, and eosinophil-derived neurotoxin [109]. 
 Like in neutrophils, the H2O2 that EPO requires for its catalytic function is derived 
from O2·
-. This species is generated by an NADPH oxidase system similar to that in 
neutrophils that undergo the ‘respiratory burst’. However, the eosinophil system is more 
robust, capable of producing 3 - 10 times more O2·
- and H2O2 than the neutrophil system 
[110]. 
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1.5.3. Lactoperoxidase 
LPO is found in a number of human exocrine secretions including saliva, tears, and milk. Its 
primary role is to prevent invasion of the body by microorganisms [111]. The human LPO 
precursor protein has a 51% sequence homology to MPO, and an analogous heme group and 
binding site [111,112]. It is further processed to a mature LPO, consisting of a single 80 kDa 
chain. 
1.5.4. Reactive intermediates generated by human heme peroxidases 
H2O2 reacts with the native, ferric (Fe
3+) forms of the human heme peroxidases to generate 
Compound I, consisting of an oxy-ferryl (Fe4+=O) heme centre, a porphyrin π-cation radical, 
and a water molecule. The oxidation of the ferric heme of the enzyme produces two electrons 
which reduce the H2O2 to water. There are two means by which Compound I may be 
converted back to its ferric state: the halogenation cycle and the peroxidase cycle, shown in 
Figure 1.7. The halogenation cycle utilises two-electron reduction by (pseudo) halides, 
whereas the peroxidase cycle involves two sequential single electron reactions requiring a 
second intermediate enzyme state. This intermediate, Compound II, retains the oxy-ferryl 
heme centre. A third intermediate, Compound III, can be produced through either the reaction 
of the ferric form of the enzyme with O2·
-, or a single electron reduction to the ferrous (Fe2+) 
state followed by a reaction with O2. However, Compound III is generally inert, and 
considered a catalytic dead-end [99].  
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1.5.5. The halogenation cycle 
The human heme peroxidases MPO, LPO, and EPO are unique in that they are the only 
known enzymes that have the ability to rapidly oxidise Cl-, Br-, and SCN-. In this reaction, 
known as the halogenation cycle, each anion donates two electrons to Compound I to 
regenerate the ferric state of the enzyme’s heme group. As a result, the (pseudo) halide’s 
corresponding hypohalous acid is formed.  At physiological pH and concentrations of the 
(pseudo) halide anions, MPO predominantly generates HOCl and HOSCN as typical 
physiologic concentrations of the anion derivatives for these acids are 100-140 mM for Cl-, 
20-100 µM for Br-, and 20-250 µM for SCN- [113]. However, SCN- is the preferred substrate, 
with specificity constants for Cl-, Br- and SCN- being 1:60:730 [114]. HOBr makes up 5-10% 
of the hypohalous acid yield of MPO, followed by HOSCN which makes up 40%. HOCl 
accounts for the remaining 50-55% [115]. SCN- concentrations can become markedly 
elevated by smoking and diet, resulting in greater HOSCN generation. Therefore, the yield of 
Figure 1.7- The enzymatic cycles of myeloperoxidase (adapted from Davies, 2011). 
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hypohalous acid can vary substantially among individuals [114]. This phenomenon will be 
discussed in detail in section 1.8. 
1.5.6. The peroxidase cycle 
In contrast to the halogenation cycle, during the peroxidase cycle radicals are generated from 
both organic and inorganic substrates. This occurs via single electron oxidation by 
Compounds I and II. O2·
- and NO· may also be oxidised. In this way, the catalytic activity of 
human heme peroxidases is shared between halogenation and peroxidation, dependent on 
competition between (pseudo) halides and peroxidase substrates for Compound I [98]. 
Peroxidase substrates include a number of endogenous compounds such as tyrosine, 
ascorbate, and urate, as well as xenobiotics and drugs.  
 
1.6. The (pseudo) hypohalous acids 
As previously mentioned, the halogenation cycle of heme peroxidases results in the oxidation 
of (pseudo) halide anions, in turn generating their corresponding (pseudo) hypohalous acids. 
Under physiological conditions where pH is 7.4, HOCl, HOBr, and HOSCN exist in 
equilibrium with their respective conjugate bases (hypochlorite, –OCl; hypobromite, –OBr; 
hypothiocyanite, –OSCN) [99].  
1.6.1. Hypochlorous acid 
HOCl is generally the major product of human MPO under physiological conditions [114]. It 
has a pKa of 7.59, so at pH 7.4, HOCl and 
–OCl occur at approximately equal concentrations 
[116]. Figure 1.8 depicts the second order rate constants for a range of HOCl reactions, 
  
 
30 
 
 
clearly demonstrating that HOCl reacts with a huge range of substrates, and avidly with 
nucleophiles, particularly those containing nitrogen and sulfur atoms [117]. In biological 
systems, these include thiols, thioethers, amines, and amides. Therefore, one of the primary 
targets of HOCl oxidation is Cys residues in proteins and GSH [118,119]. The oxidation of 
Cys residues results in the formation of a sulfenyl chloride (RS-Cl) group, which further 
reacts with either excess thiols, to generate disulfides, or water to produce sulfenic (RSOH), 
sulfinic (RSO2H), and sulfonic (RSO3H) acids. The disulfides may be further oxidised to 
thiosulfinates and thiosulfonates [120]. 
 
Figure 1.8- The second-order rate constants on a log scale for the reactions of HOCl with 
various model compounds (adapted from Davies et al., 2008 ). -S-S-, disulfide bond; α-NH2, 
α-amino group; BB, backbone amides; p-Ser, phosphoryl-Ser; p-EA, phosphoryl-
ethanolamine; ─C=C─, double bond; p-Chol, phosphoryl-choline; GlcNH2, glucosamine; 
GlcNSO3, N-sulfated glucosamine; GlcNAc, N-acetylated glucosamine; Asc, ascorbate; β-
Car, β-Carotene; CoQ0, ubiquinol-0. 
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 The susceptibility to oxidation of Cys residues has important biological implications. 
The oxidation of glutathione (GSH), one of the body’s major antioxidants, by hypohalous 
acids to glutathione disulfide (GSSG) can disrupt the cellular redox balance of cells. 
Numerous cellular enzymes which contain active site Cys residues may also become non-
functional upon its oxidation [98]. In this manner, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and creatine kinase have been observed to be inactivated by low 
levels of HOCl, correlating with free thiol depletion [121]. Conversely, the oxidation of some 
Cys residues can result in the activation of inactive enzymes. For instance, MMP-7 is 
activated by HOCl by the conversion of a key Cys residue to a RSO2H [69]. Methionine (Met) 
[122] is another key target of HOCl, with Met oxidation capable of impacting enzyme 
activity [123], protease inhibitors [124], proteinases [125], growth factors [126], and signal 
transduction pathways [127]. 
 HOCl also chlorinates amines and amides to give chloramines (RR’NCl) and 
chloramides (RC(O)N(R’)Cl) respectively [118]. This can result in chloramine formation on 
histidine (His), lysine (Lys), and arginine (Arg) residues, nucleobases, nucleosides, 
nucleotides, and DNA/ RNA [117,120,128]. HOCl also undergoes addition to aromatic rings 
and double bonds. Such targets include tyrosine (Tyr) and tryptophan (Trp) residues, 
nucleobases, and fatty acid side chains [120,129]. When reacting with the double bonds of 
cholesterol and unsaturated lipids, HOCl forms chlorohydrins (RCH(Cl)-CH(OH)R’), which 
can then go on to yield reactive epoxides [130,131]. Some of these products of HOCl are 
used as markers for its generation and specific damage. These include 3-chlorotyrosine (3-
chloroTyr), glutathione sulphonamide [132,133], and chlorinated nucleobases [134,135].  
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1.6.2. Hypobromous acid 
Of the hypohalous acids generated by MPO, HOBr occurs at the lowest abundance. HOBr 
has a pKa of 8.7, therefore at pH 7.4 HOBr is the principal species [136]. Many of the 
reactions of HOBr are analogous to those of HOCl. Like HOCl, HOBr targets thiol, thioether, 
disulfide, and amine residues. However, HOBr reacts more rapidly than HOCl with aromatic 
rings and double bonds [117]. HOBr brominates Tyr approximately 10,000 fold faster than 
chlorination by HOCl, which is of significance when using 3-bromotyrosine (3-bromoTyr) 
and 3-chloroTyr as markers of hypohalous acid damage [137]. Figure 1.9 depicts the second 
order rate constants for several HOBr reactions. Like HOCl, HOBr reacts quickly and with a 
broad range of compounds. 
Figure 1.9- The second-order rate constants on a log scale for the reactions 
of HOBr with various model compounds (adapted from Davies et al., 2008 ).  
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1.6.3. Hypothiocyanous acid 
HOSCN accounts for approximately 40% of the (pseudo) hypohalous acids generated by 
MPO [115].  However, HOSCN may also be formed by the direct reaction of SCN- with 
HOCl [138] and HOBr [139]. It has even been postulated that most of the HOBr produced by 
MPO is directly converted to HOSCN [139]. HOSCN has a pKa of 5.3, so at pH 7.4 
–OSCN 
is the predominant species [140]. 
 HOSCN is less reactive than HOCl or HOBr, as depicted in Figure 1.10. This makes 
HOSCN much more selective in its oxidative targets. The major target for HOSCN is Cys 
residues, resulting in predominantly reversible oxidation [141,142]. When thiols are depleted 
or absent, Trp residues may also become an oxidation target [143]. There is little evidence for 
other biological targets of HOSCN beyond seleno species such as Sec. The major product of 
the reaction between HOSCN and thiols is RS-SCN species, which are transitory in nature, 
reacting with either water to produce a sulfenic acid, or other Cys residues to yield disulfides 
and regenerate  SCN- [98]. While the oxidative power of HOSCN is much less than that of 
HOCl and HOBr, its thiol specific oxidation can exert substantial damage. By oxidising 
critical Cys residues, HOSCN can alter enzymatic activity. In this way, HOSCN can deplete 
the cellular GSH pool, and inactivate GAPDH, GSH S-transferases, protein tyrosine 
phosphatases, and membrane ATPases [144,145]. Inactivation of protein tyrosine 
phosphatases results in hyperphosphorylation of cellular protein tyrosines and alterations in 
mitogen-activated protein kinase (MAPK) signalling, both of which have been implicated in 
the enhanced apoptosis of HOSCN treated cells [144]. The inactivation of membrane 
ATPases by HOSCN is 10 to 1000 fold more effective than HOCl and HOBr due to 
HOSCN’s greater specificity for critical Cys residues [146]. HOSCN treated endothelial cells 
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have been shown to have elevated tissue factor activity, and also promote the expression of 
cell-adhesion molecules [147]. The postulated mechanism for these effects is the oxidation of 
specific critical Cys residues, culminating in NF-κB activation. If this is the case, HOSCN 
would be responsible for upregulating a raft of genes [147].   
 
 
 
  
Figure 1.10- The second-order rate constants on a log scale for the reactions of HOCl, HOBr, and 
HOSCN with model compounds (adapted from Davies et al., 2008 and Pattison et al., 2012).  
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1.7. Myeloperoxidase and disease: The good and the bad 
1.7.1. The good… 
The oxidants generated by neutrophil-derived MPO are generally accepted as being 
responsible for bacterial cell killing [148]. In vitro, purified MPO in the presence of H2O2 and 
halide ions has been observed to be capable of killing bacteria [149,150]. The importance of 
MPO in bacterial killing has been supported by studies using the peroxidase inhibitors azide 
and cyanide, where the two have been shown to decrease the degree of killing [151]. In 
addition, MPO deficient mice are more susceptible to bacterial infections than wild-type mice, 
providing further evidence as to the importance of MPO in immunologic defense [152]. The 
vast amount of evidence points to the generation of MPO-derived HOCl in the phagosome of 
the neutrophil, and its ensuing reaction with bacterial proteins, as the specific agent of the 
bactericidal action of neutrophils [153,154]. 
 Despite the evidence from both in vitro and mouse studies which supports the notion 
of MPO being a key enzyme in the process of bacterial killing, the majority of MPO-deficient 
human patients are not observed to be markedly more susceptible to most infections though 
they are more susceptible to some species. This is most likely due to the redundancy in cell 
killing systems [155]. Additionally, it is predominantly neutrophil-derived proteins, rather 
than bacterial proteins, that are chlorinated in in vitro experiments of the MPO-H2O2-Cl
- 
system [154]. These observations have thrown into question the significance of MPO-
mediated oxidant generation. Subsequent kinetic-modelling studies of the neutrophil 
phagosome are in agreement with the formation of high fluxes of HOCl. They also predict 
that the majority of the HOCl will react with products released from neutrophil granules, in 
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agreement with the observed experimental data. It has therefore been suggested that the 
antimicrobial effects of MPO are a result of chloramine formation, and their consequent 
reactions [156]. 
1.7.2. …the bad 
Although MPO-derived oxidants play a key role in microbial killing, generation of these 
oxidants at inappropriate concentrations, times, or locations, has been linked to host tissue 
damage. It is becoming increasingly evident that the initiation, protraction, and accumulated 
oxidative damage that results from MPO activity may play an integral role in the progression 
of a number of diseases, in particular those with an inflammatory component. The occurrence 
of active MPO and the presence of 3-chloroTyr, a specific biomarker for HOCl-mediated 
damage, in the tissue of various disease pathologies lend support to the notion that MPO does 
indeed play a role in certain disease initiation and progression. The evidence for the 
involvement of MPO in CVD is particularly convincing, and will be discussed in greater 
detail in the next section [157,158].  
 A MPO G-463A polymorphism in the MPO gene has been reported to play an 
important role in disease development. The G/A transition occurs in an Alu sequence 
promoter region, which contains a hormone response element [159]. When the G allele is 
present, MPO gene expression is enhanced resulting in high concentrations of MPO. This 
occurs due to increased binding at the SP1 transcription factor site. It has been postulated that 
the G allele is therefore detrimental, and contributes to disease development. Its occurrence 
has been observed in a number of disease pathologies [101,122,160,161]. In the United States 
populace, the G allele is present in approximately 60-65% of individuals [161]. The 
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alternative A-allele has been associated with a decrease in SP1 binding and therefore lower 
MPO concentrations. This has been associated with a decrease in the incidence of disease 
[162].  
 Chronic inflammation is associated with an increased incidence of cancer. The 
chronic cell death at these sites of inflammation results in a compensatory increase in cell 
division of the surviving cells. MPO derived oxidants may cause damage to the DNA of these 
proliferating cells which may result in mutagenesis and the development of cancerous cells 
[163,164].  
 MPO is also implicated in both cystic fibrosis and asthma. Cystic fibrosis is a 
hereditary disease characterised by progressive lung dysfunction, recurring respiratory 
infections, and chronic pulmonary inflammation as a result of defects in the membrane 
protein CFTR [165]. Due to the inflammatory nature of the disease, a greater number of 
neutrophils infiltrate the airway, and as a result large amounts of active MPO, and MPO-
derived oxidants, are expressed in mucosal secretions [166,167]. MPO activity within 
circulating neutrophils also correlates with the pulmonary phenotype of cystic fibrosis, 
further indicating that circulating neutrophils deliver active MPO to the airway culminating in 
injury to the airway [168]. High levels of 3-chloroTyr have been detected in sputum and 
alveolar fluid, implicating HOCl as a powerful damaging agent in the airways of cystic 
fibrosis patients [166,167]. Additionally, while eosinophils are not increased in cystic fibrosis, 
EPO levels are found to be elevated and in an active form, strongly correlating with lung 
dysfunction [169,170]. It therefore appears that MPO-derived HOCl may play a significant 
role in mediating lung damage in cystic fibrosis patients. In relation to asthma, while it has 
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long been associated with eosinophils and EPO, MPO only appears to play a role when the 
disease state is very severe, or in the presence of a bacterial infection [171,172].  
 Increased levels of MPO have been found in the brains of patients afflicted with a 
number of neurodegenerative disease including Alzheimer's disease [173], Parkinson's 
disease [174], and multiple sclerosis [175]. Additionally, detection of increased levels of 3-
chloroTyr suggests that MPO or its chlorinating oxidants potentially play a role in the 
development and/or progression of these neurodegenerative diseases [176]. In the case of 
Alzheimer's disease, MPO has been implicated in promoting the aggregation of β-amyloid 
peptide, plaques containing high levels of which are a defining characteristic of Alzheimer's 
disease state [177]. MPO has been shown to colocalise with β-amyloid peptide in plaques 
from sections of the cerebral cortex of Alzheimer's patients [101]. Additionally, brain tissue 
from Alzheimer's patients has been shown to contain high levels of 3-chloroTyr, indicative of 
HOCl mediated damage [173]. Parkinson's disease is characterised by destruction of the 
dopaminergic neurons in the substantia nigra pars compactor of the brain [178]. MPO 
expression is also significantly elevated in the substantia nigra pars compacta from 
Parkinson's patients. Additionally, mice treated with the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine, which specifically chemically ablates dopaminergic neurons, are 
also observed to contain elevated levels of  MPO, along with 3-chloroTyr, in the substantia 
nigra pars compacta. Thus, MPO and MPO-derived HOCl are also implicated in the tissue 
damage associated with Parkinson's disease [179]. Multiple sclerosis is characterised by 
inflammation of the central nervous system, resulting in gradual demyelination of neuronal 
axons and consequent lesion development throughout the spinal cord and brain. MPO is 
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found in these lesions suggesting it may accelerate demyelination due to oxidant generation; 
however no 3-chloroTyr was detected in the lesions examined in these experiments [175]. 
 The pathogenesis of renal disease has also been linked to MPO [180]. Patients with 
glomerulonephritis have increased concentrations of MPO in their glomeruli [181], and 
infusing rats with a MPO/H2O2/Cl
- system resulted in proteinuria and glomerular injury, 
presumably as a result of HOCl generation [182]. Again in rats, inflamed kidney tissue has 
been observed to contain high levels of MPO compared to control kidney tissue [183]. MPO-
derived HOCl has again been implicated as the causal agent in MPO-associated renal damage 
as 3-chloroTyr has been found to co-localise with MPO in renal tissue derived from patients 
with renal disease [184]. 
 Large numbers of neutrophils are seen in the synovial fluid of patients with 
rheumatoid arthritis. A number of in vitro studies have also demonstrated that MPO-derived 
HOCl degrades both cartilage and hyaluronic acid [185].  Neutrophils have also been 
observed to localise in the vicinity of damaged cartilage, and that the MPO found in synovial 
fluid of arthritis patients is active [186,187]. Additionally, rheumatoid arthritis patients have 
elevated serum levels of MPO [188].  
1.3.2.5. MPO and atherosclerosis 
 Strong evidence exists for the involvement of MPO in CVDs [157,158]. Plasma levels of 
MPO have been found to correlate with both coronary [189] and peripheral artery disease 
[190]. Plasma concentrations of MPO also predict mortality after myocardial infarction [191]. 
Active MPO has been found in human atherosclerotic lesions at all stages of progression, and 
immunostaining with anti-human MPO indicates the presence of MPO both intra- and 
  
 
40 
 
 
extracellularly throughout lesions. The highest levels of MPO are found in the shoulder 
regions of the lesion, where ruptures are more prone to occur [192]. In addition, while the 
roles neutrophils play in the development of atherosclerosis remain unclear, MPO-positive 
neutrophils have been detected in murine intermediate and late-stage lesions [193]. A number 
of markers of MPO mediated damage have also been detected in human atherosclerotic 
lesions. The intensity of HOP-1 staining for HOCl-damaged proteins correlates with intimal 
thickening in human lesions [194]. 3-chloroTyr has also been detected in human 
atherosclerotic lesion [195], along with a number of other markers of MPO-mediated damage. 
These include p-hydroxyphenylacetaldehyde, α-chloro fatty aldehydes, unsaturated 
lysophosphatidylcholine, and 5-chloro-uracil [196-198].  
 The MPO/H2O2/Cl
- system promotes LDL oxidation, a key contributor to the 
initiation and progression of atherosclerosis [199,200]. HOCl reacts with LDL, transforming 
the protein into an oxidised form which is readily taken up by macrophages, culminating in 
foam cell formation [201]. LDL isolated from human atherosclerotic lesions contains an 
approximately 30 times greater concentration of 3-chloroTyr than circulating LDL, further 
implicating a role for MPO in oxidising LDL in the artery wall [195].  
 MPO also reacts with HDL, and has been reported to result in the loss of its anti-
atherogenic effects. This is believed to be due to the modification of the ApoA-I protein, the 
major protein component of HDL, which is likely a result of the generation of chlorinating 
oxidants and reactive nitrogen species [202,203]. This is supported by the observation that 
HDL derived ApoA-I extracted from human atherosclerotic lesions has high levels of 3-
chlroTyr and 3-nitro-tyrosine (3-nitroTyr) [204,205]. In vitro studies also show that HDL 
loses it cardioprotective effects when treated with HOCl, as evidenced by a reduction in 
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HDL’s ability to efflux cholesterol [206]. MPO-mediated oxidation of HDL ApoA-I also 
correlates with impairment of the ABCA-1-dependent reverse cholesterol-transport system 
[202]. In addition, immunoprecipitation studies show that MPO binds to ApoA-I protein. 
This has implications for MPO’s efficacy of oxidation of HDL in vivo [202].  
 MPO promotes endothelial dysfunction, a key factor in the initiation of CVDs. The 
affinity that MPO shows for negatively charged structures results in its binding to the 
endothelial surface layer [207]. A rodent model of traumatic shock has previously shown that 
endothelial dysfunction correlates with a marked elevation in plasma MPO [208]. As 
previously discussed, the defining feature of endothelial dysfunction is a reduction in the 
bioavailability of NO·, an essential regulator of endothelial homeostasis. The association of 
MPO with the vascular endothelium brings it in to close proximity with eNOS.  The oxidative 
products of MPO may react with a number of components associated with the endothelial 
generation of NO· including NO· itself, BH4, L-arginine, and the eNOS complex.  
 MPO is also associated with an increased chance of plaque rupture [209,210]. In the 
setting of atherosclerosis, a myocardial infarction results from the blockage of a coronary 
artery due to plaque rupture and subsequent thrombosis, the occurrence of which positively 
correlates with circulating MPO levels [191]. The fibrous caps of unstable plaques have 
additionally been found to be more likely to contain MPO-positive cells [211]. The oxidants 
generated by MPO have been implicated in compromising plaque integrity and therefore 
causing them to be more prone to rupture [212]. One postulated mechanism for this process is 
the activation of MMPs. Evidence suggests that HOCl activates a cysteine switch domain in 
an upstream regulator of MMPs, pro-matrilysin. The subsequent activation of MMPs results 
in degradation of the fibrous cap, and an increased chance of plaque rupture [69]. 
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1.7.3. MPO as a biomarker of disease 
Both blood and leukocyte MPO levels are among the strongest known independent risk 
factors for coronary artery disease [158]. Plasma MPO levels also strongly correlate with the 
occurrence of heart failure, and the highest MPO concentrations are observed in patients with 
severe chronic disease [213]. Serum MPO levels also correlate with endothelial dysfunction 
[214]. Finally, testing for high levels of MPO has been part of cytochemical tests for the 
diagnosis of acute leukemia for a number of years [215]. 
1.7.4. Prevention of MPO-mediated damage 
With the range of disease states that MPO has been implicated in contributing to, the 
development of MPO inhibitors has garnered increased interest. Decreasing the availability of 
H2O2 is one clear and obvious means for inhibiting MPO-mediated damage. Inhibiting NOX 
complexes with compounds such as diphenylene iodinium chloride (DPI) reduces H2O2 
formation both directly and indirectly, through the inhibition of O2·
- formation and 
mitochondrial activity [148,216-218]. In an isolated system, this strategy has merit, but the 
many and various sources of H2O2 and O2·
- in vivo may rule it impractical. Additionally, low 
concentrations of H2O2 are utilised in cell signalling, and therefore manipulating these 
concentrations may result in further unforeseen and potentially detrimental effects.   
 Heme poisons pose a similar conundrum. Small anions such as CN- and azide can 
competitively bind to MPO’s heme centre inhibiting hypohalous acid generation [219]. 
However, the toxicity resulting from the plethora of other heme centres they may interact 
with make heme poisons infeasible as a therapeutic treatment.  
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 A number of other MPO binding agents have been explored as potential MPO 
inhibitors. The major copper-carrying protein in the blood, ceruloplasmin, fervently binds 
with MPO, inhibiting its catalytic functions and potentially limiting its activity in plasma 
[220].  Polyanionic glycosaminoglycans also bind MPO in an electrostatic manner, of which 
heparin is an example. Binding between the two complexes may exacerbate MPO-mediated 
damage to bound glycosaminoglycans, but in doing so draws damage away from other 
important sites [221,222]. Unfortunately, in conditions where both proteins and 
glycosaminoglycans are found, such as proteoglycans, damage is primarily contained to the 
protein, resulting in aberrant function [223]. 
 Substrates which react with MPO Compound I to generate Compound II, and 
therefore inhibit the halogenation cycle, are another mechanism that has been explored to 
inhibit hypohalous acid generation. If these substrates had a low affinity for Compound II the 
enzyme would be trapped in a state where it could not complete its catalytic cycle. However, 
the efficacy for such an approach in an in vivo setting is uncertain due to the potential 
unforeseen detrimental effects that may result and the high concentrations that would be 
required to compete against prominent (pseudo) halide substrates [98]. The most effective 
substrates that avidly interact with Compound I but not Compound II have been hypothesised 
to have redox potentials between 1.1 and 1.35 V [224]. It is also believed that the presence of 
SOD would make these substrates ineffective, as O2·
- reduces Compound II to the ferric state 
[225]. 
 The most effective MPO inhibitors, as judged by IC50
 values, are irreversible enzyme 
inhibitors, or suicide substrates. Examples of which include hydrazines and hydrazides [226], 
including the most potent current MPO-inhibitor 4-aminobenzoic acid hydrazide [227]. The 
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exact mode of action of these suicide substrates is not clear, although it has been postulated 
they generate ferrous MPO which leads to destruction of the heme centre [228]. This non-
specific mechanism may render therapeutic treatment with suicide substrates invalid  in vivo.    
 Aside from inhibiting MPO directly, promptly scavenging any excess oxidants 
generated is another possible means of limiting MPO-mediated damage. One particular class 
of oxidant scavenger, Se-sugars, have been of particular interest in recent years as 
competitive kinetic studies have indicated that a number of these water-soluble compounds 
react rapidly with HOCl and HOBr, and to a lesser extent HOSCN. Se-sugars have been 
demonstrated to protect BSA and diluted human plasma from HOCl-mediated damage, 
further conferring a protective effect against MPO-mediated oxidative damage [229]. 
However, further studies are required to determine whether Se-sugars are a viable therapeutic 
in a complex in vivo setting. 
 Finally, manipulating the concentrations of MPO’s substrates can modulate the nature 
of the oxidants generated. As HOCl is the most powerful and broad reacting oxidant MPO 
generates, reducing its production could prove beneficial. Due to the relative abundance of 
Cl- in human plasma (100-140 mM), manipulating these levels is not a practical solution 
[113]. However, modulating the levels of Br-, I-, and SCN- can be achieved by dietary and 
other means. By elevating the concentrations of these alternative substrates, the amount of 
MPO-generated HOCl may be reduced. Using SCN- as the alternative substrate is attractive 
for several reasons. Elevating SCN- is unlikely to interfere with other physiological systems 
in the way that I- would affect the thyroid gland. Additionally, the oxidant produced by MPO 
from SCN-, HOSCN, is far less reactive than the other hypohalous acids generated. Finally, 
and of most significance, MPO has a 730 fold greater affinity for SCN- rather than Cl-. Due to 
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the high concentrations of Cl- physiologically, this preference for SCN- will allow for it to 
effectively compete while at micromolar concentrations. 
 
1.8. Thiocyanate: The good and the bad 
1.8.1. Means of altering physiological thiocyanate concentrations 
Levels of SCN- in the human body can be readily modified by several means, including diet 
and smoking. Elevating plasma levels of SCN- by modifying dietary intake has been used as a 
traditional prophylactic means to combat sickle cell anaemia throughout Africa [230]. The 
agents responsible for this elevation of SCN- concentration are cyanogenic glycosides found 
in a wide number of plants commonly used as food around the world. As a mechanism 
against external attack, these cyanogenic glycosides are released from vacuoles. Cytoplasmic 
enzymes are then activated, using the cyanogenic glycosides to generate hydrogen cyanide 
(HCN) in response to tissue damage. As a result, if these plants are not washed properly 
during processing for human consumption, residual HCN is ingested and elevates blood 
cyanide (CN-) levels [231,232]. In some cases this can lead to acute cyanide intoxication, and 
may even culminate in ataxia or partial paralysis [233]. CN- is metabolised to SCN- by the 
mitochondrial enzyme rhodanese using thiosulfate as a cofactor [234]. Therefore, the 
consumption of such foodstuffs results in elevated plasma SCN- levels. One of the major 
foods containing one of these cyanogenic glycosides, linamarin, is cassava (also called 
manioc, yuca, and tapioca). Cassava is of particular importance through the tropics and 
developing world where it is a major staple food; it is the third largest carbohydrate source 
behind rice and maize [235]. A huge number of other plant-derived foodstuffs contain related 
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cyanogenic glycosides including bitter almonds, apples, apricots, cherries, peaches, plums, 
raspberries, barley, flaxseed, bamboo shoots, and lima beans [236]. In addition, broccoli, 
cabbage, and sprouts contain low levels of cyanide derivatives which would also result in 
elevation of plasma SCN- levels [236]. 
 Smoking also gives rise to elevated plasma SCN- levels. The burning of tobacco and 
other materials results in the generation of HCN gas. Its subsequent inhalation results in an 
elevation of blood CN- levels [237,238]. As a result of the detoxification process of HCN 
mentioned above, plasma SCN- levels are therefore elevated in smokers when compared to 
non-smokers (131 and 40 µM respectively) reported in one study [113]. In certain cases, 
SCN- concentrations have been observed in smokers in excess of 250 µM [113].  
 A number of exogenous compounds have also been shown to culminate in elevated 
SCN- levels. Several drugs have been shown to elevate blood SCN- concentrations, 
particularly long term treatment of patients with sodium nitroprusside, a potent and widely 
used vasodilator drug [239]. The metabolism of a number of industrial chemicals, organic 
compounds and solvents has also been shown to elevate SCN- levels, both directly and 
indirectly via CN- [240].  
 A wide range of factors can result in the elevation of blood SCN- levels. One 
consequence of this alteration is a change in ratio of MPO-derived oxidants, potentially 
altering the extent and pattern of damage induced.  
1.8.2. The good… 
The oxidants generated by heme peroxidases are a critical component of the innate immune 
response against invading pathogens and diseases. As previously discussed, one of these 
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oxidants is HOSCN, produced by the peroxidase-catalysed oxidation of SCN- [99]. The 
peroxidase/H2O2/SCN
- system is of particular importance in inhibiting bacterial growth in 
saliva, milk, and epithelial lining fluid [241,242]. 
 As has been described earlier, much of the detrimental effects of MPO are put down 
to the generation of HOCl as it rapidly oxidises the vast majority of substances it comes 
across. In contrast, HOSCN reacts almost exclusively with thiol residues in a (generally) 
reversible manner. By encouraging the formation of HOSCN at the expense of HOCl, SCN- 
has been purported as a potentially beneficial agent [243,244].  
 A recent retrospective study of subjects who suffered a first myocardial infarction has 
yielded data that support this theory, as seen in Figure 1.11. The data indicates that patients 
with high levels of MPO were more likely to die than those with low levels - further evidence 
that MPO is a key factor in biological damage. However, those with low levels of MPO and 
high levels of SCN- had a much higher survival rate than those with low levels of SCN-. It 
should also be noted that for patients with above median levels of MPO, those with above 
median SCN- concentrations have a greater survival rate [245]. Thus, this evidence would 
appear to support the concept of SCN- as a protective agent in the setting of CVD. 
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 Further evidence for a protective effect of SCN- has emerged from a study using 
atherosclerosis-prone LDL-/- mice transgenic for human MPO. When these mice were fed a 
high-fat diet with 10 mM SCN- in their drinking water, aortic root plaque areas at sacrifice 
were found to be decreased by 26% compared to controls, as seen in Figure 1.12. However, 
plaque morphology was not substantially altered. Additionally, no significant changes were 
observed in MPO protein, cholesterol or triglyceride levels [246]. This further suggests that 
elevated levels of SCN- may decrease atherosclerosis burden. Combined with the previous 
post-myocardial infarction survival data, a beneficial effect of SCN- in cardiovascular health 
is emerging.  
Figure 1.11- Kaplan-Meier survival curves in post-myocardial infarction survivors over a 12-
year follow-up period. Subjects are classified according to above- and below-median levels 
of plasma MPO and plasma SCN-. (A: MPO < med / SCN- > med; B: MPO < med / SCN- < 
med; C: MPO > med / SCN- > med; D: MPO > med / SCN- < med). Median MPO level was 
56.5 ng/mL, and SCN- median was 47.9 µM. (Adapted from Nedoboy et al., 2014). 
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 SCN- also plays a beneficial role in a number of systems beyond the vasculature. Oral 
hygiene is maintained primarily by SPO [247], a heme peroxidase closely related to LPO, and 
oral leukocyte derived MPO [248]. The reported antimicrobial agent produced by SPO and 
MPO is HOSCN, derived from the catalysed oxidation of SCN- [249]. It has been recognised 
that it readily inhibits glucose-stimulated metabolic processes of Streptococcus mutans [250]. 
Growth inhibition of oral streptococci is also observed with purified SPO [251], MPO [252], 
and whole human saliva systems [241]. In addition, Porphyromonas gingivalis, an oral 
bacterium associated with periodontal diseases, is particularly disposed to HOSCN mediated 
damage [253,254]. Oral fungi strains are also susceptible, such as Candida albicans, with 
SCN--derived oxidants resulting in a loss in viability [255].  
 SCN- also plays an important role in the innate protection and antioxidant defense of 
the airway mucosa [256]. Secreted mucus not only provides a physical barrier against inhaled 
pathogens, but also contains bactericidal agents including active heme peroxidases, primarily 
LPO [257]. It has also been observed that sufficient SCN- and H2O2 exist in such secretions 
Figure 1.12- Aortic root plaque areas, normalized to total vessel area, for SCN- 
supplemented LDLR–/– mice transgenic for human MPO and unsupplemented 
controls (Adapted from Morgan et al., 2015). 
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that LPO-catalysed production of HOSCN occurs [258,259]. The importance of this system 
in airway mucosal secretions is seen in cystic fibrosis [260,261]. 
 As was previously discussed, much of the pulmonary airway damage associated from 
cystic fibrosis results from MPO-derived HOCl.  In cystic fibrosis patients, it is also observed 
that epithelial SCN- concentrations are significantly lower due to defects in CFTR expression. 
Generation of beneficial HOSCN by peroxidases in the airway may therefore become 
compromised, and as SCN- is the preferred substrate of these systems, its absence leads to 
increased generation of HOCl [262,263]. These already low levels of SCN- may be further 
reduced due to consumption by reactions with the elevated levels of HOCl and HOBr that 
result from the elevated MPO. These low levels of SCN- in the airways of cystic fibrosis 
patients are associated with impaired lung function, and may exacerbate recurring infections 
and tissue damage of the lungs of these patients due to relief of competition for HOCl 
generation and collapse of the protective HOSCN system [262,264,265]. The addition of 
hypertonic saline has been demonstrated to induce an increase in SCN- in the epithelial lining 
fluid, aiding in the protection of the epithelium from HOCl-mediated damage [261]. 
 In this vein, SCN- has been demonstrated to protect lung tissue when challenged by 
Pseudomonas aeruginosa infection in both in vitro and in vivo models [266]. Using an in 
vitro human bronchiolar epithelial cell line, treatment with SCN- was shown to protect 
against the cytotoxicity of acute and chronic inflammation. Furthermore, nebulised SCN- has 
been demonstrated to reduce bacterial load, morbidity and inflammation in mice challenged 
with P. aeruginosa [266]. This can be explained by a reduction in HOCl generation and 
increase in HOSCN generation resulting from the increased SCN- concentration.  
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1.3.2.6. The smoker’s paradox 
Smokers, whom have elevated plasma SCN- levels [237,238], have been shown to have a 
greater short-term survival after acute myocardial infarction than non-smokers. First 
documented in 1993, this phenomenon has come to be termed the “smoker’s paradox” and 
has been observed in a number of studies over the past 20 years [179,267,268]. Initially, it 
was postulated that the pathogenesis of myocardial infarction in smokers involves far more 
thrombogenic processes than atherosclerotic, so effects are likely to be acute with less severe 
underlying coronary disease, hence conferring better outcomes [269]. However, the original 
group that first published evidence for the “smoker’s paradox” acknowledged that age 
appears to be a factor, as smokers sustained their myocardial infarctions at a significantly 
younger age than non-smokers [267,270]. A follow up study comparing young (≤40 years) 
and old (>40 years) patients who received thrombolytic therapy for acute myocardial 
infarction found that younger patients had significantly better outcomes than older patients. 
While this was suggested to be related to better baseline characteristics in the younger 
patients, the young group was also found to have a much higher prevalence of smoking [271]. 
More recently, in a study focusing exclusively on young (≤45 years) patients suffering from 
acute myocardial infarction it was found that patients whom were currently smoking were 
associated with a better survival outcome [272]. 
 The mechanisms for the “smoker’s paradox” remain elusive with a plethora of 
theories present in the literature. While some studies maintain that it is an artefact of the age 
disparity between smoking and non-smoking patients of acute myocardial infarction 
[273,274], many more provide evidence for it. One theory is that smoking induces 
inflammation, and therefore smokers sustain less damage to microvascular function following 
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initial percutaneous coronary intervention [275,276]. It has also been purported that carbon 
monoxide, another product of cigarette smoke, upsets the fibrinolytic balance of the plasma 
and may play a role in the “smoker’s paradox” [277]. Finally, in a rat model, exposure to 
tobacco smoke resulted in cardiac gap junction remodelling, which was characterised by 
alterations in the quantity and phosphorylation of the connexin 43 gap junction in rat’s hearts 
[278]. Connexin 43 is the principal gap junction in the ventricles of the heart and plays a role 
in ischemic preconditioning [279], as preconditioning of connexin 43 deficient mice does not 
induce protection [280]. Therefore, remodelling of connexion 43 may also play a role in the 
“smoker’s paradox”.  
1.8.3. …the bad 
High levels of SCN- have been demonstrated to result in impaired thyroid development and 
function in weanling mice [281,282]. Early studies have shown that the addition of SCN- to 
the diet of weanling mice results in retention of iodine within the follicles of the thyroid 
glands, due to the formation of an insoluble iodinated thyroglobulin [282]. It has been further 
demonstrated that this treatment also results in a decrease in both FT3 and FT4 thyroid 
hormones. This corresponds with an increase in plasma TSH levels and hypertrophy of the 
thyroid glands. These hypothyroidism effects could be reversed by the removal of SCN- [281]. 
 SCN- has also been demonstrated to enhance, and even induce, the development of 
arthritis [283,284].  For over 20 years it has been known that the synovial fluid of rheumatoid 
arthritis patients contains leukocytes with active MPO/H2O2 systems. Additionally, the 
addition of inactive leukocytes to the synovial fluid of rheumatoid arthritis patients results in 
their subsequent activation [187]. Elevation of serum MPO and advanced oxidation protein 
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products has also been observed in rheumatoid arthritis patients [188]. A connection between 
smoking and the incidence of rheumatoid arthritis has also been documented [285], and in 
light of the active MPO system present in the synovial fluid of rheumatoid arthritis patients, 
SCN- has been postulated as playing a role in the disease. When rats receive low levels of 
SCN- (up to 25 mmol/L) in their drinking water their levels of blood, salivary and urinary 
SCN- increase to comparable concentrations to those found in smokers [284,286]. When 
experimental arthritis is induced in these animals, outcomes are more severe. This is a result 
of an increase, and in some cases induction, of inflammatory responses to the arthritic agents 
in the SCN- treated rats [284]. In contrast, when SCN- is co-administered with otherwise 
inactive slow-acting silver drugs, the development of arthritis is inhibited. When the drug is 
removed, the previously observed increase in disease severity again ensues [283]. In this 
regard, SCN- peculiarly acts as a co-arthritigen, but also exhibits co-therapeutic properties. 
How this occurs remains unanswered.  
 
1.9. Animal models of CVDs 
1.9.1. Animal models of atherosclerosis 
One of the most crucial advances in the study of factors affecting atherogenesis has been the 
development of mouse models of atherosclerosis. Initial initiatives to develop such a model 
were met with scepticism. Given the numerous differences between humans and mice, it was 
thought that mice could not be used to model human diseases, such as atherosclerosis. 
However, the development of the apolipoprotein E-deficient (ApoE-/-) and LDL-receptor 
deficient (LDL-R-/-) mouse models has irrevocably changed this view [287]. The 
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predisposition of such mice to spontaneously develop atherosclerotic lesions has made this 
model particularly popular, allowing the study of various parameters related to atherogenesis 
and the exploration of potential therapeutic interventions [288].  
 ApoE is one of several apolipoprotein transfer genes. Specifically, ApoE plays a key 
role as a ligand for receptors responsible for the clearance of diet-derived chylomicrons and 
VLDL remnants from the circulation [289,290]. Therefore knocking out ApoE results in the 
accumulation of pro-atherogenic cholesterol in the plasma [290]. This was first achieved by 
gene targeted inactivation in mice by two independent laboratories in 1992 [290,291]. The 
ApoE-/- mice developed by Plump et al. were reported to have plasma cholesterol levels of 
494 mg/dl (12.79 mmol/L) when fed a standard low fat, low cholesterol chow diet and 
develop aortic and coronary atherosclerotic lesions within 10 weeks. Control mice recorded 
only 60 mg/dl (1.55 mmol/L). When the ApoE-/- mice were put on a high-fat diet, plasma 
cholesterol levels were elevated to 1821 mg/dl (47.16 mmol/L) compared with 132 mg/dl 
(3.42 mmol/L) in control mice [291]. 
 Numerous studies have utilised the ApoE-/- mouse model to investigate the 
pathogenesis of atherogenesis, and the potential of various interventions. The lesions seen in 
these mice, when put on a high-fat diet, are morphologically reasonably similar to the 
atherosclerotic lesions detected in humans. The additional advantage of the ApoE-/- and LDL-
R-/- models over other mouse models is that it exhibits a progression of lesion development 
which mimics that of human lesions. Plaque area and time are linked in a linear manner. This 
is less obvious in other murine models [292,293].     
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1.9.2. Animal models of acute CVDs 
Myocardial ischemia occurs when coronary blood flow to the myocardium is reduced. This 
may be in terms of absolute flow rate or relative to increased metabolic demand [294]. 
Depriving the myocardium of its O2 and nutrient supply results in an array of biochemical 
and metabolic changes within the myocardium. The lack of O2 brings oxidative 
phosphorylation to a halt, resulting in depolarisation of the mitochondrial inner membrane, 
which leads to ATP depletion, and culminates in a loss of myocardial contractility. This is 
exacerbated by the reversal of the ATPase complex. In a bid to maintain the mitochondrial 
membrane potential, the F1F0 ATPase subunits hydrolyse ATP in order to pump protons back 
against the established gradient. When additionally starved of oxygen, cellular metabolism 
switches to anaerobic glycolysis, resulting in the accumulation of lactate, which ultimately 
reduces intracellular pH. An accompanying intracellular overload of Ca2+ also occurs [80]. If 
the ischemic event is rectified, oxygen and nutrient supply is restored and ischemic 
metabolites are washed out in a process called reperfusion. However, reperfusion of ischemic 
myocardium can result in cardiomyocyte death independent of the ischemic event. This 
potential injury is largely determined by the duration of the preceding ischemia, the length of 
which is associated with a concomitant increase in mitochondrial permeability transition pore 
(MPTP) opening [295]. The MPTP has been shown to be closed during ischemia and open 
during ischemia in response to mitochondrial Ca2+ overload, oxidative stress, ATP depletion, 
and rapid pH rectification [296]. Therefore, while timely reperfusion salvages a greater 
amount of myocardium, reperfusion itself is an injurious process. Therefore, ischemia-
reperfusion (IR) injury is considered together [297]. 
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 Small animal models are attractive models for IR studies as they are economical in 
terms of cost and space. However, they can be technically difficult to perform, due to the 
need for micro-surgery. Mice are generally considered too small and have a poor recovery 
rate from such invasive surgery. A common model used is Sprague Dawley rats. The chest is 
opened at the fifth intercostal space to expose the heart. The left coronary artery is then 
ligated by suture passed through the myocardium and around the vessel. The length of time 
the suture is secured for may vary, although 30 minutes is generally deemed an appropriate 
period. In control animals, the suture is passed through the myocardium but not tightened 
[298].  
 A number of studies have utilised this model to investigate therapeutic 
cardioprotective strategies for reducing IR injury. These may come in the form of 
preconditioning or postconditioning strategies, and may be mechanical or pharmacologic in 
nature [294].  
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1.10. Summary and concluding remarks 
Accumulating evidence suggests that oxidant formation by the heme enzyme MPO plays an 
important role in the onset and development of atherosclerosis. MPO is released from 
activated leukocytes at sites of inflammation, using H2O2 (generated by both these cells and 
others, by multiple enzyme systems including NADPH oxidase complexes) and halide (Cl-; 
Br-) and pseudohalide (SCN-) ions to generate the oxidants HOCl, HOBr, and HOSCN. 
 The formation of the two primary products of MPO, HOCl, and HOSCN, occurs in 
competition with each other. SCN- is the preferred enzyme substrate (by approximately 730 
fold); however, this ion is present at much lower levels than Cl- in biological fluids (Cl- 
typically 100-150 mM; SCN- varies between 20 – 200 M). Thus, HOCl is the major species. 
However, when SCN- levels are high, HOSCN formation becomes increasingly prominent. 
Both HOCl and HOSCN can damage biological molecules, but the effects of these two 
hypohalous acids are very different due to their different chemical reactivities.  
 HOCl is known to be toxic to many cells, and this species is used by activated 
leukocytes to kill invading pathogens in the same manner as household bleach. Although 
HOCl generation by MPO is a major component of the innate immune response to pathogens, 
there is also compelling evidence that the generation of this oxidant at inappropriate 
concentrations, times or locations, can damage host tissue. This has been associated with a 
large number of human diseases including heart disease (atherosclerosis), asthma, rheumatoid 
arthritis, cystic fibrosis, kidney disease, neurodegenerative conditions, and some cancers. 
MPO mRNA, protein, and enzyme activity have been detected in diseased human arteries, as 
have proteins, DNA, and lipids damaged by the HOCl that this enzyme generates. 
Furthermore, MPO levels in human plasma have been shown to be both diagnostic of tissue 
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damage and prognostic of outcomes for people presenting at hospitals with suspected heart 
attacks, and to correlate with disease severity. High concentrations of the MPO enzyme, and 
the oxidants that it generates, can therefore be highly damaging. 
 HOSCN behaves in a very different manner to HOCl, and can be an important species 
in some circumstances. In particular, HOSCN formation is believed to be of particular 
importance in people who consume certain types of diet, or who smoke, as both of these 
factors elevate plasma levels of SCN-, the precursor of HOSCN. These high levels of SCN- 
ions have been predicted to give rise to an increase in production of SCN- -derived oxidants 
(such as HOSCN) by MPO, and may modulate the risk of atherosclerosis (and other diseases). 
 HOSCN, unlike HOCl, is highly specific in the species with which it reacts, with 
damage occurring primarily at Cys and Sec residues. The latter are rare in biological systems, 
making Cys the major site of damage. Unlike much of the damage induced by HOCl, which 
is not repairable, most of the oxidation products of Cys can be readily converted back to the 
parent compound (i.e. the damage is reversible in nature). Thus, formation of HOSCN may 
result in damage that can be repaired, whilst that generated by HOCl is not. It has therefore 
been proposed that high plasma levels of SCN- may afford protection against damage in vivo 
as it prevents the generation of widespread HOCl-induced irreparable damage. 
 A recent retrospective study of people who suffered a first heart attack has yielded 
data that support this hypothesis. The data indicates that patients with high levels of MPO 
were more likely to die than those with low levels- further evidence that MPO is a key factor 
in biological damage. However, those with low levels of MPO and high levels of SCN- had a 
much higher survival rate than those with low levels of SCN-. This data supports the 
hypothesis that high SCN- levels may be protective, and some data from other studies further 
  
 
59 
 
 
supports this argument. This is of major importance as it is already known that SCN- can be 
readily modified in humans by dietary means, and hence raising the level of this anion by 
dietary manipulation could help protect against human CVD. 
 
1.11. Thesis aims and outline 
This project aims to determine whether elevated levels of SCN- convey protection against 
CVD, with the hypothesis that high levels of SCN- result in increased formation of HOSCN, 
instead of HOCl by MPO, and that this results in decreased inflammatory damage and better 
CVD outcomes. 
The aims of this project are therefore to determine: 
1) Do elevated levels of plasma SCN- decrease the extent of IR injury in rat models? 
2) Do elevated levels of plasma SCN- decrease the extent of atherosclerosis in mouse 
models? 
3) Do elevated levels of plasma SCN- in humans correlate with systemic markers of 
MPO-derived oxidative damage in subjects with and without established CVD?  
4) Does sepsis result in an altered redox balance with increased protein oxidation and 
enhanced levels of inflammatory markers? 
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Chapter 2 
Materials and methods 
This chapter describes the overall material and methods used throughout the studies. Each 
results chapter describes methods relevant to its individual content. 
2.1. Materials 
Fatty acid free bovine serum albumin (BSA), L-glutathione reduced (GSH), sodium 
thiocyanate (NaSCN), 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), Tween 20, and monobasic 
and dibasic sodium phosphate were from Sigma Aldrich Pty. Ltd. (Castle Hill, NSW, 
Australia). Copper sulfate was purchased from ICN (Seven Hills, NSW, Australia).  Sodium 
chloride, phosphate buffered saline (20x concentrate, pH 7.5) and glacial acetic acid were 
from Amresco (Solon, OH, USA).   
All solutions were prepared using nanopure water from a Milli Q system unless 
otherwise stated (Millipore-Waters, Lane Cove, NSW, Australia) and typically treated with 
washed Chelex-100 resin to remove trace transition metal ions (Bio-Rad, Reagent Park, NSW, 
Australia).  
All other chemicals were of analytical grade and all solvents were HPLC grade.  
Methanol and acetonitrile were purchased from EM Science (Gibbstown, NJ, USA). 
Hydrochloric acid was Analar® grade and purchased from Merck Pty. Ltd. (Kilsyth, Vic, 
Australia). 
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2.2. Rat ischemia-reperfusion injury model 
Male Sprague–Dawley rats (6-8 weeks old, weight 250 to 300 g) were acclimatised for a 
period of 1 week prior to the onset of preconditioning. All procedures were approved by the 
Royal North Shore Hospital Animal Care and Ethics Committee (approval no. 5405-005A). 
After the acclimatisation period, the rats were divided into vehicle control (regular water) and 
10 mM NaSCN groups, which was dissolved into drinking water, for 1 week of 
preconditioning prior to surgery. Figure 3.1 depicts a schematic of the experimental design. 
 
Figure 2.1- Sprague–Dawley rats were preconditioned for one week with either regular water 
or 10 mM NaSCN. They then underwent either sham or IR surgery to give 4 groups: vehicle 
(V) treated shams(V/Sham), V treated IR (V/IR), SCN- treated shams (SCN/Sham), and SCN- 
treated IR (SCN/IR). 
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Myocardial IR was induced under isoflurane anaesthesia as previously described 
using an open‐chest method [298,299]. Anaesthesia was induced using 5% isoflurane with O2 
at a flow rate of 2 L/min. The animal was then intubated, placed on a heat map, and placed on 
a ventilator at approximately 80 breaths per minute with a tidal volume of 2.5 mL. The 
isoflurane level was then reduced to 2% to maintain anaesthesia. The animal was then wiped 
down with ethanol and the chest shaved from the diaphragm to the neck and under the left 
foreleg. Analgesics were then administered; lignocaine subcutaneously (10 mg/kg) and 
temgesic intramuscularly (0.1 mg/kg). The primary incision was made along the space 
between the second and third ribs. Once the pleural membrane was exposed, it was carefully 
cut along the curvature of the rib to expose the pericardium. At this point, retractor claws 
were inserted to hold the chest cavity open. The pericardium was then carefully pierced to 
expose the heart.  Ischemia was induced for 30 mins by transient suture (5-0 prolene) ligation 
of the left anterior coronary artery approximately 2 to 3 mm distal to the junction of 
pulmonary artery and left atrial appendage using artery clamps. The ligature was released 
after the appropriate period and left in place for the 24 hour animals, and removed for the 4 
week animals. Blood loss was minimised when the sutures were removed from the 4 week 
animals by applying pressure to the site with cotton buds until any bleeding had ceased. The 
rib cage, muscle, and skin was then closed up by stitches (3-0 silk). Rats were allowed to 
recover for either 24 hrs or 4 weeks depending on time point before sacrifice. Sham animals 
were treated in an identical manner, except the ligature was not tightened. No antibiotics were 
administered during the recovery period. 
 At the time of sacrifice, rats were anaesthetised with isoflurane as described above. 
Those destined for MRI had the LAD ligature retightened. The MRI contrast agent 
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gadobenate dimeglumine (Multihance, 0.5 M, 0.4 mL/kg) was then infused via a tail vein 
cannula 10 mins before sacrifice. 2 mins before sacrifice, iron microparticles (Dynabeads® 
MyOne™ Tosylactivated, 4.5 mg/kg), another contrast agent, were also infused via the tail 
vein cannula. In animals that were not infused with these contrast agents, approximately 4 
mL of blood was collected from the inferior vena cava into a 5 ml Z Serum Separator Clot 
Activator vacuette tube (Greiner Bio-One).  The vacuette was then centrifuged at 800 g for 10 
mins, and the serum was transferred and stored at -80°C. At sacrifice, whole hearts were 
excised and immediately fixed in 10% neutral buffered formalin (NBF) for 24 hrs for rats 
destined for MRI. After this period of time, they were embedded in 2% agar prior to MRI. 
We also acknowledge the contribution of Dr Sarah Tandy of the North Shore Heart Research 
group who assisted with this procedure. 
2.3. Magnetic resonance imaging 
Samples were run using an amended version of a previously described method [300,301], and 
the observer was blinded to the groups until the statistical analysis stage. All samples were 
scanned on a 400 Hz (9.4 T) Bruker Scanner. Samples were placed in the centre of the coil, 
and scanner gain was set and tuned to each sample individually. A pilot scan was used as a 
reference to align both sequences. A T2* sequence (TR (repetition time) /TE (echo time) = 
40/15 ms, FOV (field of view) = 15/15/18 mm, matrix size = 128/128/64, Spatial Resolution 
= 0.117/0.117/0.28 mm, scan duration 16 mins) was used show the location of iron particles. 
A T1 inversion recovery sequence (TR/TE/TI (inversion time) = 1000/12.5/200 ms, FOV = 
15/15/18 mm, matrix size = 96/96/32, Spatial resolution = 0.15/0.15/0.56 mm, scan duration 
= 51 mins) was used to confirm the location of the Multihance.  
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 All data analysis was performed in MATLAB with in-house software. Data from the 
scanner was reconstructed into mat format from the raw data fid files for every sequence. All 
sequences were read into MATLAB and interpolated in the inplane direction to a finer grid 
(256/256). T2* sequences were used to calculate left ventricle volume. Epi and endo-cardium 
borders were manually delineated from each slice and used to create a mask. The number of 
voxels within the mask was then multiplied by the voxel volume to calculate the left ventricle 
volume. All T2* images were thresholded from minimum to 0.66 of maximum pixel intensity 
to aid segmentation. T2* sequences were then used to define the total reperfusion volume 
from the delineation of the border of the iron microparticles. The total reperfusion mask was 
clipped by the left ventricle mask to ensure that the area stayed within ventricle. Total 
reperfusion volume was then calculated in the same way as before. Once again all T2* 
images were thresholded from minimum to 0.66 of maximum pixel intensity to aid 
segmentation.  
 Infarct volume was calculated from the real reconstruction of the T1 inversion 
recovery sequence. Pixel intensity was squared to aid with segmentation and account for 
variation in Multihance intensity from sample to sample. All T1 IR images were thresholded 
from minimum to 0.10 of maximum pixel intensity to aid segmentation. The area of 
Multihance was defined and mask was then created, again this mask was clipped by the left 
ventricle mask to ensure the area remained within left ventricle. Volume was calculated as 
described above. 
 Salvage volume was then calculated by subtracting infarct volume from total 
reperfusion volume. All 3 volumes (total reperfusion, infarct, and salvage) were also 
normalized by left ventricle volume, salvage volume was also normalized by total reperfusion 
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volume. Results were output to an excel spreadsheet for further statistical analysis. We also 
acknowledge Dr Kathryn Broadhouse and Professor Stuart Grieve of the HRI’s Cardiac 
Imaging group for running and measuring the MRI. 
2.4. Echocardiography 
2D and M-mode images of a short-axis view at the mid-papillary level were recorded prior to 
surgery and at the 48 hrs, 1, 2, and 4 week time points after surgery, using a 6.5 MHz 
transducer (Toshiba Artida). Prior to taking measurements animals were sedated. Anaesthesia 
was induced using 5% isoflurane with O2 at a flow rate of 2 L/min, before being placed on a 
nose cone and reducing the isoflurane level to 2% to maintain anaesthesia.  Measurements 
were taken from three different sections of the heart (the base, mid, and apex) to account for 
variation in chamber size throughout the length of the ventricle. Left ventricular diameters in 
diastole and systole were measured from M-mode recordings. Fractional shortening was also 
calculated as ((left ventricle (LV) diastole-LV systole)/LV diastole)) x100, and calculated for 
each individual animal, at each section, before averaging. We also acknowledge the 
contribution of Dr Sarah Tandy of the North Shore Heart Research group who assisted with 
the procedure. 
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2.5. Mouse experimental model 
4 week old ApoE-/- mice (n = 108) were maintained for 4 weeks, 8 weeks, or 18 weeks on a 
semi-pure high-fat diet formulation for laboratory rats and mice based formulated to mimic a 
“Western fast food diet” (SF00-219, Specialty Feeds, Glen Forrest, WA, Australia). Table 2.1 
demonstrates the nutritional parameters of this diet.  
Protein 19% 
Cholesterol 0.15% 
Total Fat 21% 
Crude Fibre 2.7% 
Digestible Energy 19.4 MJ/kg 
% Total Calculated Digestible Energy From Lipids 40.0% 
% Total Calculated Digestible Energy From Protein 17.0% 
 
Table 2.1- Calculated nutritional parameters for the semi-pure high-fat diet formulation 
(SF00-219, Specialty Feeds, Glen Forrest, WA, Australia). 
 
Additionally, a third of the animals were maintained on normal drinking water, a third 
on 2.5 mM NaSCN dissolved in drinking water, and a third on 10 mM NaSCN dissolved in 
drinking water. Food and water were available ad libitum. There was a total of 9 groups, each 
containing 12 animals; 4 week control, 2.5 mM, and 10 mM NaSCN; 8 week control, 2.5 mM, 
and 10 mM NaSCN; and 18 week control, 2.5 mM, and 10 mM NaSCN. Figure 2.2 illustrates 
this model in a schematic. All procedures were approved by the Sydney Local Health District 
Animal Welfare Committee (approval no. 2013/093). 
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Figure 2.2- ApoE-/- mice were placed on a high-fat diet for either 4, 8, or 18 weeks. The 
animals had access to either plain water, or water containing 2.5 mM NaSCN, or 10 mM 
NaSCN for the duration of the study. 
 
 Mice were sacrificed at the appropriate end point by exsanguination via cardiac 
puncture following anaesthesia using methoxyflurane. Blood was obtained by cardiac 
puncture into a heparin loaded syringe to prevent clotting, and was immediately transferred to 
Eppendorf tubes on wet ice. The blood was spun at 2000 g for 5 mins at 4 °C. The recovered 
plasma was then aliquoted and stored at -80 °C for further analyses. 
 The vasculature was flushed by perfusion through the left ventricle, at physiological 
pressure, with PBS at 4 °C. The aortic sinus, aortic arch, and descending thoracic aorta were 
collected for histological analysis. The aortic sinus and descending thoracic aorta were 
carefully dissected out and stored in paraformaldehyde and 70% v/v ethanol in water 
respectively, while the aortic arch was snap-frozen on dry ice. After 24 hrs the aortic sinus 
was rinsed in PBS and stored in 70% v/v ethanol in water.  
Early Disease 
Intermediate Disease 
Late Disease 
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2.6. Histology 
2.6.1. Histology materials and solutions 
Xylene, Harris’ Haematoxylin solution, and Scott’s Blueing Solution were purchased from 
Fronine Lab Supplies (Riverstone, N.S.W., Australia). DPX Mountant for cover-slipping was 
purchased from SigmaAldrich. 
Solution A for Milligan’s Trichrome staining was made by dissolving 5.625 g of 
potassium dichromate in 5.625 mL hydrochloric acid and 62.5 mL 95% v/v ethanol and 
making up to 250 mL with distilled water. Solution B was made by dissolving 0.25 g of acid 
fuchsin in 250 mL of distilled water. Solution C was made by dissolving 2.5 g of 
phosphomolybdic acid in 250 mL of distilled water. Solution E was made by making up 2.5 
mL of glacial acetic acid to 250 mL with distilled water. Solution F (which is light sensitive) 
was made by dissolving 0.25 g of fast green FCF in 0.50 mL glacial acetic acid and made up 
to 250 mL with distilled water. 
2.6.2. Dissection and paraffin embedding of aortic sinus 
The aortic sinus was dissected by removing the arterial tree along with the aorta and making a 
cut perpendicular to the aorta halfway through the heart. The dissected samples were 
enclosed in Tissue TEK cassettes and placed in 70% v/v ethanol. Tissue processing took 
place overnight through a Leica TP 1020 automatic tissue processor (Leica Microsystems, 
Nussloch, Germany) to dehydrate samples before infusing with paraffin wax. Samples were 
embedded in paraffin blocks using the Leica EG 1150 system in the desired orientation using 
a stainless steel mould (Leica Microsystems, Nussloch, Germany). 
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2.6.3. Tissue sectioning 
Five micrometre sections of tissue were initially cut on a rotary microtome and floated on a 
42 °C water bath. Sections were lifted on to a StarFrost® advanced adhesive slides (ground 
edges 90°, white) (Waldemar Knittel Glasbearbeitungs, Braunschweig, Germany) and air 
dried before placing in racks to dry overnight at 37 °C.  
The first section of the aortic slide was taken at the first appearance of the three valve 
leaflets, and the last was taken at their disappearance. Three sections were collected per slide.  
One set of replicates were used for Milligan’s Trichrome staining. The other replicate 
sections were used for immunohistological analysis for α-actin for smooth muscle cells, 
CD68 for macrophages, neutrophil gelatinase-associated lipocalin (NGAL) for neutrophils, as 
well as MPO.   
2.6.4. Dewaxing and re-hydration of paraffin-embedded sections 
Dewaxing of slides was achieved by immersing slides in two changes of xylene for 10 mins 
each. Following dewaxing, sections were progressively re-hydrated through two changes of 
100% ethanol for 2 mins each, followed by two changes in 95% v/v ethanol (2 mins each) 
and finally 2 mins in 70% v/v ethanol. Sections were then washed rinsed in tap water, and 
then PBS. 
2.6.5. Milligan’s trichrome staining 
Sections were incubated in Bouin’s Solution at 60 °C for 1 hr before being rinsed with 
distilled water. Sections were then placed in running distilled water for 5 mins. Sections were 
then placed in Solution A (see section 2.6.1) for 5 mins before being placed in running 
distilled water until the water ran clear. Sections were then placed in Solution B (see section 
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2.6.1) for 5 mins before being rinsed by quickly dipping 4 times in 2 changes of distilled 
water. Sections were then placed in Solution C (see section 2.6.1) for 5 mins before being 
rinsed by quickly dipping 4 times in 2 changes of distilled water. Sections were then placed 
in Solution D (see section 2.6.1) for 10 mins before being rinsed by quickly dipping 4 times 
in 2 changes of distilled water. Sections were then placed in Solution E (see section 2.6.1) for 
2 mins before being rinsed by quickly dipping 4 times in distilled water. Sections were then 
placed in Solution F (see section 2.6.1) for 10 mins in a light-protected chamber before being 
placed back in Solution E for 3 mins. Sections were then dehydrated. 
2.6.6. De-hydration of paraffin-embedded sections for immunohistochemistry 
After the completion of staining, the sections then went through two changes of 70% v/v 
ethanol (30 secs each), followed by two changes of 95% v/v (30 secs each), followed by two 
changes of 100% absolute alcohol (30 secs each), followed by two changes of xylene (2 mins 
each). Slides were then mounted with DPX mounting medium and cover-slipped. 
2.6.7. Immunohistochemistry materials and methods 
Alkaline phosphatase substrate (Vector Red) was purchased from Vector Laboratories Inc. 
(CA, U.S.A.) One drop of Reagent 1, 2, and 3 were added to 2.5 mL of 100 mM Tris-HCl 
(pH 8.2 - 8.5) prior to use.  
The EnVision+ System-HRP (DAB) for use with rabbit primary antibodies (Dako 
K4011) was purchased from Dako Australia Pty. Ltd. (NSW, Australia). 1 drop of Liquid 
DAB+ Chromogen was added to 1 mL of substrate buffer to make a working DAB solution 
prior to use. 
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Normal goat serum was purchased from Abcam. Upon receipt it was aliquoted and 
stored at -20°C.  Normal goat serum working solution (10% v/v in PBS) was made fresh on 
the day of experiment.  
The antigen retrieval buffer was prepared by dissolving 5.46 g of sodium citrate 
tribasic dihydrate (SigmaAldrich) in 1.5 L of nanopure water. The pH of the solution was 
measured using a pH meter (PHM 220, Meter Lab®) and adjusted to 6 with 37% w/v HCl 
(Astral Scientific). The solution was then topped up to 2 L with nanopure water. 
2.6.8. Antibodies for immunohistochemistry 
Monoclonal anti-actin, α-smooth muscle - alkaline phosphatase antibody, produced in mouse, 
was purchased from Sigma-Aldrich (A5691). Rabbit polyclonal antibody to CD68 (125212) 
and a rabbit polyclonal anitbody to MPO (45977) were purchased from Abcam. Rabbit 
polyclonal antibody to NGAL was purchased from Santa Cruz Biotechnology (50351). 
All antibodies were diluted to their working concentrations in antibody diluent with 
background reducing components (Dako). 
2.6.9. Smooth muscle-α-actin staining 
Sections were embedded and deparaffinised as described above. The sections were then 
rinsed by dipping in water and then PBS. Antigen retrieval was achieved by placing the slides 
in citrate buffer and heating them in the microwave on high power for 10 mins. The slides 
were then rapidly cooled with ice. Sections were encircled with a liquid blocker pap pen 
(Hurst Scientific, WA, Australia) to reduce the volume of reagents required. PBST was then 
added to the samples for 5 mins. Normal goat serum working solution was added to the 
samples which were incubated for 2 hrs at 21 °C in a closed humidity chamber. The serum 
  
 
72 
 
 
was then removed and, without washing, the alkaline phosphatase-conjugated anti-actin, α-
smooth muscle monoclonal antibody (1/100 dilution, Sigma-Aldrich) was applied overnight 
at 4 °C with damp paper towels inside the humidity chamber.   
The following day samples were rinsed in two changes of PBS for 5 mins each. The 
samples were re-circled with the liquid blocker pen. The Vector Red Substrate (Alkaline 
Phosphatase Substrate Kit, Vector Laboratories Inc.) was freshly prepared in Tris-HCl buffer 
at 21 °C as previously described. The prepared substrate was added to the samples and 
incubated for 10 mins. The colour development was stopped by immersing the slides in water.  
After rinsing in water, sections were counterstained with Harris’s Haematoxylin for 3 
mins. Sections were then rinsed by successive quick dips in water, followed by acid alcohol, 
followed by water again. Sections were then placed in Scott’s blueing solution for 30 secs, 
and then rinsed once more by dipping in water. Sections were then de-hydrated as above. 
2.6.10. MPO, NGAL, and CD68 staining 
Sections were embedded and deparaffinised as described above. The sections were then 
rinsed by dipping in water and then PBS. Antigen retrieval was achieved by placing the slides 
in citrate buffer and heating them in the microwave on high power for 10 mins. The slides 
were then rapidly cooled with ice. Sections were encircled with a liquid blocker pap pen 
(Hurst Scientific, Western Australia) to reduce the volume of reagents required. PBST was 
then added to the samples for 5 mins. Peroxidase blocking solution (1 ml 30% H2O2 + 9 ml 
methanol) was then added to the samples for 30 mins, after which sections were rinsed in 
PBST for 5 mins. Normal goat serum working solution was added to the samples which were 
incubated for 4 hrs at 21 °C in a closed humidity chamber. The serum was then removed and, 
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without washing, the MPO (1/100 dilution, Abcam), CD68 (1/100 dilution, Abcam), or 
NGAL (1/150 dilution, Santa Cruz) antibodies were separately applied overnight at 4 °C with 
damp paper towels inside the humidity chamber.   
The following day samples were rinsed in two changes of PBST for 5 mins each. The 
samples were re-circled with the liquid blocker pen. Pre-diluted secondary antibody 
(EnVision+ System-HRP (DAB) kit) (diluted a further two fold for NGAL) was then added 
to each section and incubated at 21 °C for 30 mins. Samples were then rinsed in two changes 
of PBST again for 5 mins each. DAB substrate was freshly prepared at 21 °C as previously 
described. The prepared substrate was added to the samples and incubated for 10 secs for 
MPO and CD68, and 90 secs for NGAL. The colour development was halted by immersing 
the slides in water.  
After rinsing in water sections were counterstained with Harris’s Haematoxylin for 3 
mins. Sections were then rinsed by successive quick dips in water, followed by acid alcohol, 
followed by water again. Sections were then placed in Scott’s blueing solution for 30 secs, 
and then rinsed once more by dipping in water. Sections were then de-hydrated as above. 
2.6.11. Determination of cholesterol clefts 
The lipid content was measured from the Milligan’s Trichrome slides, which were used to 
quantify plaque collagen content. The lipid content was assessed as extracellular lipid pools 
which appeared as white areas within atherosclerotic plaque sections following the staining 
with Milligan’s Trichrome, which included a graded ethanol concentration which solubilises 
the lipid. These delipidated white areas were clearly differentiated from collagen content 
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which was distinctly stained green. The quantification of these areas was carried out using a 
modification of previously published methods [302]. 
2.6.12. Compositional analysis of atherosclerotic plaques 
Each section from each slide was imaged digitally using an Axio Imager Upright Microscope 
(Carl Zeiss MicroImaging, Göttingen, Germany).  Measurements of smooth muscle cell, 
macrophage, neutrophil, MPO, lipid, and collagen areas were quantified using the Image J 
programme (NIH, Bethesda, MD, USA). The colour threshold settings were altered to select 
for the particular colour of each stain. The region of interest was then filtered through the 
same function, in order to detect the specific stain of interest, which was marked with red. 
The amount of red present equates to the area of interest that was then quantified.  The 
smooth muscle cell, macrophage, neutrophil, MPO, lipid, and collagen content were 
expressed as a percentage of total plaque area for each image produced.   
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2.7. Blood analysis 
2.7.1. Thiocyanate 
SCN- was measured by ion-exchange chromatography in triplicate. Serum/plasma samples 
were prepared by mixing 1:1 v/v with acetonitrile, followed by centrifugation (2000 g, 4 °C, 
7 mins) to remove proteins. The supernatant was subsequently filtered through 0.2 μm 
centrifuge filters (2000 g, 4 °C, 3 mins; Pall Nanosep MF, 500 μL capacity) before injection 
into the Dionex ICS-2100 ion chromatography system. The chromatography system consisted 
of an AS3500 autosampler (set to 4 °C), GP40 gradient pump, ASRS 300 anion suppressor (4 
mm) in AutoSuppression recycle mode, and ED40 electrochemical detector with DS3 
detector stabilizer. Eluent flow rate was 1.5 mL min-1. SCN- was quantified using an IonPac 
AS16 column (4×250 mm) and AG16 guard (4×50 mm) and eluted over 12 mins with 50 mM 
potassium hydroxide in water (25 μL injection volume) with a suppressor current of 186 mA. 
Peak areas were quantified using Chromeleon Chromatography Studio software (version 7), 
against a standard curve generated using NaSCN (0–200 μM) [303]. 
2.7.2. Protein assays 
To determine total serum/plasma protein concentration, the Pierce (Thermo Fisher Scientific, 
North Ryde, NSW) Bicinchoninic Acid (BCA) Protein Assay was used, with duplicate 
replicates. One part of Reagent B (4% (w/v) CuSO4) was mixed with 49 parts Reagent A 
(sodium carbonate, sodium bicarbonate, BCA and sodium tartrate in 0.1 N NaOH). This 
method quantifies the reduction of Cu2+ to Cu+ by a protein under alkaline conditions (Biuret 
reaction) with colorimetric detection of the Cu+: BCA complex. 10µL of sample along with 
190 µL BCA working reagent was added in each well of a 96 well plate and incubated at 60 
ºC for 30 mins. The plate was cooled for 5 mins before the absorbance was read at 562 nm. A 
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standard curve obtained using 0 - 50 µg BSA prepared in the same buffer as the samples, was 
used to calculate the protein concentration, with this expressed as µg/µL. 
2.7.3. Thiol analysis 
To determine reduced thiol concentrations, the DTNB thiol assay was utilised using duplicate 
replicates. 200 µL 0.5 mM DTNB in 100 mM phosphate buffer, pH 7.4, was added to 10 µL 
1:1 serum/plasma diluted in water in each well of a 96 well plate. 100 mM phosphate buffer 
was added to a second set of samples to act as a blank and account for non-DTNB absorbance. 
The plate was incubated at 21 °C on a plate shaker in the dark for 30 mins.  Absorbance was 
then measured at 412 nm. A standard curve obtained using 0 - 5 mM GSH prepared in the 
same manner as the samples, was used to calculate the free thiol concentration, with this 
expressed as µM. 
2.7.4. Rat serum markers 
Atrial Natriuretic Peptide (ANP), Brain Natriuretic Peptide (BNP), C-Reactive Protein (CRP), 
and galectin-3 were all quantified using commercial kits (Atrial Natriuretic Peptide EIA Kit, 
Brain Natriuretic Peptide EIA Kit, and Rat CRP/C-Reactive Protein ELISA Kit, Sigma-
Aldrich; Rat Galectin-3 ELISA, Ray Biotech) in accordance with the manufacturers’ 
instructions, and using duplicate replicates. 
 For the EIA and ELISA kits, rat serum was diluted as required by the assays: ANP 
(1:10), BNP (1:10), CRP (1:10,000), and galectin-3 (1:10) with the provided sample diluent 
buffer. Standards were also prepared according to the manufacturers’ guidelines; ANP (0-
1000 pg/mL), BNP (0-1000 pg/mL), CRP (0-60 ng/mL), and galectin-3 (0-800 pg/mL). 
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 100 μL aliquot of the prepared samples/standards were incubated overnight at 4 °C 
for the ANP and BNP, and 2 hrs at 21 °C for the CRP and galectin-3, on a plate shaker. Each 
well was then manually aspirated and washed 4 - 5 times with 200 μL of wash buffer. 100 μL 
of biotinylated secondary antibody was added and incubated for 1 hr at 21 °C on a plate 
shaker. Wells were then aspirated and washed again 4 - 5 times, followed by the addition of 
100 μL of HRP-streptavidin conjugate for 45 mins at 21 °C on a plate shaker. The wells were 
washed again 4 - 5 times and 100 μL of tetramethylbenzidine (TMB) was added. The plate 
was mixed and incubated for up to 30 mins in darkness at 21 °C on a plate shaker. The 
reaction was stopped by adding 50 μL of Stop Solution. The optical density of each well was 
then read by the spectrometer at 450 nm.  
2.7.5. Mouse plasma markers 
Tumour Necrosis Factor-α (TNF-α), Monocyte Chemoattractant Protein-1 (MCP-1), 
Inteleukin-6 (IL-6), serum amyloid A (SAA), and MPO were all quantified using commercial 
kits. Mouse Quantikine ELISA kits were purchased from R & D systems (Mineapolis, MN, 
U.S.A) for determining TNF-α and MCP-1. The murine MPO ELISA kit was purchased from 
Hycult Biotech, Inc. (Uden, Netherlands). The mouse IL-6 ELISA kit was purchased from 
Ray Biotech, Inc. (Norcross, GA, U.S.A.).  The mouse SAA ELISA kit was purchased from 
Tridelta Development Ltd. (County Kildare, Ireland). All samples were measured in duplicate 
replicates. Reagents supplied by the manufacturers were brought to 21 °C before the 
commencement of the specified procedure. 
 For the ELISA kits, mouse plasma was diluted as required by the assays: TNF-α (1:1), 
MCP-1 (1:2), IL-6 (1:2), SAA (1:400), and MPO (1:10) with the provided sample diluent 
buffer. Standards were also prepared according to the manufacturers’ guidelines: TNF-α (0-
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700 pg/mL), MCP-1 (0-1000 pg/mL), IL-6 (0-600 pg/mL), SAA (0-0.5 µg/mL), and MPO (0-
100 ng/mL). 
 50 μL of the prepared samples/standards along with 50 μL of assay diluent were 
added to each well and incubated for 2 hrs at 21 °C for the TNF-α and MCP-1 ELISAs, on a 
plate shaker. Each well was then manually aspirated and washed 4 - 5 times with 200 μL of 
wash buffer. 100 μL of mouse TNF-α/MCP-1 conjugate was added to each well and 
incubated for 2 hr at 21 °C on a plate shaker. Wells were then aspirated and washed again 4 - 
5 times, followed by the addition of 100 μL of Substrate Solution for 30 mins at 21 °C on a 
plate shaker protected from light. The reaction was stopped by adding 100 μL of Stop 
Solution. The optical density of each well was then read by the spectrometer at 450 nm. 
For the IL-6 and MPO ELISAs, 100 μL of the prepared samples/standards were added to 
each well and incubated for 2.5 hrs in the case of IL-6, and 1 hr in the case of MPO at 21 °C, 
on a plate shaker. Each well was then manually aspirated and washed 4 - 5 times with 200 μL 
of wash buffer. 100 μL of biotinylated secondary antibody was then added and incubated for 
1 hr at 21 °C on a plate shaker. Wells were then aspirated and washed again 4 - 5 times, 
followed by the addition of 100 μL of HRP-streptavidin conjugate for 45 mins for IL-6 and 
30 mins for MPO at 21 °C on a plate shaker. The wells were washed again 4 - 5 times and 
100 μL of TMB was added. The plate was mixed and incubated for up to 30 mins in darkness 
at 21 °C on a plate shaker. The reaction was stopped by adding 50 μL of Stop Solution to IL-
6 and 100 μL to MPO. The optical density of each well was then read by the spectrometer at 
450 nm. 
For the SAA ELISA, 50 μL of anti-SAA/HRP conjugate was added to each well followed 
by 50 μL of the prepared samples/standards.  The plate was then incubated at 37 °C for 1 hr. 
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Each well was then manually aspirated and washed 4 - 5 times with 200 μL of wash buffer. 
100 μL of TMB was then added. The plate was mixed and incubated for up to 15 mins in 
darkness at 21 °C on a plate shaker. The reaction was stopped by adding 100 μL of Stop 
Solution, and the optical density of each well was then read by the spectrometer at 450 nm. 
2.7.6. Human plasma MPO 
Human MPO was quantified using a commercial kit purchased from Immundiagnostik 
(Bensheim, Germany). Human plasma was diluted as required by the assays (1:10) with the 
provided sample diluent buffer. MPO standards and controls were also prepared according to 
the manufacturer’s guidelines (0-30 ng/mL). Due to the limited amount of sample plasma 
available, only single replicate determinations were measured. 
 Each well was initially manually washed and aspirated 4 - 5 times with 250 μL of 
wash buffer. 100 μL of the prepared samples/standards were added to each well and 
incubated for 1 hrs at 21 °C on a plate shaker. Each well was then again manually aspirated 
and washed 4 - 5 times with 250 μL of wash buffer. 100 μL of mouse monoclonal anti-MPO 
detection antibody was added to each well and incubated for 1 hr at 21 °C on a plate shaker. 
Wells were then aspirated and washed again 4 - 5 times, followed by the addition of 100 μL 
of streptavidin peroxidase labelled conjugate for 1 hr at 21 °C on a plate shaker. Each well 
was then again manually aspirated and washed 4 - 5 times with 250 μL of wash buffer. 100 
μL of TMB substrate was added to each well for 10-20 mins at 21 °C on a plate shaker 
protected from light. The reaction was stopped by adding 100 μL of Stop Solution. The 
optical density of each well was then read by the spectrometer at 450 nm against 620 nm as a 
reference. 
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2.8. Metabolic profiling 
2.8.1. Sample preparation for metabolic profiling 
Sample preparation and acquisition methods were based on published protocols by Dona et al. 
[304]. 300 µL aliquots of rat serum were mixed with 300 µL of aqueous (20% D2O) 
phosphate buffer solution (0.075 M NaH2PO4, pH = 7.4 plus 0.1% sodium azide, 1 mM 3-
trimethylsilyl-1-[2,2,3,3,-2H4] propionate (TSP)). The samples were centrifuged at 3000 g for 
10 mins and aliquots of the supernatants (500 µL) from each serum sample were transferred 
into 5 mm NMR tubes for 1H NMR analysis. 
2.8.2. Acquisition of 1H NMR spectra 
1H NMR spectra were acquired with a Bruker Avance III 400 MHz spectrometer operating at 
approximately 400.13 MHz for 1H at 310 K. It was equipped with a 5 mm broad-band inverse 
configuration probe. Samples were randomly analysed in automation with a 24 sample 
SampleCase changer system. Serum samples were analysed using two experiments run 
sequentially, including a water suppressed 1D NMR NOESYPRESAT pulse sequence (256 
transients). This was followed by a Carr-Purcell-Meiboom-Gill (CPMG) spin echo sequence 
with water presaturation (196 transients). Both experiments included irradiation of the solvent 
(water) resonance that was applied during presaturation delay (2.0 secs) for all spectra. The 
pulse sequence parameters including the 90° pulse (12 µsecs), pulse frequency offset (1,890.6 
Hz), receiver gain (90.5), and pulse powers were optimised and set consistent for each 
experiment over the whole sample cohort. The spectral width was 20 ppm for all spectra. The 
NMR was processed with an exponential line broadening of 0.3 Hz prior to Fourier 
transformation, which were collected with approximately 32 k real data points. 
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2.8.3. NMR spectral data pre-processing 
Data [-1.0 to 10.0 ppm] were imported into MATLAB R2014b software (MathWorks, Natick, 
MA). They were then automatically phased, baseline corrected and referenced to the TSP 
peak (0.00 ppm) using Topspin 3.2. To reduce analytical variation between samples the 
residual water signal (4.67 – 4.98 ppm) was truncated from the data set. Normalization of 
each spectrum was performed across the sample cohort by use of probabilistic normalisation. 
Assignment of endogenous serum metabolites was made by reference to published literature 
data [305-308].  
2.8.4. Statistical methods and software 
Following the processing of the NMR data, multivariate statistical analysis was performed 
using MATLAB 2014b. Principal component analysis (PCA) [309] which aided the 
identification of unusual spectra and obvious trends in the metabolite profiles was performed. 
Otherwise, MATLAB was used for orthogonal partial-least squares discriminant analysis 
(OPLS-DA) and to statistically recouple variables to quantify metabolites for univariate 
analysis. All OPLS models were run through random permutation testing to assess the 
validity of the supervised model. 
2.8.5. Metabolite identification 
All detected metabolites were manually cross-referenced against the Chenomx NMR Suite 
8.1 (version 8.11) database. 
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2.9. Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM) in this thesis.  
Statistical analyses were undertaken using Prism 6.04 (GraphPad software, San Diego, 
CA, USA). For pair comparisons, unpaired t tests with Welch’s correction were employed as 
indicated in the text and figure legends. For multiple comparisons, one-way analysis of 
variance (ANOVA) with Tukey’s Multiple Comparison test was used to assess differences. 
Two-way ANOVA with Dunnett’s Multiple Comparison test was applied when two different 
conditions were applied, as in the echocardiography analysis. Differences were considered 
statistically significant at p < 0.05. 
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Chapter 3 
Investigation of the potential protective role of 
thiocyanate in acute myocardial ischemia-
reperfusion injury 
3.1. Introduction 
Cardiovascular disease is the leading cause of death globally [4]. As such, recent research has 
targeted an advance in surgical or therapeutic interventions for cardiovascular diseases. Both 
primary and secondary prevention modalities in high risk populations have also received a lot 
of attention from research groups. A number of animal models that simulate human cardiac 
disease have been developed including myocardial infarction (MI) and ischemia-reperfusion 
(IR) models that induce heart failure [310-312]. These models simulate acute cardiovascular 
events which are the leading cause of cardiovascular morbidity and mortality [312]. A 
number of physiologic changes ensue in the aftermath of such acute events. The loss of viable 
myocardium in the wake of MI results in increased loading conditions, inducing ventricular 
remodelling in both the area at risk and the non-infarcted myocardium. Increased myocyte 
apoptosis, necrosis, and greater hemodynamic load contribute to the initiation of ventricular 
dilatation and hypertrophy, ventricular shape distortion, as well as collagen scar formation. 
Failure to remodel to compensate for the increased wall stresses results in pathological 
remodelling associated with progressive dilatation, recruitment of the area at risk into the scar, 
and ultimately deterioration in myocardial contractile function. In rats, this ventricular 
dysfunction and heart failure can be used to mimic that observed in patients who suffer a MI, 
survive, and then experience heart failure [311]. 
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 Simulation of MI in animal models can be achieved by transient ligation of the left 
anterior descending (LAD) coronary artery, thus preventing the flow of blood through one of 
the major coronary arteries [310]. The duration of the ischemic period in animal models can 
be altered to mimic different scenarios. The LAD ligature may be tightened temporarily and 
removed after a given period of time to simulate an acute event (for instance, a 30 minute 
period, i.e. an acute MI), or it may be tied off indefinitely to simulate a chronic event 
(permanent MI). The duration of a subsequent reperfusion event following this initial 
ischemic period can also be altered. A short reperfusion period (such as 24 hours) may be 
utilised in order to determine infarct size and area at risk, whereas a prolonged period (such 
as 4 weeks) may be used in order to evaluate cardiac function and remodelling. The degree of 
pathological cardiac remodelling (apoptosis, necrosis and ventricular dysfunction) is known 
to depend on the selected time intervals of ischemia and reperfusion [312]. 
 Animal models of MI and IR have been an important tool in cardiovascular research 
for decades. Regenerating cardiac tissue damaged as a result of MI has been a major focus, 
and a number of studies have examined the use of cardiomyocytes [313], bone marrow cells 
[314], and stem cells [315] to facilitate the repair of the infarcted heart. Ischemic 
preconditioning, the phenomenon in which a period of sub-lethal ischemia can profoundly 
protect against infarction during a subsequent ischemic insult, has also been a huge focus of 
cardiovascular research [295,316]. Various pharmacological agents have been found to 
activate biological pathways at a number of levels which mimic ischemic preconditioning. 
Therefore, the development of specific therapeutic agents that offer the same profound 
protection seen with ischemic preconditioning has been another main goal [316]. Whilst 
reperfusion is the absolute treatment for MI, it also has the potential to exacerbate tissue 
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injury in a unique form of myocardial damage, a process termed reperfusion injury [317]. 
Brief repetitive episodes of IR at the immediate onset of reperfusion have been identified to 
reduce the extent of reperfusion injury, now termed postconditioning [318]. In much the same 
vein as agents that have been developed to mimic the effects of ischemic preconditioning, the 
development of therapeutic agents that mimic the same protection seen with postconditioning 
have also been sought [319-321]. 
 Acute obstruction of the coronary artery results in the area of the myocardium 
supplied by that vessel to experience acute myocardial ischemia, and in so doing determines 
the salvageable area of the MI, should the coronary occlusion be temporary or permanent. 
Following the onset of acute myocardial ischemia, prompt myocardial reperfusion is crucial 
to salvaging viable myocardium, as this limits MI size, preserves left ventricle systolic 
function, and prevents the onset of heart failure. If the period of acute myocardial ischemia is 
sustained for a period of time extending beyond approximately 20 minutes, cardiomyocyte 
death begins. This starts in the subendocardium and spreads as a ‘wavefront’ transmurally 
toward the epicardium [78]. However, as mentioned above, while reperfusion represents the 
absolute treatment for acutely ischemic myocardium, it can also independently induce 
cardiomyocyte death [80]. Myocardial reperfusion injury can cause damage in a number of 
ways including the induction of reperfusion-induced arrhythmias [81], myocardial stunning 
[82], microvascular obstruction [83], and lethal tissue injury [84]. 
 Myocardial reperfusion injury occurs upon the restoration of blood flow to the 
ischemic heart. The deprivation of both oxygen and nutrients to the myocardium as a result of 
MI results in a cascade of rapid metabolic and biochemical changes. The absence of oxygen 
brings oxidative phosphorylation to a halt, which leads to depolarisation of the mitochondrial 
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membrane, the depletion of ATP, and also inhibition of myocardial contractility. These 
alterations are exaggerated as the F1F0 ATPase functions in reverse, to maintain the 
mitochondrial membrane potential, which leads to hydrolysis of any remaining available ATP 
[80].  
 The absence of oxygen during ischemia also switches cellular metabolism to 
anaerobic glycolysis, which results in the accumulation of intracellular lactate and a reduction 
in pH. Protons accumulate intracellularly, activating the Na+-H+ ion exchanger, extruding 
protons from the cell in exchange for Na+. ATP depletion during ischemia also deactivates 
the 3Na+-2K+ ATPase, thereby exacerbating the intracellular Na+ overload. This activates the 
reverse function of the 2Na+-Ca2+ ion exchanger, as the cell tries to extrude Na+ but this 
results in intracellular Ca2+ overload [79]. 
 Neutrophils are the primary responders in IR injury and have been implicated in 
mediating lethal myocardial reperfusion injury, acting in a fashion similar to the bacterial 
invasion of a host [85-87]. Ischemia without reperfusion results in a slow infiltration of 
neutrophils into the salvageable area over a 12-24 hour period, and is restricted to the border 
of the myocardium’s salvageable area. With reperfusion, however, neutrophil infiltration and 
accumulation is markedly accelerated and increased, with a greater degree of accumulation in 
the subendocardium [86]. This is because myocardial reperfusion injury shares many 
characteristics with that of an inflammatory response. The reperfusion component of IR 
injury prompts a release of reactive oxidants, cytokines and other pro-inflammatory 
mediators, as well as granting greater access to the ischemic tissue [87]. This results in the 
activation of both neutrophils and the coronary vascular endothelium, which promotes the 
expression of adhesion molecules. In this way, neutrophils are recruited to the surface of the 
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endothelium (within minutes of the onset of reperfusion), and initiate a specific cascade of 
cell-cell interactions. Neutrophils first adhere to the vascular endothelium, before undergoing 
transendothelial migration, and finally directly interacting with myocytes [85]. When present 
in the post-ischemic myocardium and activated, neutrophils may cause damage in several 
ways, including via MPO-mediated damage. 
As has been detailed in Chapter 1, neutrophil-derived MPO, and particularly the 
MPO-derived oxidant HOCl, is a potentially damaging agent when produced at inappropriate 
times, locations, and concentrations. This includes in the context of the reperfused 
myocardium. We have hypothesised that by increasing the concentration of the preferred 
MPO substrate, SCN-, this ion will outcompete Cl- for the reaction with MPO compound I 
and therefore decrease HOCl formation and subsequent tissue damage, and therefore the 
extent of IR injury may be suppressed.  
3.2. Aims 
The aim of this study was to determine whether preconditioning rats by supplementing with 
oral SCN- might attenuate myocardial damage when challenged with IR injury. 10 mM 
NaSCN in sterile water was used as the preconditioning supplement and was available ad 
libitum. IR challenge was simulated by LAD ligation.  
3.3. Rat IR injury model design 
Male Sprague–Dawley rats were acclimatised for a period of 1 week prior to the onset of 
preconditioning. After the acclimatisation period, the rats were divided into vehicle control 
(n=32) and 10 mM NaSCN groups (n=32), where the latter was dissolved into drinking water, 
for 1 week of preconditioning prior to surgery. Both food and water were available ad libitum. 
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Figure 3.1 depicts a schematic of the experimental design. Myocardial IR was induced as 
outlined in section 2.2. Rats were then allowed to recover for either 24 hours or 4 weeks 
before sacrifice, and echocardiography was performed at regular intervals over the recovery 
period.  
 
 
Figure 3.1- Rat IR experimental model. Sprague–Dawley rats were preconditioned for one 
week with either regular water or 10 mM NaSCN. They then underwent either sham or IR 
surgery to give 4 groups: vehicle (V) treated shams(V/Sham), V treated IR (V/IR), SCN- 
treated shams (SCN/Sham), and SCN- treated IR (SCN/IR). 
 
 At the time of sacrifice, rats destined for MRI analysis had the LAD ligature 
retightened. MRI contrast agents were infused via a tail vein cannula. Other animals that were 
not infused with these contrast agents had blood samples collected which was destined for a 
number of assays, including for assessment of SCN- concentrations, biomarkers of heart 
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failure, as well as metabolomic analysis. At sacrifice, whole hearts were excised and 
immediately fixed in 10% neutral buffered formalin (NBF) for 24 hours for rats destined for 
MRI. After this period of time, they were embedded in 2% agar prior to MRI. The survival 
rate of all animals was 95% and the success rate of inducing an infarction was approximately 
60%. 
3.4.  Assessment of thiocyanate concentration 
3.4.1. Introduction 
Rat serum SCN- levels were measured by ion-exchange chromatography. It was crucial to 
determine and validate the dosing concentration, and length of time for preconditioning, as 
sufficient to significantly elevate serum SCN- levels at the time of MI challenge.  
3.4.2. Methods 
Serum samples were prepared by mixing 1:1 v/v with acetonitrile before centrifugation to 
remove precipitated proteins. The supernatant was then filtered through 0.2 μm centrifuge 
filters to prepare the working sample. SCN- was measured using a Dionex ICS-2100 ion 
chromatography system as outlined in section 2.7.1. Statistical analysis was carried out using 
unpaired two way t tests with Welch’s correction to avoid false positive results arising from 
the comparison of multiple data set, as used previously [322]. 
3.4.3. Results 
The mean serum SCN- concentrations for each treatment group at 24 hours post-surgery are 
depicted in Figure 3.2. These data indicate that serum SCN- levels were significantly elevated 
in both the SCN/Sham (95 µM) and SCN/IR (107 µM) groups compared to V/Sham (67 µM) 
and V/IR (59 µM) control groups. The SCN- concentrations in the SCN/Sham and SCN/IR 
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groups were not significantly different. It should be noted that this measurement was taken 24 
hours after SCN- treatment has ceased, and therefore the concentration of SCN- is expected to 
have decreased from the peak value, as the serum half-life of SCN- is approximately 3 days 
[323]. It is therefore likely that the serum SCN- levels were even greater at the time of surgery. 
3.4.4. Conclusion 
Preconditioning rats with 10 mM NaSCN for one week was sufficient to significantly raise 
serum SCN- levels in rats. The levels attained by the supplementation protocol are similar to 
those seen in human subjects [238,245]. 
 
 
  
 Figure 3.2- Mean serum SCN
- concentration (µM), as determined by ion-exchange chromatography, of 
the Sprague Dawley rats from each group at 24 hours post-surgery (n = 9, 11, 9, 9 respectively). The data 
are expressed as mean ± SEM. Unpaired one-tailed t tests with Welch’s correction for multiple 
comparisons indicate that a significant elevation in serum SCN- levels was observed in the SCN/Sham and 
SCN/IR groups compared to both vehicle control groups (where ** = p < 0.01, and *** = p < 0.001).  
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3.5.  Magnetic resonance imaging 
3.5.1. Introduction 
Magnetic resonance imaging (MRI) is a technique that uses a magnetic field and radio waves 
to create detailed images of the organs and tissues. Cardiac MRI is a non-invasive technique 
which specifically looks at the heart and the structures within it. Cardiac MRI can be used to 
create both still and moving images of the heart and major blood vessels. By using various 
contrasting agents, different information can be obtained. Molecular MRI contrast agents can 
alter either the T1 (such as gadolinium) or T2/T2* (iron oxide) relaxation of water protons 
near the target. The signal changes induced by the contrast component of the complex 
therefore reflect the location of specific regions of interest [300]. In this regard, and as used 
here, MRI can be used to determine infarct area, salvageable area, and total reperfusion area.  
3.5.2. Methods 
The MRI contrasting agents Multihance and iron microparticles were administered prior to 
sacrifice with the help of Dr. Sarah Tandy. All samples were run on a 400 Hz (9.4 T) Bruker 
Scanner by Dr. Kathryn Broadhouse and Prof. Stuart Grieve as outlined in section 2.3. Total 
reperfusion, infarct, and salvageable areas were calculated from the output. 
3.5.3. Results 
MRI analysis was performed to determine the extent of infarct and salvageable areas in the 
wake of IR injury. Figure 3.3 is a representative sample of the MRI output, exhibiting total 
reperfusion area, infarct area, and salvageable area.  
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 Both infarct and salvageable areas have been expressed as percentages of the total 
reperfusion area to minimise variation between individual animals and surgeries. The mean 
infarct size from the control animals constituted 74 ± 5% (and 26 ± 5% salvageable area), 
while the mean infarct size for the SCN- treated animals constituted 54 ± 6% (and 46 ± 6% 
salvageable area) of the total reperfusion area, resulting in a 20% protection by SCN- against 
permanent myocardial injury. Figure 3.4 shows the significant reduction in infarct size as a 
percentage of total reperfused area in the SCN- treated rats compared to vehicle controls 
which have not been supplemented with NaSCN. Figure 3.5 depicts the concomitant 
significant increase in salvageable area.  
 
 
Figure 3.3- (L-R) T2* map showing location of iron microparticles, indicating total 
reperfusion area. T1 map of Multihance location, indicating infarct area. Overlay of the two 
maps, with the difference between the total reperfused area and infarct area highlighted in 
blue. This highlighted region represents the salvageable area. 
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3.5.4. Conclusion 
The MRI data suggests that SCN- supplementation was associated with protection against MI 
induced IR injury. A significant reduction in infarct size is seen, and therefore a significant 
increase in salvageable area is also observed. This is indicative of less permanent damage 
Figure 3.4- Area of infarct as a percentage of total reperfusion area in vehicle (n = 4) and SCN- 
treated (n = 8) animals. A significant decrease in infarct size is observed in the SCN- treated rats 
as assessed using an unpaired two-tailed t test with Welch’s correction (where *=p<0.05). 
Figure 3.5- Salvageable area as a percentage of total reperfusion area in vehicle (n = 4) and SCN- 
treated (n = 8) animals. A significant increase in salvageable area is observed in the SCN- treated rats 
as assessed using an unpaired two-tailed t test with Welch’s correction (where *=p<0.05). 
 
  
 
94 
 
 
occurring in the SCN- supplemented heart compared to the control after 24 hours of recovery. 
Therefore, a greater region of the heart has the potential to recover as a lesser degree of 
permanent IR damage has occurred, and therefore less lasting damage is induced. 
 
3.6.  Echocardiography  
3.6.1. Introduction 
Echocardiography is one of the most widely used diagnostic tools in cardiology, and has 
become routinely used in the diagnosis, management, and follow-up of patients with any 
suspected or known heart diseases.  Echocardiography allows for a non-invasive, real-time 
means of assessing cardiac function by generating a sonogram. A number of measurements 
can be made from echocardiograms, including the size and shape of the heart, pumping 
capacity, and the location and extent of tissue damage. An echocardiogram can also give 
physicians other estimates of heart function such as a calculation of the cardiac output, 
ejection fraction, and diastolic function. 
3.6.2. Methods 
Echocardiography was performed prior to surgery and at 48 hrs, 1, 2, and 4 weeks after 
surgery, as described in section 2.4. Measurements were taken, with the help of Dr. Sarah 
Tandy, from three different sections of the heart (the base, mid, and apex) to account for 
variation in chamber size throughout the length of the ventricle.  From the output produced, 
left ventricular diameters in diastole and systole were determined, along with fractional 
shortening.  
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3.6.3. Results 
Figure 3.6 depicts the change in fractional shortening over time for each section of the heart 
and for each of the 4 groups. No significant trends are observed with either time or treatment. 
Figure 3.7 depicts the change in left-ventricle end diastolic (LVED) area. For the overall 4 
week period, a significant increase in LVED area is observed only in the mid section of the 
V/IR group when compared to the V/Sham group. Figure 3.8 depicts the change in left-
ventricle end systolic (LVES) area. For the overall 4 week period, a significant increase in 
LVES area is observed in the base section of the heart for the V/IR group compared to the 
V/Sham group, and in the mid and apex sections for the V/IR group when compared to all 
other groups. This significant difference between the V/IR group and the SCN/IR group is 
consistent with a protective effect of the elevated SCN- levels.  
3.6.4. Conclusion 
An increase in LVED and LVES area is detrimental and is associated with worse prognostic 
outcomes, as this is known to be associated with heart failure [324,325]. An increase in the 
LVED area was observed in the mid section of the heart for the V/IR group, and an increase 
in the LVES area was also observed in the same group at all regions of the heart. Conversely, 
the SCN/IR group shows no significant differences compared to the control groups. It can 
therefore be concluded that elevated SCN- affords protection against ventricle chamber 
dilatation, and thus protects against heart failure in the wake of MI/IR injury over the 4 week 
period examined. 
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Figure 3.6-  Fractional shortening over the base (A), mid (B), and apex (C) sections from 
pre-surgery to 4 weeks post. The red symbols and lines represents the V/Sham group (n = 8), 
the blue symbols and lines represents the V/IR group (n = 6), the pink symbols and lines 
represents the SCN/Sham (n = 8) group, and the green symbols and lines represents the 
SCN/IR group (n = 7).  Using a two-way ANOVA and Tukey’s Multiple Comparison Test, 
no significant differences were observed between any of the groups. 
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Figure 3.7- Left-ventricle end diastolic (LVED) area over the base (A), mid (B), and apex (C) 
sections from pre-surgery to 4 weeks post. The red symbols and lines represents the V/Sham group 
(n = 8), the blue symbols and lines represents the V/IR group (n = 6), the pink symbols and lines 
represents the SCN/Sham group (n = 8), and the green symbols and lines represents the SCN/IR 
group (n = 7).  Using a two-way ANOVA and Tukey’s Multiple Comparison Test, a significant 
overall difference was observed in the mid section for the V/IR group when compared to the other 
groups (where *=p<0.05). 
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Figure 3.8- Left-ventricle end systolic (LVES) area over the base (A), mid (B), and apex (C) 
sections from pre-surgery to 4 weeks post. The red symbols and lines represents the V/Sham group 
(n = 8), the blue symbols and lines represents the V/IR group (n = 7), the pink symbols and lines 
represents the SCN/Sham group (n = 8), and the green symbols and lines represents the SCN/IR 
group (n = 6).  Using a two-way ANOVA and Tukey’s Multiple Comparison Test, a significant 
overall difference was observed across all sections of the heart for the V/IR group when compared 
to the other groups (where *=p<0.05, and **=p<0.01). 
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3.7.  Serum analyses 
3.7.1. Introduction 
Molecular biomarkers are a powerful tool in disease diagnosis and prognosis, and as such 
several circulating biomarkers of heart failure and inflammation were investigated in this 
study. 
Atrial natriuretic peptide (ANP) is typically produced in the left and right atrium and 
released in direct proportion to increased atrial stretch, intravascular volume expansion, and 
heart rate. The serum concentration of ANP can therefore change rapidly in response to acute 
alterations in posture, volume loading, or tachycardia, and elevated levels of circulating ANP 
are a well-established biomarker of heart failure [326]. The therapeutic use of recombinant 
human ANP for heart failure has also been trialled [327].  
Brain natriuretic peptide (BNP) is primarily produced by ventricles subject to chronic 
pressure or volume overloads, and is stored to a much lesser extent than ANP. In contrast to 
ANP, increased secretion of BNP is preceded by an increase at the transcription level and a 
longer-term stimulus of increased ventricular wall tension, hypertrophy, or myocardial 
dysfunction is required to increase serum BNP concentrations. BNP is a well-known 
biomarker of heart failure [326], and has been trialled clinically as a treatment for heart 
failure, but it’s benefit has been questioned [328]. 
Galectin-3 is a protein secreted by macrophages which plays an important regulatory 
role in cardiac fibrosis and remodelling due to its collagen crosslinking properties [329]. 
Previous studies have shown that genetic disruption (knock-out mouse models) and 
pharmacological inhibition of galectin-3 reduces cardiac fibrosis and LV dysfunction, which 
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subsequently lessens the development of heart failure [330]. As a result of these observations, 
galectin-3 has become a useful biomarker of fibrosis and heart failure [331,332]. 
C-reactive protein (CRP) is a non-specific acute-phase protein, the levels of which are 
elevated in response to inflammation, infection, and tissue damage. Transcriptional regulation 
of CRP is predominantly controlled by IL-6. CRP has been widely associated with 
cardiovascular diseases, including atherosclerosis and myocardial infarction [333]. Due to its 
broad range of antagonists, the main clinical relevance of CRP is as a highly sensitive 
biomarker of inflammation [334].  
3.7.2. Methods 
ANP, BNP, CRP, and galectin-3 were quantified in the serum samples obtained from all of 
the different groups at both 24 hours and 4 weeks post IR using commercial kits in 
accordance with the manufacturer’s instructions, as described in section 2.7.3. Statistical 
analysis was carried out by using two-tailed t tests with Welch’s correction. 
3.7.3. Results 
 Atrial natriuretic peptide 
Figure 3.9 depicts the serum ANP levels across the 4 treatment groups at both 24 hours and 4 
weeks post-surgery. At 24 hours post-surgery, the V/Sham and SCN/Sham rats had elevated 
ANP levels compared to their IR counterparts, although this increase was not statistically 
significant. At 4 weeks post-surgery, the V/IR group had elevated circulating ANP levels 
compared to all other groups. However, this too failed to reach statistical significance. 
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 Brain natriuretic peptide 
Figure 3.10 depicts the serum BNP levels across the 4 treatment groups at both 24 hours and 
4 weeks post-surgery. At 24 hours post-surgery, the V/Sham and SCN/Sham rats had 
elevated, but not statistically significantly, BNP levels compared to their IR counterparts, in a 
similar manner to that seen with ANP. At 4 weeks post-surgery, the V/IR group had elevated 
circulating BNP levels compared to all other groups, but this was not statistically significant. 
 Galectin-3 
V/S h a m V/IR S C N /S h a m S C N /IR
0
5 0 0
1 0 0 0
1 5 0 0
S
e
r
u
m
 B
N
P
 (
p
g
/m
L
)
Figure 3.10- Serum BNP (pg/mL) concentrations at 24 hours (n = 7, 8, 8, 6 respectively) and 4 
weeks post-surgery (n = 8, 8, 8, 8 respectively). Two-tailed t tests with Welch’s correction indicated 
no significant differences between any of the groups. 
Figure 3.9- Serum ANP (pg/mL) concentrations at 24 hours (n = 7, 8, 8, 6 respectively) and 4 
weeks (n = 8, 8, 8, 8 respectively)  post-surgery. Two-tailed t tests with Welch’s correction 
indicated no significant differences between any of the groups. 
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Figure 3.11 depicts the serum galectin-3 levels across the 4 treatment groups at both 24 hours 
and 4 weeks post-surgery. At 24 hours post-surgery, the V/IR and SCN/IR rats had elevated 
galectin-3 levels compared to their sham counterparts, with the V/IR group clearly having the 
greatest abundance. However, these differences are not statistically significant. At 4 weeks 
post-surgery, the galectin-3 levels appear to level out across all groups, with no statistically 
significant differences detected. 
 
 
 C-reactive protein 
Figure 3.12 depicts the serum CRP levels across the 4 treatment groups at both 24 hours and 
4 weeks post-surgery. No statistically significant differences were detected in CRP across the 
groups at either time point. 
 
Figure 3.11- Serum galectin-3 (ng/mL) concentrations at 24 hours (n = 7, 8, 8, 6 respectively)  and 
4 weeks (n = 8, 8, 8, 8 respectively)  post-surgery. Two-tailed t tests with Welch’s correction 
indicated no significant differences between any of the groups. 
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3.7.4. Conclusion 
No significant differences in serum ANP, BNP, galectin-3, or CRP were observed with either 
NaSCN treatment or IR surgery at both 24 hours and 4 weeks after surgery. 
 
3.8. Metabolomics 
3.8.1. Introduction 
While much is known about the direct physiologic changes that occur as a result of MI and 
IR [335-338], rafts of changes are also expected to occur in metabolic pathways, though these 
have been explored to a lesser extent than direct tissue damage [339,340]. Metabolomics is 
the systematic study of unique chemical fingerprints that cells leave behind in a wide range of 
biofluids [341]. Global metabolic profiling involves measuring and quantifying multiple 
small molecules in urine, blood derivatives, tissue extracts and other human or animal 
biofluids. It allows for a broad overview of changes that can occur in numerous metabolic 
and signalling pathways, and their interactions [342-344]. Over the past decade, advances in 
Figure 3.12- Serum CRP (µg/mL) concentrations at 24 hours (n = 7, 8, 8, 6 respectively) and 4 
weeks (n = 8, 8, 8, 8 respectively)  post-surgery. Two-tailed t tests with Welch’s correction 
indicated no significant differences between any of the groups. 
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high-throughput analysis, curation, and statistical analysis have allowed researchers to 
understand alterations in cellular and tissue metabolism arising from metabolomic analyses. 
 Physiological regulation is based on the concept that the body is constantly adapting 
itself towards a stable biochemical and physiological condition [345]. Allostasis is the 
extension of this model to take an opposed view that biochemical and physiological 
parameters fluctuate with respect to complex physical, environmental or stress conditions 
[346]. The studies reported in this section aimed to describe the changes in the serum 
metabolome in rats preconditioned with SCN- after IR surgery compared with both vehicle 
fed and sham operated controls, and identify the metabolomic changes that occur in the 
serum of rats as a result of IR injury.  
3.8.2. Methods 
Metabolomic analysis was undertaken as described in section 2.8 in collaboration with Dr 
Anthony Dona, and using the NMR Facility of the School of Chemistry at The University of 
Sydney. 
3.8.3. Results 
 24 hours 
Figure 3.13 depicts the representative NMR spectra for serum samples of the four treatment 
groups at 24 hours post IR surgery. Spectral peaks were assigned to particular species using 
the Chenomx NMR Suite 8.1 as detailed in section 2.8.5. A list of these identified 1H NMR 
detected metabolites, their assigned chemical shifts (ppm), and average fold changes with 
treatment at 24 hours are detailed in Table 3.1. 
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Metabolite Chemical 
Shift 
(ppm) 
Average Fold Change 
at 24 hours V/Sham 
vs V/IR 
Average Fold Change at 
24 hours SCN/Sham vs 
SCN/IR 
Average Fold Change 
at 24 hours V/IR vs 
SCN/IR 
Formate 8.52 0.95 1.41 1.02 
Cytidine 7.80 0.93 0.97 0.96 
Methylhistidine 7.74 0.88 1.08 0.95 
Histidine 7.71 0.98 1.07 1.08 
Phenylalanine 7.40 0.82 1.09 0.94 
Tyrosine 7.17 0.89 1.05 0.96 
Lactate 4.11 1.01 1.01 1.11 
Isoleucine 3.65 0.95 0.99 0.99 
Creatinine/creatinine 
phosphate 
3.03 0.94 1.13 0.95 
Creatine 3.00 0.95 1.08 0.95 
Trimethylamine 2.91 1.02 1.06 1.00 
Methylguanidine 2.81 1.08 1.07 0.97 
Methionine 2.64 0.95 1.07 0.98 
Glutamine 2.46 0.98 1.15 1.00 
Acetoacetate 2.22 1.18 0.84 1.05 
Acetyl Groups (1) 2.13 0.96 1.07 0.98 
Acetyl Groups (2) 2.06 1.01 1.02 1.03 
Acetate 1.91 0.83 0.89 0.95 
Leucine 1.72 0.95 1.09 0.97 
Lipids (VLDL) 1.57 1.23 0.82 1.04 
Alanine 1.47 0.98 1.08 1.04 
Hydroxyisobutyrate 1.08 1.02 1.03 0.99 
Valine 1.03 0.90 1.02 0.99 
Lipids (LDL) 0.87 1.04 0.96 1.00 
Table 3.1- Concentrations of major endogenous metabolites quantified in rat serum by 1H-
NMR, and their change in expression in V/IR and SCN/IR rats at 24 hours following surgery 
(n = 7, 9, 6, 10 respectively). Significant differences between groups were determined by 
two-tailed t tests with Welch’s correction, and are indicated in bold and italicised. 
  
Figure 3.14 depicts the data presented in Table 3.1 in the form of a heat map, where 
red indicates elevated levels, and blue represents reduced levels, of metabolites relative to 
respective controls. 
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 Statistically significant fold reductions in several metabolites were detected for the 
V/IR group relative to V/Sham at 24 hours post-surgery. Thus, phenylalanine (7.40 ppm) had 
a fold change of 0.82, acetate (1.91 ppm) had a fold change of 0.83, and valine (1.03 ppm) 
had a fold change of 0.90. In contrast, the SCN/IR group only showed a statistically 
significant fold increase relative to the SCN/Sham control at 24 hours post-surgery, in regard 
to glutamine (2.46 ppm) levels, which had a fold change of 1.15. No significant differences in 
metabolite expression were observed between the SCN/IR and V/IR groups. 
 4 weeks 
Figure 3.15 depicts the representative NMR spectra for serum samples of the four treatment 
groups at 4 weeks post IR surgery. Spectral peaks were assigned to particular species using 
the Chenomx NMR Suite 8.1 as detailed in section 2.8.5. A list of these identified 1H NMR 
detected metabolites, their assigned chemical shifts (ppm), and average fold changes with 
treatment at 4 weeks are detailed in Table 3.2.  
Figure 3.16 depicts the data presented in Table 3.2 in the form of a heat map, where 
red indicates elevated levels, and blue represents reduced levels of metabolites, relative to the 
respective controls. The only statistically significant fold reductions are seen in the VIR 
group relative to V/Sham at 4 weeks post-surgery. Creatinine/creatinine phosphate (3.03 ppm) 
had a fold change of 0.85, creatine (3.00ppm) had a fold change of 0.82, trimethylamine 
(2.91 ppm) had a fold change of 0.88, and leucine (1.72 ppm) had a fold change of 0.89. In 
contrast, the SCN/IR group showed no statistically significant fold changes relative to the 
SCN/Sham control at 4 weeks post-surgery. No significant differences in metabolite 
expression were observed between the SCN/IR and V/IR groups. 
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Metabolite Chemical 
Shift 
(ppm) 
Average Fold Change 
at 4 weeks V/Sham vs 
V/IR 
Average Fold Change 
at 4 weeks SCN/Sham 
vs SCN/IR 
Average Fold 
Change at 24 hours 
V/IR vs SCN/IR 
Formate 8.52 0.76 1.00 0.84 
Cytidine 7.80 0.85 0.93 0.91 
Methylhistidine 7.74 0.94 0.86 1.02 
Histidine 7.71 0.84 0.82 0.97 
Phenylalanine 7.40 0.99 0.96 1.02 
Tyrosine 7.17 0.82 0.92 0.90 
Lactate 4.11 1.05 1.05 1.07 
Isoleucine 3.65 0.96 0.92 1.08 
Creatinine/creatinine 
phosphate 
3.03 0.85 0.90 0.90 
Creatine 3.00 0.82 0.88 0.91 
Trimethylamine 2.91 0.88 0.98 0.92 
Methylguanidine 2.81 1.01 0.96 1.05 
Methionine 2.64 0.95 0.97 0.97 
Glutamine 2.46 0.91 0.95 0.94 
Acetoacetate 2.22 1.08 1.16 0.96 
Acetyl Groups (1) 2.13 0.92 0.95 0.93 
Acetyl Groups (2) 2.06 0.95 0.98 0.95 
Acetate 1.91 1.26 0.96 1.09 
Leucine 1.72 0.89 0.90 0.95 
Lipids (VLDL) 1.57 1.08 1.17 0.96 
Alanine 1.47 0.94 0.92 0.95 
Hydroxyisobutyrate 1.08 1.00 0.93 1.02 
Valine 1.03 0.99 0.98 1.00 
Lipids (LDL) 0.87 1.02 1.05 0.97 
Table 3.2- Concentrations of major endogenous metabolites quantified in rat serum by 1H-
NMR, and their change in expression in V/IR and SCN/IR rats at 4 weeks following surgery 
(n = 8, 5, 8, 4 respectively). Significant differences between groups were determined by two-
tailed t tests with Welch’s correction, and are indicated in bold and italicised. 
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3.8.4. Conclusion 
A number of significant differences were observed between the V/IR group and the control 
V/Sham group while only a single difference was seen between the SCN/IR and SCN/Sham 
groups. At 24 hours post-surgery, a 0.82 fold change in phenylalanine, a 0.83 fold change in 
acetate, and a 0.90 fold change in valine were observed in the V/IR group when compared to 
the V/Sham. The only significant change in the SCN/IR group compared to the SCN/Sham 
was a 1.15 fold change in glutamine. At 4 weeks post-surgery, creatinine/creatinine 
phosphate had a 0.85 fold change, creatine had a 0.82 fold change, trimethylamine had a 0.88 
fold change, and leucine had a 0.89 fold change in the V/IR group when compared to the 
V/Sham. No significant changes were observed in the SCN/IR group compared to the 
SCN/Sham at this time point. 
No direct significant differences in metabolite expression were detected between the 
V/IR and SCN/IR groups, despite the differences detected between these groups and their 
respective controls. This may be due to the smaller sample sizes of the V/IR and SCN/IR 
groups; when they are compared to each other there is not enough statistical power to detect 
the differences that are seen when compared to the larger sample size control groups. 
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3.9. Discussion 
As outlined in the introduction to this chapter, the increased migration and infiltration of 
neutrophils into ischemic tissue is believed to play an important role in the pathophysiology 
of myocardial IR injury [347]. Previous studies have used MPO as a marker for neutrophil 
infiltration into various ischemic tissues, and thus greater MPO levels and activity have been 
reported to be present in IR tissue [348,349]. MPO itself has been shown to be a mediator of 
neutrophil recruitment because of its positive electrostatic surface charge [350]. Additionally, 
in a renal model of IR injury, it has been shown that MPO-/- mice have improved renal 
function and reduced neutrophil influx compared with wild-type controls 24 hours after IR 
challenge [351]. The apparent important contribution of MPO to the resulting organ damage 
after renal IR is also likely to be applicable to other tissues, including the myocardium. MPO-
dependent structural remodelling of the ventricle wall has been demonstrated to translate into 
increased electrical instability, and thus a greater vulnerability to atrial fibrillation [352]. As 
such, manipulating the levels of MPO, and the concentration and type of oxidants it generates, 
may be a potential therapeutic strategy to reduce IR injury.  
Modulation of MPO activity has been investigated in a number of different ways. 
Decreasing O2·
- and H2O2 levels, which are key substrates for the enzymes halogenation and 
peroxidase cycles, would be a means of decreasing MPO activity, but this is unlikely to be a 
viable therapeutic approach due to the crucial role that these species, and the processes and 
enzymes that generate them (such as mitochondria and NADPH oxidases) play in other 
cellular processes. An inhibitor could however block formation of compound I of MPO by 
preventing the entrance of H2O2 or its binding and reduction at the MPO active site. In this 
way both the halogenation and peroxidase cycles of the enzyme would be inhibited [353]. 
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Thus, MPO ligands could be used to bind to the distal heme cavity which is required to be 
free for the entrance and binding of H2O2 [354]. However, irreversible MPO inhibitors are 
unfavourable due to the concern that global MPO knockdown may impact in a negative 
manner on the host innate immune response, due to the critical role MPO plays in that system 
[157]. Therefore, MPO inhibitors are generally classified into three main categories: 
promoters of the accumulation of compound II, suicide substrates, and reversible inhibitors 
[355]. Inhibitors that cause accumulation of compound II favour the peroxidase cycle over 
the halogenation cycle and thus divert the enzyme away from the generation of damaging 2-
electron oxidants, such as HOCl. Such substrates include nitroxides [225] and paracetamol 
[356].  
The oxidation of suicide substrates, such as 4-aminobenzoic acid hydrazide [227] and 
2-thioxanthines [357], by MPO results in the inactivation of the enzyme by either destruction 
or covalent modification of the MPO’s heme prosthetic groups [355]. Reversible inhibitors 
compete with native MPO substrates by occupying the heme binding pocket. This is possibly 
the most attractive means of inhibition, as this would simply block MPO’s oxidising 
capability without permanently altering the enzyme. However, the efficacy of such inhibitors 
is problematic as one such reversible inhibitor, salicylhydroxamic acid, has been shown to 
perform poorly in MPO inhibition assays when compared to suicide substrates such as 
benzoic acid hydrazides [226,358]. While these three types of substrate each show some 
promise, they each fall down for one reason or another with a view to clinical applications, 
and the development of better MPO inhibitors is ongoing [359,360]. 
Manipulating the generation, and therefore product ratios, of MPO-derived oxidants 
by altering the halide substrate levels may also represent a potential approach. As it is not 
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possible to alter the very high millimolar levels of Cl- seen physiologically (typically 100-140 
mM), increasing the normal micromolar levels of SCN- is a potentially attractive tactic. In a 
retrospective study investigating all-cause mortality over a 12-year period in subjects who 
survived a first myocardial infarction, elevated plasma MPO levels were found to be 
associated with increased mortality, as also seen in multiple other studies [158,191,361]. 
However, subjects with high levels of plasma SCN- also had a greater survival rate than those 
with low levels, and the overall greatest survival rate was seen in subjects with low plasma 
MPO and high SCN- levels [245]. While low MPO levels will result in a diminished MPO-
derived oxidant yield, the significant elevation in plasma SCN- levels in these subjects would 
also be predicted to modify the proportions of oxidants produced by MPO, with greater 
generation of the thiol-specific oxidant HOSCN, and decreased formation of the more 
reactive, and less specific, HOCl [114]. Unlike HOSCN-mediated damage, which is largely 
reversible, HOCl generates higher yields of non-repairable oxidation [243]. Thus, elevated 
plasma SCN- levels were hypothesised in this study to be potentially capable of inhibiting 
myocardial IR injury.  
This study aimed to identify whether preconditioning rats with oral supplementation 
of SCN- could protect against IR injury, and was assessed through several means. Oral 
treatment of Sprague Dawley rats with 10 mM NaSCN in their drinking water was shown to 
significantly increase serum SCN- levels by almost double, and this resulted in a reduction in 
infarct area by 20 % at 24 hours after reperfusion. In addition, the left ventricle dilatation that 
developed in the V/IR rats over the 4 week recovery period was absent in the SCN/IR group. 
While there was no effect of elevated serum SCN- on circulating biomarkers of heart failure 
and circulation, limited changes were detected in the serum metabolome in the V/IR rats 
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following reperfusion that were not detected in the SCN/IR group. Therefore, these data 
suggest, overall, that elevated serum levels of SCN- have a cardioprotective effect in the 
context of myocardial IR injury. 
 The 1 week 10 mM NaSCN preconditioning protocol was shown to be successful in 
significantly raising serum SCN- levels. Due to experimental constraints, which prevented 
blood sampling at the time of surgery, these measurements were taken 24 hours after SCN- 
treatment had ceased, and therefore the serum concentrations of SCN- in the treated animals 
would be expected to have decreased to some extent, as the serum half-life of SCN- is 
approximately 3 days [323]. Thus, at the time of surgery, the serum SCN- levels would be 
expected to have been greater. The 10 mM NaSCN in water dosing protocol used in this 
study has also been previously utilised in other rat models, achieving a 150 % increase in 
plasma SCN- levels in Hooded Wistar and Dark Agouti rats [284]. While a similar % increase 
was seen in this study (159 %, despite the quantification occurring 24 hours after cessation of 
dosing) the absolute levels of SCN- detected in both the controls and NaSCN treated rats was 
significantly less in the current study. There are several possible reasons for this discrepancy, 
including variation in SCN- metabolism between rat strains, differences in the SCN- content 
of the feed, and differences in SCN- detection protocols.  
 Numerous previous studies have investigated the effects of preconditioning protocols 
on a subsequent MI challenge [316,362-365].  The most well-known preconditioning 
protocol is perhaps ischemic preconditioning. Ischemic preconditioning relates to the ability 
of short bouts of ischemia to make the myocardium more resistant to a subsequent ischemic 
challenge. This was first demonstrated in a canine model, where 4 consecutive periods of 
coronary occlusion of 5 minutes, each separated by 5 min of reperfusion, were capable of 
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reducing the infarct size caused by a subsequent period of occlusion of 40 minutes by as 
much as 75 % [366]. This effect has since been demonstrated in several different animal 
species as well as with isolated human cardiomyocytes subjected to hypoxia and 
reoxygenation cycles [364,367]. Since this effect was discovered, numerous studies have 
subsequently attempted to replicate the cardioprotective effect observed with ischemic 
preconditioning through pharmacological means [362,363,365,368], as this could potentially 
represent a cardioprotective therapy for individuals at risk of MI. The preconditioning 
protocol using 10 mM NaSCN used in this study has provided evidence of protection in rats 
against MI induced IR injury. A significant 20 % reduction in infarct size was detected, and 
therefore a significant increase in salvageable area was also observed, indicating a lesser 
degree of permanent and irreparable damage occurring in the SCN- supplemented hearts 
compared to the control group. This finding supports the hypothesis that increasing 
SCN- levels can reduce the production of the irreparable damage induced by HOCl. The 
neutrophil infiltration and accumulation into the myocardium that occurs upon reperfusion 
also results in a higher concentration of MPO in myocardial tissue than is normally present 
[80]. Therefore, by elevating SCN- levels to create an environment more favourable for 
HOSCN production, at the expense of HOCl, this is likely to result in reduced damage, as has 
been demonstrated in this study. 
 An increase in LVED and LVES area is known to be associated with heart failure. 
This is due, in the wake of MI, to myocardial necrosis in the infarct zone which results in 
disproportionate thinning of the myocardium at the site of infarction. The weakened region of 
the wall is unable to withstand the pressure and volume load on the ventricle in the same 
manner as a healthy ventricle. As a result, there is dilatation of the ventricle chamber in the 
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area surrounding the infarct region. Initial remodelling after MI appears to represent an  
attempt to repair the salvageable area. However, additional remodelling over time may 
become pathological, resulting in the ventricle becoming less elliptical and more spherical. 
As ventricular mass and volume increase, cardiac function is adversely affected. Eventually, 
diastolic function may become impaired, resulting in heart failure [324,325]. This 
phenomenon was observed in the V/IR group, examined here, as an increase in LVED and 
LVES area. This change was not seen in the SCN/IR group, supporting a cardioprotective 
effect of SCN-. The SCN/IR group had a significantly reduced infarct region, and thus less of 
the myocardial wall appears to be subjected to damage. As a result, the adverse ventricle 
chamber dilatation that was observed in the V/IR group may be absent in the SCN/IR group. 
This degree of protection appears to be sufficient enough to save the SCN/IR heart from the 
pathological ventricular remodelling seen in the V/IR group. However, this should be 
confirmed by histological analyses.  
It is somewhat surprising that none of the serum biomarkers of heart failure and 
inflammation measured in this study, ANP, BNP, galectin-3, nor CRP, were significantly 
elevated in IR animals. This may be indicative of several different possibilities. The first 
being that there is an effect of SCN- on systemic inflammation following IR injury, but the 
time points used in this study are not appropriate to observe this effect. A second possibility 
is that SCN- is having a tissue specific effect, inhibiting inflammation in the myocardium 
(where high levels of MPO and oxidants may be present) but not systemically. While the 
inflammatory response triggered by a myocardial infarction is essential for repair, if it is not 
repressed in a timely manner it can result in pathological remodelling of the myocardium and 
subsequent heart failure [369]. If the SCN- treatment is specifically dampening myocardial 
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inflammation, this would be seen as a positive effect. A third possibility could be the effect is 
diluted out in larger volumes of blood/plasma. Finally, the absence of serum biomarkers of 
heart failure and inflammation may be due to the damage experienced in the sham controls. 
Ideally, sham surgery would result in no adverse effects, allowing only the effects of MI/IR 
injury to be observed in the absence of any confounding factors associated with the surgery. 
While several studies have reported that no inflammatory response was found in sham 
animals when compared to IR animals [370,371], given the highly invasive nature of sham 
surgery it is plausible that the surgery could result in some inflammatory response 
independent of the MI/IR injury challenge, and therefore resulting in non-significant changes.  
 The changes in cardiac metabolism that occur in the wake of myocardial infarction, 
and the causes and effects of these changes, have not yet been clearly elucidated. However, 
for some time now, it has been known that there is increased catabolism following acute 
myocardial infarction [372]. Studies carried out over the past 20 years have suggested that 
myocardial substrate selection remains relatively normal in the early stages of heart failure, 
but that in later stages there is a downregulation in fatty acid oxidation, increased glucose 
oxidation and glycolysis, reduced respiratory chain activity, and an impaired reserve for 
mitochondrial oxidative flux [373]. The heart also requires a high rate of ATP production and 
turnover to maintain its continuous function, therefore perturbations in ATP-generating 
processes would be expected to directly affect contractile function [374].  
 In the current study, 24 hours after the IR injury challenge, a significant reduction was 
seen in the serum levels of phenylalanine, acetate and valine in the V/IR group compared to 
its control, while a significant increase in glutamine was seen in the SCN/IR group compared 
to its control group. At 4 weeks post IR surgery, a significant reduction was seen in the serum 
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levels of creatine, the creatinine / creatinine phosphate ratio, trimethylamine, and leucine in 
the V/IR group compared to its control, while no significant changes were seen in the 
SCN/IR group compared to its control group. Given that it is already known that there is 
increased catabolism following acute myocardial infarction [372], it is not surprising to see 
reductions in metabolites following IR.  The increase seen in glutamine levels in the SCN- 
treated animals 24 hours after IR surgery is therefore surprising. This may reflect changes in 
metabolic processes, as glutamine plays a key role in cell metabolism [375].   
Of all the metabolites that showed a significant decrease in the V/IR group but not the 
SCN/IR group, the impact of the reduction in creatine may have the greatest effect on the 
post MI/IR injury heart. Previous studies have suggested that the failing myocardium suffers 
from a significant reduction in total creatine [376,377]. However, the precise cellular 
mechanisms by which alterations to high-energy phosphate levels may compromise cardiac 
energy metabolism and contractility are not well understood [378]. Creatine is not 
synthesized by cardiomyocytes, but is taken up into the myocardium from serum via the 
action of a specific Cl−- and Na+-dependent creatine cotransporter, which has also been found 
to be down regulated in heart failure [376]. This decrease in creatine levels, along with 
diminished creatine kinase activity combine to limit energy reserves in the failing heart [379]. 
A physiological consequence of a decreased capacity for phosphoryl transfer via creatine 
kinase, is an increased cost of mechanical work and decreased contractile reserve, rendering 
the heart muscle more susceptible to ischemic injury [379,380]. This has been demonstrated 
in otherwise normal rat hearts, in which either creatine kinase activity or creatine levels were 
decreased [381]. While it is not completely clear how or why alterations occur in creatine 
levels in the post IR injury heart, the finding of this study of reduced creatine and creatinine 
  
 
121 
 
 
(/phosphate) levels at 4 weeks post IR surgery is in accordance with this hypothesis. However, 
as this has not been noted before, caution should be taken in the interpretation of these data.  
The numerous changes that occur in the V/IR metabolome are absent in that of the 
SCN/IR group. This is therefore suggestive of a protective effect of SCN- on the metabolic 
profile, which potentially gives some insight into the possible mechanisms by which SCN- is 
conveying its protection. Overall, the metabolomic model developed in this study can in 
theory be extended into the human phenotype to understand the response to the physiological 
stress of IR injury, how SCN- preconditioning may affect this at a metabolic level, and to 
holistically better understand the adaptive metabolic processes that occur in the circulatory 
system. 
3.10.  Conclusions 
The oral preconditioning of Sprague Dawley rats with 10 mM NaSCN for one week was 
sufficient to significantly elevate serum SCN- levels. Using MRI, a 20% decrease in infarct 
area was observed in NaSCN preconditioned rats on induction of MI with subsequent 
reperfusion. Cardiac function, determined by echocardiography, was shown to be protected 
against pathological ventricular remodelling. However, no statistically significant differences 
were observed in serum levels of ANP, BNP, CRP, and galectin-3. At a metabolic level, 
SCN- preconditioning protected against the reduction of a number of metabolites at 24 hours 
and 4 weeks, indicating that SCN- treatment may also protect against metabolic insult, as well 
as allow for a more rapid recovery of metabolic homeostasis. These results suggest that 
preconditioning with oral SCN- does indeed protect against damage arising from an acute 
myocardial IR injury in this rat model, and may therefore present itself as a potential 
therapeutic agent for at risk individuals.  
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Chapter 4 
Investigation of the potential protective effects of 
thiocyanate in a murine model of atherosclerosis 
4.1. Introduction 
Atherosclerosis is a progressive vascular disorder leading to numerous cardiovascular 
pathologies, and still remains the principal cause of mortality and morbidity in the world. The 
pathogenesis of atherosclerosis involves a number of different stages. 
 While it was initially believed that neutrophils, and other sources of MPO, only 
played a marginal role in atherosclerosis, this view has now changed [382]. All stages of 
atherosclerotic lesions are characterised by the presence of active MPO, which is released by 
neutrophils, monocytes, and possibly tissue macrophages. MPO is present in the lesion intima, 
both intra- and extracellularly. Markers of MPO mediated damage, including material 
recognised by the antibody 2D10G9 [383], 3-ClTyr [195], and chlorinated nucleobases [384] 
are also present in human lesions at elevated levels compared to normal healthy tissue. All 
this evidence supports a role of MPO in atherosclerosis [99].  
 The developmental process of atheromatous lesions is referred to as atherogenesis. 
The early stages of atherogenesis are known to require recruitment of monocytes, and their 
ultimate differentiation into macrophages [60,61]. Once recruited to the arterial intima, 
monocytes mature into macrophages. Macrophages are known to express a number of 
scavenger receptors which bind to modified forms of LDL [68]. The modified LDL is then 
internalised and the lipid from these particles accumulates intracellularly as cytoplasmic 
droplets. Lipid-laden macrophages undergo several alterations, including taking on a foamy 
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appearance when viewed under a microscope, hence the terminology “foam cell”. Foam cells 
amplify the local inflammatory signals of the lesion site through the production of reactive 
oxygen species (ROS), pro-inflammatory cytokines, and tissue-damaging proteins (such as 
matrix metalloproteinases (MMPs)). Clusters of foam cells form fatty streaks and represent 
the next stage in the progression of atherogenesis: the formation of complex atherosclerotic 
lesions [68]. 
 The same cytokines that promote the development of atherogenesis are also capable 
of regulating cell death. As a result, in advanced lesions a necrotic core develops within the 
atheroma. This occurs due to a combination of oncosis and apoptosis, the extent of which 
increases with the progression of atherosclerosis [70]. The death of smooth muscle cells 
(SMCs) within the plaque is especially significant as they provide much of the interstitial 
collagen that strengthens the fibrous cap of the plaque. Therefore, increased apoptosis and 
necrosis of SMCs contributes to plaque destabilisation [71,72]. High concentrations of 
cholesterol within the plaque may also crystallise, forming cholesterol clefts [385].  
As has been detailed previously, the MPO system, and particularly the MPO-derived 
oxidant HOCl, are potentially damaging when produced at inappropriate times, locations, and 
concentrations. This includes in the context of cardiovascular disease. We have hypothesised 
that by increasing the concentrations of the preferred MPO substrate SCN-, thus 
outcompeting Cl- and therefore decreasing the degree of highly damaging HOCl formation in 
favour of the less damaging HOSCN, less damage will occur, or will occur more slowly, and 
therefore the development of atherosclerosis may be suppressed.  
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4.2. Aims 
The aim of this study was to determine whether supplementing ApoE-/- mice with oral SCN- 
can suppress atherosclerosis associated systemic inflammation, and also to examine if SCN- 
supplementation attenuates atherosclerotic plaque development in obesity-associated 
atherosclerosis.  
4.3.  Animal model design 
3 week old male ApoE-/- mice were acclimatised for 1 week before starting on high-fat diets 
supplemented with either regular drinking water or 2.5 or 10 mM NaSCN, as outlined in 
section 2.5. Both food and water were available ad libitum. Animals were maintained for 
either 4, 8, or 18 weeks with regular monitoring and body mass checks. Figure 4.1 depicts a 
schematic of the experimental design. At the end of the experimental time course, animals 
were sacrificed, and blood and tissue samples were taken for analysis.  
Figure 4.1- Animal model schematic. The animal study consisted of 108 ApoE-/- mice. The mice 
were split into 3 groups of 36, one for each of the time points (4, 8, and 18 weeks). Each group was 
then subdivided again to give the three treatment groups (water, 2.5 mM NaSCN, or 10 mM 
NaSCN) consisting of 12 animals each. 
Early Disease 
Intermediate Disease 
Late Disease 
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4.4.  Body mass 
4.4.1. Introduction 
The body mass of each mouse was closely monitored over the experimental period primarily 
as a measure of animal health. Additionally, measuring body mass can give information as to 
whether feeding supplementation is significantly impacting the animal’s diet. This is of 
importance in this study as changing regular water for water with NaSCN dissolved in it 
could impact the animal’s diet in a number of ways. The water could have an aversive taste 
and reduce drinking, or the increased salt content could potentially affect the diet. Therefore, 
this is an important measure in the context of this study as, ideally, the NaSCN supplemented 
drinking water should be having no impact on the animal’s dietary patterns, and therefore 
body mass, compared to regular drinking water. 
 Additionally, an issue that arose throughout the course of the animal husbandry in this 
study was the prevalence of ulcerative dermatitis in the ApoE-/- mice in the longer 18 week 
time course. Lesions typically began to develop around 12 weeks into the study. When 
lesions were detected, mice were separated from their littermates and wounds were treated 
with an analgesic cream containing corticosteroids. However, the vast majority of lesions 
proved unresponsive to treatment. When lesions reached a point where they were determined 
to be having a significantly detrimental impact on animal welfare (as deemed by an existing 
scoring system [386]),  the animals were euthanised.  To limit this impact, mice that were 
deemed to have only minor, or at least manageable, ulcerative dermatitis were allowed to 
complete the time course. 
  
 
126 
 
 
4.4.2. Methods 
The animal husbandry was carried out at the Heart Research Institute (Sydney, Australia) as 
outlined in Section 2.5. The body mass of each mouse was measured every week, as well as 
immediately prior to sacrifice. A two-way ANOVA with Tukey’s Multiple Comparison Test 
were used for detecting significant differences. 
4.4.3. Results 
The body mass of the mice in each of the three groups, for each of the three time points, 
increased at approximately the same rate regardless of NaSCN supplementation as exhibited 
in Figure 4.2. No significant differences were detected between any of the groups at any of 
the three time points. 
4.4.4. Conclusion 
Replacing the drinking water of ApoE-/- mice from regular water to 2.5 or 10 mM NaSCN 
dissolved in water had no significant effect on animal body mass, suggesting that SCN- 
supplementation does not impact on overall metabolism in these animals. 
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Figure 4.2- The mean body mass (g) of the ApoE-/- mice from each group during the 4 week 
(A) (n = 12, 12, 12), 8 week (B) (n = 11, 12, 12), and 18 week (C) (n = 9, 11, 12) time 
courses. The data are expressed as mean ± SEM. Using a two-way ANOVA and Tukey’s 
Multiple Comparison Test, no significant differences between groups were observed in any 
of the time courses. Error bars, when not visible, are concealed by the symbols. 
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4.5.  Plasma thiocyanate concentrations 
4.5.1. Introduction 
Mouse plasma SCN- levels were measured by ion-exchange chromatography, as it was 
crucial to determine and validate that the dosing concentrations were sufficient to 
significantly elevate plasma SCN- levels during atherosclerotic development and progression.  
4.5.2. Methods 
Plasma samples were prepared by mixing 1:1 v/v with acetonitrile before centrifugation to 
remove precipitated proteins. The supernatant was then filtered through 0.2 μm centrifuge 
filters to prepare the working sample. SCN- was measured using a Dionex ICS-2100 ion 
chromatography system as outlined in section 2.7.1. Statistical analysis was carried out using 
unpaired two way t tests with Welch’s correction. 
4.5.3. Results 
The mean serum SCN- concentrations for each treatment group at 4, 8, and 18 weeks are 
depicted in Figure 4.3. It is clear that serum SCN- levels are significantly elevated in a dose-
dependent manner. By 4 weeks it appears that plasma SCN- levels have peaked and remain 
stable, as there are no further significant changes with time. The average fold increase in 
plasma SCN- levels was 2.3 in the 2.5 mM NaSCN treatment group and 5.4 in the 10 mM 
NaSCN treatment group when compared to the control group. As SCN- treatment took place 
up until immediately before sacrifice, no decrease in plasma SCN- is likely to have occurred 
as was seen in the rat study reported in the previous Chapter (section 3.1).  
 
  
 
129 
 
 
 
4.5.4. Conclusion 
Dosages of both 2.5 and 10 mM NaSCN in drinking water are sufficient to significantly raise 
plasma SCN- levels in mice in a dose-dependent manner. This is of critical importance as 
without this result, no further results could be deemed to be due to elevated SCN- levels. The 
plasma levels of SCN- achieved in this study are comparable to those seen in moderate-heavy 
human smokers [113,114]. 
  
Figure 4.3- Mean plasma SCN- concentration (µM), as determined by ion-exchange 
chromatography, of the ApoE-/- mice from each group during the 4 week (n = 12, 12, 12), 8 
week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) time courses. The data are expressed as 
mean ± SEM. Unpaired one-tailed t tests with Welch’s correction indicated that the 2.5 mM 
and 10 mM NaSCN treatments significantly increased plasma SCN- concentrations compared 
to the control group at all time points (where *** = p < 0.001, and **** = p < 0.0001). A 
significant increase was also observed in the 10 mM NaSCN group when compared to the 2.5 
mM group at all time points (### = p < 0.001, and #### = p < 0.0001). 
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4.6. Plasma protein concentrations 
4.6.1. Introduction 
Measuring plasma protein levels is a common diagnostic test run when examining blood, 
particularly in the context of inflammation. Low levels of plasma protein, or 
hypoproteinaemia, has several causes, including malabsorption and sepsis, and results from 
either decreased production or increased protein loss. Reduced plasma protein levels decrease 
the osmotic pressure of the blood, leading to loss of fluid from blood or lymph into the 
interstitial tissues, resulting in oedema [387]. Conversely, high levels of plasma protein, or 
hyperproteinaemia, may be observed as a result of dehydration due to either inadequate water 
intake or excessive water loss. Hyperproteinaemia can also result from increased production 
of proteins associated with reactive, inflammatory processes [388]. Therefore, measuring 
plasma protein levels was important in this study as an indicator of an inflammatory disease 
state. Additionally, as NaSCN supplementation increases the intake of dietary salt, this may 
impact on blood osmolality and therefore plasma protein concentrations. Finally, differences 
in total plasma protein levels between individual animals complicates comparing the levels of 
specific marker species (such as cytokines). Therefore, by normalising specific protein 
concentrations against total protein concentrations, this may give a fairer representation of the 
true impact of treatment. 
4.6.2. Methods 
Total plasma protein levels were determined by BCA protein assay, as described in section 
2.7.2. Statistical analysis of the assay was carried out by using unpaired two way t tests with 
Welch’s correction. 
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4.6.3. Results 
Total plasma protein content remained fairly stable across all time courses, as exhibited in 
Figure 4.4. However, at 8 weeks total plasma protein levels were significantly elevated by 
approximately 1.2 fold in both the 2.5 and 10 mM NaSCN treatment groups when compared 
to the control group. Furthermore, at 18 weeks a significant dose-dependent reduction in total 
plasma protein was observed in both the 2.5 and 10 mM NaSCN treatment groups.  
4.6.4. Conclusion 
No change in total plasma protein was seen at 4 weeks with either the 2.5 or 10 mM NaSCN 
treatments. However, a significant increase in total plasma protein was seen at 8 weeks in 
both the 2.5 and 10 mM NaSCN treatments, before a dose-dependent decrease in total plasma 
protein was seen at 18 weeks. The reason for these differences is unknown, particularly the 
marked decrease in the control samples at 8 weeks. 
Figure 4.4- Mean plasma protein levels (mg/mL), as determined by BCA assay, of the ApoE-/- 
mice from each group during the 4 week (n = 12, 12, 12), 8 week (n = 11, 12, 12)and 18 week 
(n = 9, 11, 12) time courses. The data are expressed as mean ± SEM. Unpaired two-way t-tests 
with Welch’s correction indicated that the 2.5 mM and 10 mM NaSCN treatments had 
significantly elevated plasma protein levels compared to the control group at 8 weeks (where 
**** = p < 0.0001). A significant decrease was also observed in the 2.5 and 10 mM NaSCN 
groups when compared to the control group at 18 weeks (where * = p < 0.05, and ** = p < 
0.01). 
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4.7. Protein thiol concentrations 
4.7.1. Introduction 
In mammalian tissues, thiols are primarily present in the form of cysteine (Cys) residues 
present in proteins and GSH. A major role for reduced thiols present on proteins is as plasma 
antioxidants. A reduction in the concentration of reduced thiols is therefore indicative of 
increased oxidative stress, which is known to be associated with numerous inflammatory 
conditions [389]. 
 In biological systems, HOCl reacts very rapidly with Cys residues with a second order 
rate constant of ~108 M-1 s-1 [390]. Hence extensive HOCl generation would be expected to 
reduce plasma thiol levels [117]. HOSCN also targets Cys residues, however it has a much 
lower second order rate constant of ~104-105 M-1 s-1 [141]. Therefore, thiol reduction may be 
less with elevated plasma SCN-, and hence HOSCN formation. 
4.7.2. Methods 
Total plasma thiol levels were determined by DTNB assay, as described in section 2.7.3. 
Relative plasma thiol levels were calculated by dividing the total plasma thiol levels by the 
corresponding total protein levels. Statistical analysis of all assays was carried out by using 
unpaired two way t tests with Welch’s correction. 
  
  
 
133 
 
 
4.7.3. Results 
A significant increase was seen in total plasma thiols at 4 weeks for the 10 mM NaSCN 
treatment group compared to the controls with an increase of 61 % detected over the control 
animals, as exhibited in Figure 4.5 (A). This trend was also seen in the relative thiol 
Figure 4.5- Mean plasma thiol levels (µM, A) and relative thiols levels (nM thiols per mg 
total protein, B), as determined by DTNB assay, of the ApoE-/- mice from each group during 
the 4 week (n = 12, 12, 12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) time 
courses. The data are expressed as mean ± SEM. Unpaired two-way t tests with Welch’s 
correction indicated that the 10 mM NaSCN treatment had significantly elevated total and 
relative plasma thiol levels compared to the control group at 4 weeks (where ** = p < 0.01, 
and *** = p < 0.001).  
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concentrations, where the 10 mM NaSCN treatment group was observed to have significantly 
greater thiols by 58 % than the control group, as seen in Figure 4.5 (B). No significant 
differences were detected between groups at 8 and 18 weeks. 
4.7.4. Conclusion 
An increase in both total and relative plasma protein thiols was seen at 4 weeks with the 10 
mM NaSCN treatment only. No significant changes in either total or relative plasma protein 
thiols were observed at the 8 or 18 week time points. 
4.8.  Inflammatory cytokines 
4.8.1. Introduction 
Biomarkers indicate a change in expression or state of a protein that correlates with the risk 
or progression of a disease. They may be characteristic biological molecules, such as 
cytokines, that can be detected and measured in the blood or tissue.  
As discussed earlier, MPO and its derived oxidants play critical roles in the onset and 
progression of atherosclerosis. Elevation of plasma MPO levels have been reported to be an 
early biomarker of atherosclerosis and correlate positively with the incidence of obesity and 
cardiovascular disease in both children and adults [391,392]. 
TNF-α is a cytokine involved in systemic inflammation and is one of the cytokines 
that make up the acute-phase reaction. As an endogenous pyrogen, TNF-α is able to induce a 
number of multiple inflammatory pathways culminating in effects including fever and 
apoptotic cell death. TNF-α is also known to be crucially involved in the pathogenesis and 
progression of atherosclerosis [393]. TNF-α has been demonstrated to stimulate the formation 
of atherosclerotic lesions with a more advanced phenotype, with greater lesion necrosis and 
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reduced apoptosis [394]. In addition, inhibition of TNF-α in ApoE-/- knockouts has been 
shown to reduce atherosclerotic lesion size [395].  
IL-6 is secreted by T cells and macrophages to stimulate the immune response. It is an 
upstream pro-inflammatory cytokine that has a key role in the acute-phase reaction. It is also 
involved in transmitting the downstream inflammatory response associated with 
atherosclerosis [396]. Increased plasma levels of IL-6 are associated with an increase in 
lesion size in ApoE-/- mice [397], and have also been shown to contribute to plaque 
destabilisation [398]. 
MCP-1 is one of the key chemokines that regulates monocyte and macrophage 
migration and infiltration [399]. It is also a cytokine involved in the pathogenesis and 
progression of atherosclerosis. ApoE-/- mice overexpressing a murine MCP-1 transgene 
showed increased lipid staining, an increase in the amount of oxidized lipid, and increased 
immunostaining for macrophage cell surface markers [400]. Additionally, MCP-1 knockout 
mice transgenic for human apolipoprotein B have been shown to be protected from 
macrophage recruitment and atherosclerotic lesion formation, without altering lipoprotein 
metabolism [401].  
SAA is a family of apolipoproteins associated with HDL in plasma, which also 
contributes to the acute-phase reaction [402]. It is another cytokine associated with the 
pathogenesis and progression of atherosclerosis is SAA. An increase in plasma SAA has been 
shown to directly accelerate the progression of atherosclerosis in ApoE⁻/⁻ mice [403]. Even 
only a brief elevation in SAA has been shown to increase atherosclerosis as a result of greater 
LDL retention [404]. 
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4.8.2. Methods 
Plasma MPO, TNF-α, MCP-1, IL-6 and SAA were all quantified using commercial kits in 
accordance with the manufacturer’s instructions, as described in section 2.7.5. Statistical 
analysis of all assays was carried out by using unpaired two way t tests with Welch’s 
correction. 
4.8.3. Results 
 MPO 
The total amount of plasma MPO was observed to significantly decrease in the 10 mM 
NaSCN treatment group compared to the control group at 8 weeks by 25 %, as exhibited in 
Figure 4.6 (A). This trend was also observed in the relative plasma MPO concentrations. A 
significant and dose-dependent decrease in the relative plasma MPO levels was seen in both 
the 2.5 (27 % decrease) and 10 mM NaSCN (38 % decrease) treatment groups when 
compared to the control group at 8 weeks, as seen in Figure 4.6 (B). A similar trend was seen 
at 4 weeks, however this failed to reach significance.  
 TNF-α 
The total amount of plasma TNF-α was observed to strongly and significantly increase in the 
10 mM NaSCN treatment group compared to both the 2.5 mM NaSCN treatment group as 
well as the control group by 9 and 7-fold respectively at 4 weeks, as exhibited in Figure 4.7 
(A). This effect was also observed in the relative plasma TNF-α concentrations. A significant 
increase in relative plasma TNF-α levels was seen in the 10 mM NaSCN treatment group 
when compared to both the 2.5 mM treatment group and the control group at 4 weeks at the 
same fold change, as seen in Figure 4.7 (B). 
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 IL-6 
No statistically significant differences were seen in the total amount of plasma IL-6, as shown 
in Figure 4.8 (A). However, significant differences were seen in the relative plasma 
concentrations of IL-6. A significant 86-fold increase in relative plasma IL-6 levels was seen 
in both the 2.5 and 10 mM NaSCN treatment groups when compared to the control group at 8 
weeks, as seen in Figure 4.8 (B).  
 MCP-1 
No statistically significant differences were seen in either the total or relative concentrations 
of plasma MCP-1, as shown in Figure 4.9. 
 SAA 
No statistically significant differences were seen in either the total or relative concentrations 
of plasma SAA, as shown in Figure 4.10. 
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Figure 4.6- Average total plasma MPO concentrations (ng/mL, A) and relative plasma 
MPO concentrations (ng per mg total protein, B) of the ApoE-/- mice from each group 
during the 4 week (n = 12, 12, 12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) 
time courses. The data are expressed as mean ± SEM. Unpaired two-way t tests with 
Welch’s correction indicated a significant decrease in both total and relative plasma MPO 
levels at 8 weeks in the 10 mM NaSCN treatment group when compared to the control 
group (where * = p < 0.05 and **** = p < 0.0001). A significant decrease in relative 
plasma MPO was also observed at 8 weeks in the 2.5 mM NaSCN treatment group when 
compared to the control group (where *** = p < 0.001).   
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Figure 4.7- Average total plasma TNF-α concentrations (pg/mL, A) and relative plasma 
TNF-α concentrations (pg per mg total protein, B) of the ApoE-/- mice from each group 
during the 4 week (n = 12, 12, 12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) 
time courses. The data are expressed as mean ± SEM. Unpaired two-way t-test with 
Welch’s correction indicated a significant increase in both total and relative plasma TNF-
α levels at 4 weeks in the 10 mM NaSCN treatment group when compared to both the 
control group (where ** = p < 0.01), and the 2.5 mM NaSCN treatment group (where ## 
= p < 0.01).   
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Figure 4.8- Average total plasma IL-6 concentrations (pg/mL, A) and relative plasma 
IL-6 concentrations (pg per mg total protein, B) of the ApoE-/- mice from each group 
during the 4 week (n = 12, 12, 12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) 
time courses. The data are expressed as mean ± SEM. Unpaired two-way t tests with 
Welch’s correction indicated no significant differences in total plasma IL-6 at any time 
points. However, a significant increase in relative plasma IL-6 levels at 8 weeks was 
observed in both the 2.5 and 10 mM NaSCN treatment groups when compared to the 
control group (where * = p < 0.05).  
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Figure 4.9- Average total plasma MCP-1 concentrations (pg/mL, A) and relative plasma 
MCP-1 concentrations (pg per mg total protein, B) of the ApoE-/- mice from each group 
during the 4 week (n = 12, 12, 12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) 
time courses. The data are expressed as mean ± SEM. Unpaired two-way t tests with 
Welch’s correction indicated no significant differences in either total or relative plasma 
MCP-1 concentrations at any time points.  
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Figure 4.10- Average total plasma SAA concentrations (µg/mL, A) and relative plasma 
SAA concentrations (µg per mg total protein, B) of the ApoE-/- mice from each group 
during the 4 week (n = 12, 12, 12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) 
time courses. The data are expressed as mean ± SEM. Unpaired two-way t tests with 
Welch’s correction indicated no significant differences in either total or relative plasma 
SAA concentrations at any time points. 
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4.8.4. Conclusion 
Total plasma MPO levels were found to be significantly reduced by 25 % at 8 weeks in the 
10 mM NaSCN treatment group. A dose-dependent decrease in relative MPO was also seen 
at 8 weeks for the 2.5 mM NaSCN dose by 27 % and the 10 mM NaSCN dose by 38 %. This 
trend was also seen at 4 weeks, however it was not significant. A significant and marked 
increase in both total and relative plasma levels of TNF-α by 7-9-fold was observed at 4 
weeks in the 10 mM NaSCN treatment group compared to both the 2.5 mM NaSCN 
treatment group as well as the control group. Both the 2.5 and 10 mM NaSCN treatments 
were found to significantly increase relative plasma IL-6 levels by 86-fold at 8 weeks. No 
significant differences were seen at all for total or relative plasma MCP-1 and SAA. 
 
4.9.  Histology 
4.9.1. Introduction 
Histological techniques provide a way of examining the detailed structure of tissues at a 
cellular level. In this study, histology was used to identify atherosclerotic plaque formation in 
the aortic sinus. The aortic sinus is situated at the origin of the aorta, within the base of the 
heart. This was located by taking the top third of the heart and sectioning until all three of the 
leaflets that characterise the aortic sinus were visible. Differences in plaque area as well as 
the constitutional components between plaques were examined. Various staining protocols 
were utilised to examine different plaque components, and the data for which is presented as 
both total content as well as expressed relative to plaque area as a percentage.  
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Milligan’s trichrome stain consists of three coloured components. It is a differential 
stain for connective tissue and smooth muscle. Nuclei and muscle appear magenta, collagen 
appears green, and red blood cells appear orange to orange red [405].  
Collagen is an integral component of the extracellular matrix of the arterial wall. The 
amount and organization of collagen within atherosclerotic plaques is associated with the 
mechanical stability of the plaque’s fibrous cap. SMCs migrate from the media to the intimal 
layer of the plaque, stimulating collagen synthesis. In contrast, inflammatory cells within the 
plaque such as macrophages release MMPs, causing the proteolysis of matrix collagen. An 
imbalance between collagen synthesis and degradation can result in a net reduction in 
collagen content in the fibrous cap, predisposing the plaque to rupture [406].  
In all stages of plaque development, crystalline cholesterol deposits can be found, 
appearing as acellular, needle-like clefts. Cholesterol is known to accumulate in 
atherosclerotic plaques primarily in the form of intracellular cholesterol esters in foam cells. 
However, if such cells undergo necrosis the cholesterol can be released extracellularly where 
it can precipitate out as cholesterol crystals. These sharp-edged cholesterol crystals have the 
potential to penetrate biological membranes and thus have the potential to increase cell 
necrosis and perforate the outer layers of atherosclerotic plaques. Therefore, a greater 
proportion of cholesterol clefts is indicative of an unstable plaque [385]. 
Neutrophil gelatinase-associated lipocalin (NGAL) is a protein expressed by 
neutrophils. It is also known as lipocalin-2 (LCN2) in humans. It plays a role in the innate 
immune system, sequestering iron that in turn limits bacterial growth [407]. NGAL is also a 
recently discovered urinary biomarker of acute kidney disease, which has had a significant 
impact in clinical nephrology [408]. As has been previously mentioned, neutrophils play a 
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key role in the initial stages of atherosclerosis. As NGAL is primarily restricted to neutrophils, 
NGAL staining has previously been used to identify neutrophil populations in atherosclerotic 
plaques, and may itself play an important role in the pathogenesis of atherosclerosis [409-
411]. 
As has been extensively discussed previously, the neutrophil-derived enzyme MPO 
has been implicated in the pathogenesis of atherosclerosis. As such, numerous previous 
studies have identified MPO in atherosclerotic plaques by way of histology [209,211], and it 
was clearly important, in the context of the hypothesis of this thesis, to quantify this 
parameter in lesions. 
CD68 (cluster of differentiation 68) is a macrophage-derived glycoprotein which 
binds to low density lipoprotein. As has been previously discussed, macrophages play an 
important role in the pathogenesis of atherosclerosis. It has been previously reported that the 
quantification of the number of infiltrated macrophage in the atherosclerotic plaque is a 
predictor of the extent of inflammation and risk of rupture of vulnerable plaques in both 
symptomatic and asymptomatic patients [412,413]. Numerous previous studies have used 
histological techniques to examine the presence of CD68+ macrophages in atherosclerotic 
lesions [414,415]. 
SMCs have been implicated in the initiation and progression of atherosclerosis [416], 
as well as playing a crucial role in maintaining plaque integrity and stability [417]. SMC 
migration into the vessel intima is a classical early sign of plaque development [416]. SMCs 
have also been shown to change their phenotype, undergoing transdifferentiation into 
macrophage-like cells during the pathogenesis of atherosclerosis promoting further adverse 
outcomes [415,418]. In the context of late-stage atherosclerotic plaques, SMCs  may migrate 
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into the neointima and secrete matrix proteins to stabilise the plaque [419]. Thus, SMCs have 
various roles in the development of atherosclerosis during the progression of the disease. By 
staining for SMC α-actin, previous studies have identified SMCs within atherosclerotic 
plaques [415].  
In the light of the above data, each of the above parameters was assessed in the mouse 
artery samples obtained from the control and SCN- treated animals by examining the aortic 
sinus region. 
4.9.2. Methods 
Plaque area, as well as MPO, NGAL, CD68+, collagen and total pooled lipid content were 
quantified as described in section 2.6. Statistical analysis was carried out by unpaired two-
tailed t tests with Welch’s correction. 
4.9.3. Results 
 Plaque area 
A significant 30 % reduction in plaque size was observed at 4 weeks in the 2.5 mM, but not 
10 mM NaSCN treated group when compared to the control group, as exhibited in Figure 
4.11. While there was a trend towards a reduction in plaque size at 8 weeks with both the 2.5 
(33 % reduction) and 10 mM (36 % reduction) NaSCN treatments, this was not statistically 
significant (p = 0.0971 and 0.0815 respectively). No significant differences were seen 
between any of the groups at the 18 week time point. 
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 Additionally, a significantly non-zero negative correlation between average plaque 
area and plasma SCN- was observed at 8 weeks (r = 0.204), as seen in Figure 4.12. While a 
trend towards a similar negative correlation was observed at 4 weeks, this failed to reach 
significance. At 18 weeks, no correlation was observed between average plaque area and 
plasma SCN-.  
Figure 4.11- Average plaque area (pixels) in the aortic sinus of the ApoE-/- mice from each 
group during the 4 week (n = 12, 12, 12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) 
time courses. The data are expressed as mean ± SEM. Unpaired two-tailed t tests with 
Welch’s correction indicated a significant reduction in plaque size at 4 weeks in the 2.5 mM 
NaSCN treated group when compared to the control group (where * = p < 0.05). 
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Figure 4.12- Two-tailed Pearson correlation plots of average plaque size against plasma  
SCN- concentration for the ApoE-/- mice from all groups during the 4 week (A), 8 week 
(B), and 18 week (C) time courses. The 4 and 18 week groups showed no significant 
correlation. However, at 8 weeks a significant non-zero trend line was observed (y = -
512.6x + 487662, r = 0.204) (** = p < 0.01 ).  
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 NGAL 
The total amount of NGAL staining detected in the aortic sinus was found to increase at 
approximately the same rate regardless of the absence or presence of NaSCN 
supplementation at all time points as exhibited in Figure 4.13 (A). However, a significant and 
dose-dependent decrease is seen in the % NGAL content at 8 week, as seen in Figure 4.13 
(B). A significant decrease in % NGAL was seen between both the control and 10 mM 
NaSCN treatment (23 % reduction), as well as the 2.5 and 10 mM treatments (17 % 
reduction). A significant decrease in % NGAL was also observed at 18 weeks. The % NGAL 
in the 2.5 mM NaSCN treatment group was reduced by 16 % and the 10 mM NaSCN 
treatment group was reduced by 15 % compared to the control group. 
 MPO 
The total amount of MPO was also found to increase at approximately the same rate 
regardless of the absence or presence of NaSCN supplementation across all time points, with 
a significant 51 % increase in total MPO observed at 18 weeks in the 10 mM NaSCN 
treatment group when compared to the control group, as exhibited in Figure 4.14 (A). A 
significant 29 % decrease in the % MPO content in the 2.5 mM NaSCN treatment group was 
also seen at 4 weeks when compared to the control group, as seen in Figure 4.14 (B). 
However, a significant and dose-dependent increase in % MPO was observed at 18 weeks, 
with the 10 mM NaSCN treatment containing 53 % more relative MPO level compared to the 
control group, and 22 % compared to the 2.5 mM NaSCN treatment group. These findings 
are consistent with a delayed disease progression for the 2.5 mM NaSCN treatment group. 
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Figure 4.13- Average total NGAL area (A) and percent NGAL of total plaque area (B) in 
the aortic sinus of the ApoE-/- mice from each group during the 4 week (n = 12, 12, 12), 8 
week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) time courses. The data are expressed as 
mean ± SEM. Unpaired two-tailed t tests with Welch’s correction indicated no significant 
differences in total NGAL area. However, a significant decrease in % NGAL content was 
observed at 8 weeks in the 10 mM NaSCN treatment animals when compared to both the 
control group (where **** = p < 0.0001), and the 2.5 mM NaSCN treatment group (where 
## = p < 0.01). A significant decrease in % NGAL content was also observed at 18 weeks in 
both the 2.5 and 10 mM NaSCN treatment animals when compared to the control group 
(where * = p < 0.05). 
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Figure 4.14- Average total MPO area (A) and percent MPO of total plaque area (B) in the 
aortic sinus of the ApoE-/- mice from each group during the 4 week (n = 12, 12, 12), 8 week 
(n = 11, 12, 12), and 18 week (n = 9, 11, 12) time courses. The data are expressed as mean ± 
SEM. Unpaired two-tailed t tests with Welch’s correction indicated a significant increase in 
total MPO area at 18 weeks in the 10 mM NaSCN treatment group when compared to the 
control group (where * = < 0.05). However, a significant decrease in % MPO content was 
observed at 4 weeks in the 2.5 mM NaSCN treatment animals when compared to the control 
group (where * = p < 0.05). A significant increase in % MPO content was also observed at 
18 weeks in the 10 mM NaSCN treatment animals when compared to the control group 
(where *** = p < 0.001) as well as the 2.5 mM NaSCN treatment group (where # = p < 
0.05).   
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 CD68+ macrophages 
The total amount of CD68+ macrophages was shown to be significantly decreased by 36 % in 
the 10 mM NaSCN treatment group when compared to the 2.5 mM NaSCN treatment group 
at 4 weeks, but increased by 98 % at 8 weeks in the 10 mM NaSCN treatment group when 
compared to the control group, as exhibited in Figure 4.15 (A). This significant increase was 
also evident in the % CD68+ content, with this occurring in a dose-dependent manner, as 
demonstrated in Figure 4.15 (B). The 10 mM NaSCN treatment group was seen to have a 
significantly greater % CD68+ content when compared to both the control group (70 % 
increase), as well as the 2.5 mM treatment group (30 % increase), at 8 weeks. The % CD68+ 
content in the 2.5 mM NaSCN treatment group was also significantly greater than the control 
group (31 % increase). No change in either total or % CD68+ was observed at 18 weeks. 
These findings are consistent with delayed disease progression for both treatment groups. 
 SMC α-actin 
The total amount of SMCs was seen to increase as lesions develop, but was shown to be 
significantly decreased at 4 weeks in the 2.5 mM NaSCN treatment group when compared to 
both the control (87 % decrease) and 10 mM NaSCN treatment (81 % decrease) groups, as 
exhibited in Figure 4.16 (A). A similar significant decrease was also evident in the % SMC 
content as demonstrated in Figure 4.16 (B). The 2.5 mM NaSCN treatment group was seen to 
have a significantly reduced % SMC content when compared to both the control (83 % 
decrease) and 10 mM NaSCN treatment (85 % decrease) groups at 4 weeks. No significant 
differences in either total or % SMCs was observed at the 8 and 18 week time points. These 
findings are consistent with delayed SMC infiltration and therefore slower disease 
progression for the 2.5 mM NaSCN treatment group. 
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Figure 4.15- Average total CD68+ area (A) and percent CD68+ of total plaque area (B) in 
the aortic sinus of the ApoE-/- mice from each group during the 4 week (n = 12, 12, 12), 8 
week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) time courses. The data are expressed as 
mean ± SEM. Unpaired two-tailed t tests with Welch’s correction indicated a significant 
increase in total CD68+ at 4 weeks and 8 weeks in the 10 mM NaSCN treatment animals 
when comparted to the 2.5 mM NaSCN treatment group (where # = p < 0.05) and the 
control group respectively (where ** = p < 0.01). A significant increase in % CD68+ content 
was also observed at 8 weeks in the 10 mM NaSCN treatment animals when compared to 
both the control group (where **** = p < 0.0001), as well as the 2.5 mM NaSCN treatment 
group (where # = p < 0.05).  The % CD68+ in the 2.5 mM NaSCN treatment group was also 
significantly greater than the control group at 8 weeks (where * = p < 0.05). 
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Figure 4.16- Average total SMC area as measured by α-actin staining (A) and percent SMC 
of total plaque area (B) in the aortic sinus of the ApoE-/- mice from each group during the 4 
week (n = 12, 12, 12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) time courses. The 
data are expressed as mean ± SEM. Unpaired two-tailed t tests with Welch’s correction 
indicated a significant decrease in both total and % SMCs at 4 weeks in the 2.5 mM NaSCN 
treatment animals when compared to both the control and 10 mM NaSCN treatment groups 
(where ** = p < 0.01, and # = p < 0.05).  
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 Collagen 
The total amount of collagen was shown to be significantly decreased at 4 weeks in the 2.5 
mM NaSCN treatment group when compared to both the control (42 % decrease) and 10 mM 
NaSCN treatment (49 % decrease) groups, as exhibited in Figure 4.17 (A). This significant 
decrease was also evident in the % collagen content as demonstrated in Figure 4.17 (B). The 
2.5 mM NaSCN treatment group was seen to have significantly smaller % collagen content 
when compared to the control (14 % decrease) and 10 mM NaSCN treatment (21 % decrease) 
groups at 4 weeks. Several more additional significant differences were observed in the % 
collagen content. The 10 mM NaSCN treatment group was also seen to have a significantly 
greater % collagen content when compared to both the control (92 % increase) and 2.5 mM 
NaSCN treatment (32 % increase) groups at 8 weeks. At 18 weeks, the 2.5 mM NaSCN 
treatment group was observed to have a significantly greater % collagen content when 
compared to the control group (10 % increase) as well as the 10 mM NaSCN treatment group 
(18 % increase). No significant changes in total collagen were observed at either 8 or 18 
weeks. This data is consistent with the SMC data, supporting previous reports that SMCs are 
major sources of lesion collagen. 
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Figure 4.17- Average total collagen area (A) and percent collagen of total plaque area (B) in 
the aortic sinus of the ApoE-/- mice from each group during the 4 week (n = 12, 12, 12), 8 
week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) time courses. The data are expressed as 
mean ± SEM. Unpaired two-tailed t tests with Welch’s correction indicated a significant 
decrease in both total and % collagen at 4 weeks in the 2.5 mM NaSCN treatment animals 
when compared to the control and 10 mM NaSCN treatment groups (where * = p < 0.05, ** 
= p < 0.01, # = p < 0.05, and ## = p < 0.01). A significant increase in % collagen content 
was also observed at 8 weeks in the 10 mM NaSCN treatment animals when compared to 
both the control and 2.5 mM NaSCN treatment groups (where *** = p < 0.001, and # = p < 
0.05). A significant increase in % collagen content was also observed at 18 weeks in the 2.5 
mM NaSCN treatment animals when compared to the control and 10 mM NaSCN treatment 
groups (where * = p < 0.05, and ### = p < 0.01 ).    
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 Total lipid content 
The total amount of lipid, both as lipid pools and cholesterol clefts, was found to increase at 
approximately the same rate regardless of the absence or presence of NaSCN 
supplementation across all time points, with a significant 41 % decrease in total cholesterol 
observed at 4 weeks in the 10 mM NaSCN treatment group when compared to the control 
group, as exhibited in Figure 4.18 (A). Many significant differences were also observed in 
the % cholesterol content, as demonstrated in Figure 4.18 (B). At 4 weeks, the 2.5 mM 
NaSCN treatment group was seen to have a significantly increased % cholesterol content 
when compared to both the control (26 % increase) and 10 mM NaSCN treatment (89 % 
increase) groups. Also at 4 weeks, the 10 mM NaSCN treatment group was shown to have a 
significant 33 % decrease in cholesterol compared to the control group. At 8 weeks, both the 
2.5 (35 % increase) and 10 mM (43 % increase) NaSCN treatment groups were seen to have a 
significantly increased % cholesterol content when compared to the control group. Finally, at 
18 weeks, the 10 mM NaSCN treatment group was shown to have a significant increase in 
cholesterol compared to both the 2.5 mM NaSCN treatment group (41 % increase), as well as 
the control group (43 % increase). 
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Figure 4.18- Average total cholesterol area (A) and percent cholesterol of total plaque area 
(B) in the aortic sinus of the ApoE-/- mice from each group during the 4 week (n = 12, 12, 
12), 8 week (n = 11, 12, 12), and 18 week (n = 9, 11, 12) time courses. The data are 
expressed as mean ± SEM. Unpaired two-tailed t tests with Welch’s correction indicated a 
significant decrease in total cholesterol at 4 weeks in the 10 mM NaSCN treatment group 
compared to the control group (where * = p < 0.05). A significant increase in % cholesterol 
content was observed at 4 weeks in the 2.5 mM NaSCN treatment animals when compared 
to the both the 10 mM NaSCN treatment group and the control group (where * = p < 0.05, 
and #### = p < 0.0001). A significant decrease in % cholesterol content was also observed at 
4 weeks in the 10 mM NaSCN treatment animals when compared to the control group 
(where ** = p < 0.01). A significant increase in % cholesterol content was also observed at 8 
weeks in both the 2.5 and 10 mM NaSCN treatment groups when compared to the control 
group (where * = p < 0.05 and ** = p < 0.01). At 18 weeks a significant increase was also 
observed in the 10 mM NaSCN treatment groups when compared to both the control group 
(where ** = p < 0.001), and the 2.5 mM NaSCN treatment group (where #### = p < 
0.0001).    
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 Correlations between plaque components 
Several significant correlations in plaque constituents were also observed when the above 
parameters were compared to each other. 
 Significantly non-zero correlations between total plaque CD68+ and total plaque 
NGAL content were seen at each of the three time points, as seen in Figure 4.19. At 4 weeks 
the CD68+ vs NGAL correlation was significant for the control (r = 0.435) and 2.5 mM 
NaSCN treatment (r = 0.417) groups. At 8 weeks, the CD68+ vs NGAL correlation was 
significant for the 2.5 (r = 0.675) and 10 mM NaSCN treatment (r = 0.554) groups. At 18 
weeks, the CD68+ vs NGAL correlation was significant for the control (r = 0.462) and 2.5 
mM NaSCN treatment (r = 0.380) groups. Given that these are markers of increased 
inflammation and damage, we would expect that if there are more neutrophils, there would 
also be a concomitant increase in macrophage numbers. 
Significant non-zero correlations were also observed between total plaque cholesterol 
and total plaque CD68+ content at 8 weeks, as seen in Figure 4.20. Given that increased 
inflammation is associated with increased macrophage numbers, we suspect this is the reason 
for the increased lipid accumulation. The cholesterol vs CD68+ correlation was significant for 
the control (r  = 0.488), 2.5 (r  = 0.537) and 10 mM NaSCN treatment (r  = 0.509) groups. 
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Figure 4.19- Two-tailed Pearson correlation plots of total plaque CD68+ against total plaque 
NGAL for the ApoE-/- mice from each group during the 4 week (A), 8 week (B), and 18 week 
(C) time courses. Significant non-zero trend lines at 4 weeks are seen in the control (y = 
0.883x + 6929, r = 0.435) and 2.5 mM NaSCN treatment (y = 0.5196x + 12434, r = 0.417) 
groups (where * = p < 0.05). Significant non-zero trend lines at 8 weeks are seen in the 2.5 
(y = 1.268x + 59316, r = 0.675) and 10 mM NaSCN treatment (y = 1.156x + 22040, r = 
0.554) groups (where ** = p < 0.01). Significant non-zero trend lines at 18 weeks are seen in 
the control (y = 0.8137x + 258021, r = 0.462) and 2.5 mM NaSCN treatment (y = 2.401x + 
28536, r = 0.380) groups (where * = p < 0.05). 
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4.9.4. Conclusion 
Overall, treatment of ApoE-/- mice with 2.5 mM NaSCN resulted in a reduction in total 
plaque area by 30 % at 4 weeks. Additionally, at 4 weeks the 2.5 mM NaSCN treatment 
significantly reduced the % MPO content by 29 % and % SMC plaque content by 87 %. A 
reduced % neutrophil component was also observed at 18 weeks. However, the 2.5 mM 
NaSCN treatment also significantly increased the total lipid pool at 4 and 8 weeks by 26 % 
and 35 % respectively, before increasing the proportion of collagen by 10 % at 18 weeks.  
 The 10 mM NaSCN condition had a similarly complex effect on plaque composition. 
No effect was seen on total plaque area. However, treatment with 10 mM NaSCN 
significantly decreased % cholesterol by 33 % at 4 weeks, while % neutrophils were 
decreased by 23 % and 15 % at 8 and 18 weeks respectively. However, CD68+ macrophages 
were increased by 70 % at 8 weeks. In addition, at 18 weeks the 10 mM NaSCN 
concentration increased the % MPO and cholesterol contents by 53 % and 43 % respectively.  
Figure 4.20- Two-tailed Pearson correlation plot of total plaque cholesterol against total 
plaque CD68+ for the ApoE-/- mice from each group during the 8 week time courses. 
Significant non-zero trend lines at 8 weeks are seen in the control (y = 0.1389x + 27608, 
r = 0.488), 2.5 (y = 0.473x - 13146, r = 0.537), and 10 mM NaSCN treatment (y = 
0.3105x + 44911, r = 0.509) groups (where * = p < 0.05, and ** = p < 0.01). 
 
  
 
162 
 
 
 Additionally, a significantly negative correlation between average plaque area and 
plasma SCN- was detected at 8 weeks across all animals. A positive correlation between total 
CD68+ and total NGAL content was also observed at all time points. Positive correlations 
between total cholesterol and total CD68+ were also detected at 8 weeks for each treatment. 
 Overall, it appears that elevating plasma levels of SCN- by oral supplementation of 
NaSCN impairs the onset and progression of atherosclerosis in the early and middle stages of 
the disease. However, at longer time points, it seems that any protective effect is 
overwhelmed and the disease state is able to catch up to the levels seen in controls. 
 
4.10.  Discussion 
Previous studies have provided substantial evidence that elevated levels of MPO are 
associated with increased atherosclerosis and cardiovascular disease, and this has encouraged 
significant interest in the development of therapeutic strategies to inhibit MPO. One potential 
problem with the development of an MPO inhibitor, however, is the concern that such a drug 
may result in adverse outcomes associated with impairment of the role of MPO in the host 
innate immune response [157]. However, this does not appear to be a major issue in MPO 
deficient people. Thus, while some studies have shown that there is an increased 
susceptibility to infection and inflammatory conditions [106], MPO deficiency is of itself not 
a life-threatening condition. This is likely to be due to a redundancy in killing mechanisms 
for pathogens due to the great importance of this process [107]. In saying that, there is 
evidence in support of MPO as an essential contributor to normal innate host defense when 
exposure to pathogens overwhelms the capacity of other host defense mechanisms [420].   
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While many investigations have been reported on the role of MPO in the context of 
cardiovascular disease [421-423], the nature of the MPO-derived oxidants that give rise to 
this elevated risk have not yet been fully characterised. This study has examined 
atherosclerotic plaque development and plasma biomarkers of inflammation upon 
supplementation of an atherosclerosis-prone ApoE-/- mouse model with SCN-, a major 
alternative MPO substrate. This treatment increased plasma SCN- levels in a significant and 
dose-dependent manner to give concentrations that are physiologically comparable to those 
reported for moderate-heavy human smokers when compared to non-smokers [113,114]. This 
significant elevation in plasma SCN- levels in the supplemented mice would be predicted to 
modify the proportions of oxidants produced by MPO, with greater generation of the thiol-
specific oxidant HOSCN, and decreased formation of the more reactive, and less specific, 
HOCl [114]. Unlike HOSCN-mediated damage, which is largely reversible, HOCl generates 
higher yields of non-repairable oxidation [243]. Thus, elevated plasma SCN- levels may be 
capable of protecting against the pathogenesis of atherosclerosis. 
 In this study, oral supplementation of ApoE-/- mice with 2.5 and 10 mM NaSCN in 
drinking water was shown to significantly increase plasma SCN- levels. Several SCN- feeding 
studies have been carried out previously to assess the effects of SCN- in vivo. The 
Whitehouse laboratory in Canberra have reported extensive investigations into the effects of 
SCN-, primarily in the context of arthritis, over the past 50 years. They have investigated 
several different SCN- containing salt compounds in various concentrations, including LiSCN 
[424], KSCN, and NaSCN [283,284], as a means of elevating plasma SCN- levels. As in this 
study, Whitehouse et al. have previously utilised a NaSCN supplementation dose of 10 mM 
[284]. They achieved a significant elevation in plasma SCN-, however the absolute levels of 
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enhancement were somewhat different to the levels observed in this study. They observed an 
average plasma SCN- concentration of 568 µM in Hooded Wistar rats and a concentration of 
379 µM in Dark Agouti rats after 3 days of 10 mM NaSCN supplementation [284], whereas 
the highest average plasma concentration achieved in the current study was 399 µM. Clearly, 
there appears to be some differences in the levels of SCN- achieved between rat strains, let 
alone between rats and mice. In addition, their means of quantifying plasma SCN- involved 
colourimetric measurements in contrast to the ion-exchange chromatography used in this 
study, which could also account for some of the differences. Despite these differences in total 
plasma SCN- across different animal models, it is clear that a consistent and significant 
elevation in plasma SCN- can be attained by oral supplementation with 10 mM NaSCN 
across all these studies. These previous studies, along with previous NaSCN dosing studies 
performed by our group, did not detect any alterations in fluid intake or weight gain 
[246,284]. 
 The significant effect of NaSCN supplementation on total plasma protein levels in this 
study was somewhat unexpected and is difficult to explain. At 4 weeks, no significant effect 
of NaSCN supplementation on plasma protein levels was observed. However, at 8 weeks, 
both concentrations of NaSCN significantly elevated plasma proteins before a significant 
dose-dependent decrease in plasma protein was observed at 18 weeks. As there were no 
significant changes in total plasma protein at 4 weeks, it is unlikely that the later changes in 
plasma protein at 8 and 18 weeks are a direct result of the NaSCN treatment (such as 
dehydration or increased drinking behaviour), but rather the effect that SCN- has on the 
progression of the disease. As mentioned earlier, hyperproteinaemia can result from increased 
production of proteins associated with reactive inflammatory processes which could 
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potentially explain this phenomenon [388]. However, while there was a significant increase 
in circulating relative IL-6 levels at 8 weeks in the 2.5 and 10 mM NaSCN groups, there was 
also a significant decrease in circulating MPO at this time as well. It is probable that there 
was increased production of other proteins that were not measured in this study that could 
account for this increase in plasma protein.  
A high salt diet could feasibly result in hypoproteinemia, as the increased salt 
concentration alters the osmolality of the blood, drawing in more water and thus diluting the 
plasma protein levels. This hypothesis could potentially explain the dose-dependent decrease 
in plasma protein seen at 18 weeks. Hypoproteinemia can also result from systemic 
inflammation [387], but this is felt to be unlikely in this case as there were no significant 
differences in circulating inflammatory cytokines at 18 weeks. 
 A dose-dependent increase in total and relative thiols was evident at 4 weeks, and 
significant for the 10 mM NaSCN treatment group. No other significant effects were 
observed at either 8 or 18 weeks. This would suggest that elevating plasma SCN- protects 
against plasma thiol loss. As a reduction in the concentration of reduced thiols is indicative of 
increased oxidative stress [389], it would appear that NaSCN treatment may result in a dose-
dependent global protection from oxidative stress in the short term. As mentioned previously, 
this may be due to SCN- outcompeting Cl- for the generation of its corresponding hypohalous 
acid [114]. By reducing the amount of HOCl generated, which reacts rapidly with thiols, and 
increasing the formation of HOSCN, which reacts less rapidly with thiols, this affords greater 
protection against thiol oxidation [117]. However, HOSCN does target Cys residues, but at a 
much slower rate. This means that over a greater period of time it may be expected that thiol 
levels will still be reduced, as is seen at the 8 and 18 week time points in this study. There is 
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also the possibility that other effects that were not examined in this study are occurring which 
modulate the thiol levels and are driven by the disease progression. 
 Elevated levels of SCN- have been shown to have some effect on circulating 
inflammatory cytokines in this study, namely TNF-α, MPO and IL-6. Initially, at 4 weeks a 
massive spike in both total and relative plasma levels of TNF-α was observed in the 10 mM 
NaSCN treatment group compared to both the 2.5 mM NaSCN treatment and control groups. 
TNF-α is produced upon activation of the immune system [425], which suggests that the 10 
mM NaSCN treatment elicits an early primary immune response which is not seen with the 
2.5 mM NaSCN treatment. It is therefore plausible that a threshold concentration lies 
between 2.5 and 10 mM NaSCN which results in the induction of an inflammatory response. 
Both total and relative plasma MPO levels were found to be significantly reduced 
with NaSCN treatment at 8 weeks. This could be a result of the early TNF-α spike. In a 
previous irradiation study in human HL60 promyelocytes, which contain constitutively high 
levels of MPO protein and mRNA, TNF-α has been demonstrated to decrease the levels of 
MPO transcripts. HL60 cells produce TNF-α, and irradiation markedly increased the TNF-α 
production in these cells. In turn, the high TNF-α levels reduced the levels of MPO 
transcripts. Additionally, treatment of HL60 cells with an anti-TNF-α antibody blocked the 
drop in MPO levels induced by irradiation [426]. Thus, increased TNF-α levels have been 
shown to have an inhibitory effect on MPO production. The spike in TNF-α at 4 weeks could 
have had an impact on downstream MPO levels, resulting in the reduction in MPO levels 
seen at 8 weeks.   
This also coincides with the significant increase in relative plasma IL-6 levels (by 86-
fold) in the NaSCN treatment groups at 8 weeks. While IL-6 has pro-inflammatory properties, 
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it can also act as an anti-inflammatory cytokine. It has been shown that IL-6 has an inhibitory 
action on TNF-α [427], which could explain why any elevation induced by TNF-α is not 
present at the 8 week time point.  
In terms of the plasma profile, it appears that high SCN- concentrations instigate an 
inflammatory response, as indicated by elevated circulating TNF-α levels at 4 weeks. In 
response, IL-6 levels are increased to dampen TNF-α, but not before TNF-α has inhibited 
later MPO levels. By 18 weeks, no significant differences were observed in cytokine levels.  
 This study was also able to demonstrate that oral supplementation with 2.5 mM 
NaSCN was capable of reducing plaque area by 30% at 4 weeks. Also at 4 weeks, a negative 
correlation between average plaque size and plasma SCN- levels was seen, although this was 
not significant. Both the 2.5 and 10 mM NaSCN treatments came close to achieving a 
significant reduction in plaque size at 8 weeks. While the total reduction in plaque size may 
not have been significant, a significant negative correlation between average plaque size and 
plasma SCN- levels was seen across all groups, indicating that high levels of circulating 
SCN- are associated with reduced plaque area. No change in plaque size was achieved with 
either treatment at 18 weeks, nor was any form of correlation between average plaque size 
and plasma SCN- levels observed. A previous SCN- feeding study, similar to this one, by 
Morgan et al. [246] investigated atherosclerotic plaque development, and various 
biochemical parameters, in an LDL receptor (LDLR)-/- mouse model transgenic for human 
MPO. This study showed that atherosclerotic plaque growth was markedly decreased by 12 
weeks of dietary supplementation with 10 mM SCN- by 26%, the first demonstration of a 
positive effect of SCN- in an atherosclerotic model [246], and a very similar degree of 
protection to the 30% reduction seen with 2.5 mM NaSCN at 4 weeks in this study. The 
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reason for using this transgenic human MPO model is that murine neutrophils have 
approximately 20% of the MPO activity of human neutrophils, therefore potentially 
suggesting that mice are not appropriate models of human atherosclerosis development [428]. 
Regardless of this difference, these results are similar to those found in this study, where 
SCN- supplementation has been found to reduce the size of mid-stage atherosclerotic plaques. 
However, in the previous study only one time point was used, so no comparisons can be 
drawn for early and late-stage disease. In addition, Morgan et al. determined that there was 
no effect on plaque morphology, however they did not investigate the wide panel of markers 
examined in the current study. Regardless, the current study supports the previous conclusion 
that manipulating the MPO system to favour the generation of the less reactive oxidant 
HOSCN, at the expense of HOCl, can reduce atherosclerotic plaque size. 
This study was also able to show for the first time that oral supplementation with 
NaSCN has profound effects on plaque composition. A related study has been performed 
examining the inhibition of generation of MPO-derived oxidants, utilising TEMPOL (4-
hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl radical). TEMPOL is a cell permeant nitroxide, 
which has a well characterised superoxide dismutase-mimetic activity [421]. It is capable of 
reacting with, and thus detoxifying, a number of free radicals and reactive oxygen species, 
including MPO-derived oxidants [421,429,430]. However, TEMPOL has also been shown to 
be an excellent substrate for compound I of MPO, but very poor for compound II, resulting in 
an accumulation of the compound II form of the enzyme. Ultimately, this results in inhibition 
of consumption of H2O2 and therefore the inhibition of MPO-mediated generation of HOCl, 
and other hypohalous acid [225]. Dietary supplementation with TEMPOL over 12 weeks was 
shown to have no impact on plaque size, but did modulate atherosclerotic plaque composition 
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in ApoE-/- mice on a high-fat diet, including increasing macrophage and collagen content, 
while reducing the cholesterol and lipid levels [421]. In contrast, the current study did not 
seek to inhibit MPO itself, but direct product formation in favour of a less reactive, and 
therefore less damaging, oxidative species. 
The initiation of atherosclerosis is associated with endothelial dysfunction, one of the 
characteristics of which is the development of a pro-inflammatory state of the endothelium, 
enhancing expression of chemokines and adhesion molecules. In the early stages of 
atherosclerosis development, this results in the recruitment of neutrophils to the initial sites of 
lesion development [431]. Neutrophils also play a role in early monocyte recruitment, as the 
absence of neutrophils has been previously shown to reduce the number of monocytes, and 
subsequent tissue macrophages they differentiate into, within the arterial wall [432]. Upon the 
uptake of ox-LDL, macrophages in the arterial wall become foam cells when they ingest 
large amounts of lipid from modified LDL [433]. A greater degree of macrophage infiltration 
and foam cell formation in the atherosclerotic plaque increases the risk of rupture of 
vulnerable plaques [412,413]. Neutrophils have also been shown to be present in later stage 
lesions, particularly in highly inflamed regions. As they produce large amounts of oxidative 
species through MPO, among other sources, they are thus also associated with vulnerable 
plaque traits in later stages of the disease [434,435]. Neutrophils and macrophages are also 
major sources of MMPs, which are also likely to compromise plaque stability by degrading 
the extracellular matrix [431].  
In this regard, an abundance of neutrophils is likely to have a detrimental impact, 
accelerating atherosclerotic plaque progression as well as resulting in greater plaque burden 
and instability. Both the 2.5 mM and 10 mM NaSCN treatments used in this study 
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significantly reduced the % neutrophil content of plaques at 8 and 18 weeks. This could be 
interpreted as a potentially protective phenomenon, as this should (in theory) reduce 
macrophage numbers and arterial wall inflammation, slowing disease progression, while also 
reducing the production of damaging oxidative species. However, this is not entirely 
consistent with what has been observed here. Whilst there was an initial reduction in both 
MPO and CD68+ macrophages at 4 weeks, at 8 weeks CD68+ macrophage content was 
increased with NaSCN treatment, and at 18 weeks MPO content was also increased. A 
significant correlation between plaque neutrophil and macrophage content was also seen at all 
time points, again suggesting the greater the number of neutrophils the greater the number of 
macrophages recruited. Therefore, NaSCN appears to have dose-dependent effects on the 
immune cells involved in atherogenesis. While NaSCN treatments appear to be protective in 
early disease stages, plaque progression then accelerates through the mid-stages of disease, 
via increased macrophage recruitment, culminating in an environment that could potentially 
promote plaque instability, with elevated levels of MPO present in late-stage plaques. 
The aforementioned immune cells are not the only contributors to atherogenesis and 
plaque stability. While SMC infiltration into the intima is of itself undesirable, SMCs within 
the plaque play a significant role as they generate interstitial plaque collagen. The amount 
and organisation of collagen within an atherosclerotic plaque is associated with the 
mechanical stability of the plaque’s fibrous cap, and thus greater collagen content affords 
greater plaque stability [71,72]. In all stages of plaque development, lipid accumulation also 
occurs which can result in the formation of crystalline cholesterol, appearing as acellular 
cholesterol clefts. Whilst initial cholesterol accumulation in plaques primarily occurs in the 
form of intracellular cholesterol esters in foam cells, macrophage necrosis can result in 
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extracellular deposits and precipitation as crystals. The sharp-edged cholesterol crystals have 
the potential to penetrate biological membranes, damaging the mechanical integrity of the 
plaque, and thus have the potential to perforate the outer layers of atherosclerotic plaques. 
Therefore, a greater proportion of cholesterol clefts promotes unstable plaque formation and 
lesion rupture [385]. 
The 2.5 mM NaSCN treatment gave rise to a reduction in SMCs at 4 weeks. This is 
likely to be due to an initial retardation in atherogenesis, as indicated by the reduction in 
plaque size, MPO, and CD68+ macrophages discussed previously, resulting in reduced SMC 
recruitment. As a consequence of the reduced number of SMCs, a low level of collagen in the 
plaque was seen for the 2.5 mM treatment group, as SMCs are the main source of collagen 
production in the plaque. SMCs subsequently increase in a non-significant but dose-
dependent manner at 8 weeks, which is also mirrored by a significant dose-dependent 
increase in collagen at the same time point. At the 18 week time point, no significant changes 
in SMC levels were observed with either treatment. However, the 2.5 mM NaSCN treatment 
shows an increase in the % collagen content of the plaque at 18 weeks. Overall, SCN- 
supplementation during the initial period of disease appears to result in a reduction in SMCs 
and collagen levels as atherogenesis is impaired at this concentration and time. At 8 weeks, 
SMCs and collagen increase in a dose-dependent manner, and at 18 weeks only the collagen 
content is significantly greater in the 2.5 mM NaSCN treatment. Overall, this suggests that 
low levels of SCN- supplementation slow the course of atherosclerosis development, and that 
greater collagen deposition occurs with NaSCN treatment, particularly at 2.5 mM. This may 
provide greater structural integrity to the fibrous cap of the atherosclerotic plaque, providing 
greater stability and less likelihood of plaque rupture. 
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 While both concentrations of NaSCN show promise in promoting the formation of 
more stable plaques through increased collagen content, the treatments also had varying 
effects on plaque cholesterol content. In the early stages of disease, plaque cholesterol 
accumulation appears to be promoted by the 2.5 mM treatment, but diminished by the 10 mM 
treatment. However, at 8 weeks a very strong and significant positive correlation is seen in all 
groups between macrophage numbers and cholesterol levels. This association is likely 
indicative of foam cell formation, and therefore appears that greater cholesterol-laden foam 
cell formation occurs in a dose-dependent manner at 8 weeks. However, by 18 weeks, in the 
advanced lesions, cholesterol content was only elevated in the 10 mM NaSCN treatment 
group. Therefore, in the 2.5 mM NaSCN treatment, cholesterol deposition is increased 
through the early and intermediate stages of the disease when foam cell formation is 
prevalent, but returns to normal levels in the late-stage lesion. In contrast, in the 10 mM 
NaSCN treatment, cholesterol deposition was decreased in the initial early stages of the 
disease, and then remains elevated in the late-stage lesion. As a result, these late-stage lesions 
may be more unstable and prone to rupture as a result of the high cholesterol content 
promoted by the 10 mM NaSCN treatment. 
Overall, this study has demonstrated that the oral supplementation of NaSCN as a 
means to elevate global plasma and arterial SCN- levels has complex effects which have the 
potential to be both protective and detrimental in the context of atherosclerosis depending on 
dose and time. In terms of plaque area, the 2.5 mM NaSCN treatment significantly reduced 
plaque size in the early stage of the disease, and a strong negative correlation between plaque 
size and plasma SCN- levels was also seen at 8 weeks. In terms of plaque composition, the 
2.5 mM NaSCN treatment also appears to promote a more stable plaque over the course of 
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disease with a decrease in neutrophil content and increase in collagen content seen over the 
time course. In contrast, the 10 mM NaSCN treatment appears to protect against 
atherogenesis in the early stages of disease before promoting unstable plaque formation 
through the mid to late-stages of the disease through increased MPO, macrophage and 
cholesterol content. Overall, it appears that both NaSCN concentrations may slow the 
initiation and early stages of atherosclerosis. However, this possible protective effect is lost 
over increasing time. During the intermediate stage of the disease sees a dose-dependent 
increase in detrimental foam cell formation, before the late-stage lesions settle into a more 
stable profile for the 2.5 mM NaSCN treatment and a more unstable profile for the 10 mM 
NaSCN treatment. This effect may be due to the generation of other oxidant species, such as 
peroxynitrite, by elevated numbers of macrophages as they accumulate in the lesion and are 
stimulated [436]. Like many therapies, when treatment is not given at the optimal dose or 
time, the treatment may be ineffective, or at worse, detrimental. Promising signs were 
detected in this study for a potential protective effect of elevated plasma SCN- levels, 
however this needs to be examined much more robustly in terms of concentration and timing.  
  One limitation of the current study, and the data obtained from it was the unexpected, 
and potentially complicating, issue that arose with the occurrence of ulcerative dermatitis in 
the 18 week mice. It should be noted that this condition was not confined to the SCN- 
supplemented mice, as it was also seen in non-supplemented animals. Therefore, we do not 
believe this is in any way a side-effect of the SCN- dosing. It occurred in approximately 50 % 
of 18 week mice, and 90 % of these mice were required to be euthanised prematurely.  
Ulcerative dermatitis is a severe inflammatory skin disorder which appears to arise 
spontaneously and for unknown reasons in C57BL/6 mice, or mice on a C57BL/6 
  
 
174 
 
 
background such as the ApoE-/- mice used in this study [437-439]. The condition appears to 
be multifactorial, and is likely to be associated with genetic factors, obsessive‐compulsive 
disorders, diet, environment, sex, and age [440,441].  A high-fat western-style diet has been 
demonstrated to potentiate the occurrence of ulcerative dermatitis [386]. The condition is 
characterized by intense pruritus leading to the development of dermatitis with alopecia, 
which often progresses to epidermal ulceration [442]. The most common sites where 
ulcerative dermatitis occurs are where the mouse can scratch, including the face, head, neck, 
shoulders, and back. Epidermal lesions are often colonized by opportunistic bacteria which 
can enhance irritation, increasing the degree of self-trauma, contributing to greater wound 
severity and delayed wound healing. This can therefore result in an ongoing cycle of irritation 
and infection [386,440]. Once ulcerative dermatitis has developed, the lesions are generally 
unresponsive to treatment [437,443]. Several of the aforementioned factors associated with 
ulcerative dermatitis were definitively present in this study; C57BL/6 background, high-fat 
western-style diet, and age. As such, a significant number of the older, 18 week time course 
mice were severely affected. None of the 4 or 8 week mice contracted the condition. Lesions 
typically began presenting around 12 weeks into the study, and when lesions were detected 
they were treated with an analgesic cream containing corticosteroids. However, the vast 
majority of lesions proved unresponsive to treatment. When lesions reached a point where 
they were determined to be having a significantly detrimental impact on animal welfare, the 
animals were euthanised.  This had a severe impact on animal numbers and the length of 
duration of the study as replacements were required. To limit this impact, mice that were 
deemed to have only minor, or at least manageable, ulcerative dermatitis were allowed to 
complete the time course. This could potentially have had some effect on the results of this 
study, as both atherosclerosis and ulcerative dermatitis are inflammatory disease states. 
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Significantly increased levels of some circulating cytokines in mice that have developed 
ulcerative dermatitis have been previously identified, including the acute inflammatory 
cytokines IL6 and TNFα, however no change was seen in MCP-1 and CRP [386]. The 
idiopathic nature of ulcerative dermatitis makes it difficult to determine whether this had an 
impact on the pathogenesis of atherosclerosis, or the parameters measured in this study, but it 
is plausible that it may have.  
 
4.11.  Conclusion 
Replacing the drinking water of ApoE-/- mice from regular water to 2.5 or 10 mM NaSCN 
dissolved in water had no significant effect on animal body mass. Dosages of both 2.5 and 10 
mM NaSCN in drinking water were sufficient to significantly raise plasma SCN- levels in 
mice in a dose-dependent manner. The 2.5 mM NaSCN treatment had a limited impact on the 
mouse circulating inflammatory cytokine profile. It did significantly raise total plasma 
protein content at 8 weeks, as well as significantly reducing relative plasma MPO levels at 
the same time point. Finally, the 2.5 mM NaSCN treatment significantly increased relative 
plasma IL-6 levels at 8 weeks. 
 The 10 mM NaSCN had a more pronounced effect on the plasma profile. Like the 2.5 
mM NaSCN treatment, the 10 mM NaSCN treatment significantly elevated total plasma 
protein content at 8 weeks before giving rise to a significant decrease at 18 weeks. It also 
significantly reduced relative plasma MPO levels at 8 weeks, while significantly increasing 
relative plasma IL-6 levels at the same time point. However, the 10 mM NaSCN treatment 
saw a drastic and significant spike in both total and relative plasma TNF-α concentrations at 4 
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weeks. No significant differences were seen at all for MCP-1 and SAA for either treatment at 
any time point. In terms of atherosclerotic plaque formation, the 2.5 mM NaSCN treatment 
was shown to significantly reduce total plaque area at 4 weeks. Additionally, a significant 
negative correlation between average plaque area and SCN- was observed at 8 weeks, 
indicating that high levels of SCN- are associated with a smaller plaque size in the 
intermediate disease stage. In addition, the 2.5 mM NaSCN treatment reduced the % MPO 
and SMC plaque content at 4 weeks, and NGAL at 8 and 18 weeks. However, the 2.5 mM 
NaSCN treatment also increased the cholesterol and lipid levels at 4 and 8 weeks before 
increasing the proportion of collagen at 18 weeks. 
 Treatment with 10 mM NaSCN decreased both % collagen and cholesterol at 4 weeks, 
while the % neutrophils were decreased and % CD68+ macrophages increased at 8 weeks. 
However, at 18 weeks the 10 mM NaSCN increased % MPO and cholesterol, while 
decreasing the % collagen component.  
 Overall, both positive and negative effects are exhibited by both NaSCN dosages over 
the time course. However, in general, the 2.5 mM NaSCN concentration appears to result in 
better outcomes compared to controls in the context of atherosclerosis, while the 10 mM 
NaSCN dose may give rise to poorer outcomes.  
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Chapter 5 
Pilot studies investigating potential associations 
between MPO levels, oxidation, and thiocyanate 
concentrations in human cardiovascular disease and 
sepsis 
5.1.  Introduction 
While mouse models of human disease are useful, they are not without their limitations. 
Historically, mouse models have played a critical role in the exploration and characterisation 
of disease pathophysiology, and the in vivo evaluation of novel therapeutic agents and 
treatments [444]. However, murine neutrophils have approximately 20% of the MPO activity 
of human neutrophils, therefore potentially suggesting that mice are not appropriate models 
for inflammatory conditions [428]. In addition, mice have been shown to have significant 
differences in liver metabolism, which impacts on drug testing, as well as different 
inflammatory responses to common cross-species etiologies [445,446]. Therefore, when 
investigating more complex human conditions, it is also useful to explore the condition in the 
clinical setting as well. 
 As the MPO system is a critical component of the innate immune response, it is 
thought to play roles in many inflammatory disease states beyond CVD, including 
rheumatoid arthritis [447], cystic fibrosis[448], and neurodegenerative diseases [449,450]. As 
has been described in detail in Chapter 1, MPO-derived oxidants are potentially damaging 
when produced at inappropriate times, locations, and concentrations. We have hypothesised 
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that during these known inflammatory pathologies, plasma MPO levels will be elevated, and 
this will result in greater oxidative damage in diseased individuals compared to controls. We 
also hypothesised that individuals with elevated levels of SCN- might suffer from lower 
levels of oxidative damage and diminished severity of disease.  
5.2.  Aims 
The aim of the pilot studies reported in this chapter was to determine whether, and to what 
extent, MPO and its derived oxidants might contribute to oxidative damage in patients with 
asymptomatic versus symptomatic CVD in humans, and also in humans suffering from acute 
sepsis. The chapter will be split into two parts reporting separately on CVD and sepsis 
respectively. 
5.3. Asymptomatic vs. symptomatic cardiovascular disease 
5.3.1. Introduction 
CVD is a broad term and encompasses various forms and stages of disease. Therefore, a 
number of subclasses of CVD exist, including asymptomatic and symptomatic CVD. As 
atherosclerotic plaques progressively narrow the arterial lumen, they impair blood flow to the 
myocardium. This reduction in coronary artery flow may be symptomatic or asymptomatic, 
depending on the severity of the occlusion. Asymptomatic CVD is defined when impairment 
of blood flow occurs without routine symptoms presenting. The identification of individuals 
with asymptomatic CVDs has increased greatly due to incidental detection following MI 
[451], as well as by specific screening of people with factors deemed to be at high risk of 
developing CVD, such as hypertension, hyperlipidemia, or type 2 diabetes [452]. The first 
common symptom to generally appear upon sufficient lumen obstruction is angina, that is the 
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sensation of chest pain, pressure, or squeezing, due to restricted myocardial blood flow. 
Angina can be further defined as stable angina, where it occurs under exertion; or unstable 
angina, where it occurs at rest [453]. Beyond angina, the most common symptom to occur is 
a MI, which can be lethal. Therefore, determining risk factors and prognostic markers 
associated with disease progression is attractive, as is identifying patients who are 
progressing towards a disease state where there is a greater chance of suffering an MI, and 
therefore greater patient mortality, and intervening early gives the best prognostic outcomes.  
This study was conducted in collaboration with Professor Gilles Lambert of the 
University of Nantes, France [454]. Sample collection and handling was performed in 
accordance with the guidelines of the Medical and Ethical Committee in Nantes, France, and 
a written informed consent was requested for each patient. In this study, plasma derived from 
the carotid artery was analysed for MPO concentration, SCN- ions, and levels of protein 
oxidation in a cohort of 73 patients exhibiting either asymptomatic (n = 49) or symptomatic 
(n = 24) CVD, as well as 43 subjects who provided femoral artery derived plasma samples 
who acted as controls. It should be noted that the only accessible demographic information on 
these subjects was gender (92 males and 24 females) and age, and only a small amount of 
plasma (~ 20-50 µL) from each subject was available.    
5.3.2. Methods 
Plasma MPO was quantified using commercial kits in accordance with the manufacturer’s 
instructions, as described in section 2.7.6. Samples were stored at -80 °C and researchers 
were blinded until statistical analysis took place. 
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Plasma SCN- levels were quantified by treating plasma with acetonitrile in a 1:1 v/v 
ratio before centrifugation to precipitate plasma proteins. The supernatant was then filtered 
through 0.2 μm centrifuge filters to prepare the working sample. SCN- was measured using a 
Dionex ICS-2100 ion chromatography system as outlined in section 2.7.1. Total plasma thiol 
levels were determined by DTNB assay, as described in section 2.7.3.  
Statistical analysis of all data was carried out by using unpaired two way t tests with 
Welch’s correction, and correlation analysis was achieved using two-tailed Pearson 
correlation plots.  
5.3.3. Results 
To ensure that age was not a confounding variable on disease state, the ages of each group 
were compared. No statistically significant difference in the mean age was detected between 
Figure 5.1- Average age (years) of subjects who supplied the plasma samples from the 
femoral artery (n = 44), as well as from the carotid artery samples from patients exhibiting 
either asymptomatic (n = 49) or symptomatic (n = 24) cardiovascular disease. The data are 
expressed as maximum to minimum box plots. Unpaired two-way t tests with Welch’s 
correction indicated no significant differences in age across all groups. 
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the femoral (69 years), asymptomatic (69 years), and symptomatic (71 years) donor subjects, 
as shown in Figure 5.1. 
 By normalising specific protein concentrations against total protein concentrations, 
this may give a fairer representation of the true impact of treatment. Therefore, it was 
necessary to determine whether total plasma protein levels were a confounding factor on 
disease state. No statistically significant differences in the average total plasma protein 
concentrations was detected between the femoral (54 mg/mL), asymptomatic (53 mg/mL), 
and symptomatic (53 mg/mL) samples, as shown in Figure 5.2. 
  
Figure 5.2- Average total plasma protein concentrations (mg/mL) in the femoral artery 
plasma samples (n = 44), as well as in the carotid artery plasma samples of patients exhibiting 
either asymptomatic (n = 49) or symptomatic (n = 24) cardiovascular disease. The data are 
expressed as maximum to minimum box plots. Unpaired two-way t tests with Welch’s 
correction indicated no significant differences in total plasma protein levels across all groups. 
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The total amount of plasma MPO protein was found to be significantly increased in 
the carotid samples of both asymptomatic (average of 123 ng/mL) and symptomatic (average 
of 145 ng/mL) CVD patients compared to the femoral samples (average of 104 ng/mL), as 
shown in Figure 5.3. The symptomatic CVD samples also had significantly greater MPO 
concentrations than the asymptomatic samples. Thus, MPO levels appear to be associated 
with disease severity in the context of CVD in this cohort of subjects. 
 
 
Figure 5.3- Average total plasma MPO concentrations (ng/mL) in the femoral artery plasma 
samples (n = 44), as well as in the carotid artery plasma samples of patients exhibiting either 
asymptomatic (n = 49) or symptomatic (n = 24) cardiovascular disease. The data are 
expressed as maximum to minimum box plots. Unpaired two-way t tests with Welch’s 
correction indicated a significant increase in total plasma MPO levels in both asymptomatic 
and symptomatic patients’ carotid samples when compared to the femoral samples (where * 
= p <0.05 and ** = p < 0.01). A significant increase in total plasma MPO levels was also 
observed in the symptomatic group when compared to the asymptomatic group (where # = p 
<0.05). 
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The concentration of SCN- in plasma was observed to be significantly decreased in 
the carotid samples of both asymptomatic (average of 36 µM) and symptomatic (average of 
34 µM) CVD patients compared to the femoral samples (average of 55 µM), as seen in 
Figure 5.4. This may be due to advice to cease smoking in patients with diagnosed CVD or 
differences in diet (as various fruits and vegetables are a significant source of SCN-) and 
lifestyle which are known to modify SCN- levels. 
 
 
Figure 5.4- Average total plasma thiocyanate (µM) in the femoral artery plasma samples (n = 
44), as well as in the carotid artery plasma samples of patients exhibiting either asymptomatic 
(n = 49) or symptomatic (n = 24) cardiovascular disease. The data are expressed as maximum 
to minimum box plots. Unpaired two-way t tests with Welch’s correction indicated a 
significant decrease in total plasma thiocyanate levels in both asymptomatic and symptomatic 
patients’ carotid samples when compared to the femoral samples (where ** = p < 0.01). 
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The concentration of thiols on plasma protein, which has been used previously as a 
marker of oxidative stress [113], was observed to be significantly decreased only in the 
carotid artery plasma samples of symptomatic (average of 448 µM) CVD patients compared 
to the femoral artery plasma samples (average of 493 µM), as seen in Figure 5.5. One 
explanation for this observation is that this is due to a greater level of oxidative damage in the 
patients with diagnosed symptomatic CVD, compared to the plasma samples obtained from 
the subjects with asymptomatic CVD and the plasma samples obtained from the femoral 
artery plasma sample donors.  
Figure 5.5- Average total plasma thiols (µM) in the femoral artery plasma samples (n = 44), 
as well as in the carotid artery plasma samples of patients exhibiting either asymptomatic (n = 
49) or symptomatic (n = 24) cardiovascular disease. The data are expressed as maximum to 
minimum box plots. Unpaired two-way t tests with Welch’s correction indicated a significant 
decrease in total plasma thiocyanate levels only in the symptomatic patients’ carotid samples 
when compared to the femoral samples (where * = p < 0.05). 
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When the samples were pooled and examined together, a significant non-zero 
correlation was observed between total plasma thiols and MPO levels, as shown in Figure 5.6. 
These data support the hypothesis that greater MPO concentrations are associated with 
greater oxidative damage. A significant non-zero correlation was also observed between total 
plasma thiols and SCN- levels, as shown in Figure 5.7. These data support the overall 
hypothesis that SCN- may be protective, indicating that elevated levels of SCN- may reduce 
global oxidative stress as determined by plasma thiol concentration.  
 
 
Figure 5.6- Two-tailed Pearson correlation plot of total plasma thiols (µM) against plasma 
MPO concentration (ng/mL) for all groups. A significant non-zero trend line was observed (y 
= -0.4342x + 522.9, r = 0.059) (** = p < 0.01). 
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Finally, each group was also investigated based on the plasma samples containing 
above or below median levels of MPO and SCN-, as has been used previously [245]. With 4 
possible permutations (above median MPO and above median SCN-, above median MPO and 
below median SCN-, below median MPO and above median SCN-, below median MPO and 
below median SCN-), with all things being equal, it would be expected that each permutation 
would account for 25% of that group’s population. Therefore, any deviation from 25% would 
be indicative of an over-representation or under-representation of that combination of 
variables, as shown in Figure 5.8.  
Figure 5.7- Two-tailed Pearson correlation plot of total plasma thiols (µM) against plasma 
thiocyanate concentration (µM) for all groups. A significant non-zero trend line was observed 
(y = 0.443x + 452.1, r = 0.054) (* = p < 0.05). 
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For the samples obtained from the femoral artery of subjects (Figure 5.8 A), an under 
representation was seen in the below median MPO and above median SCN- combination, and 
an equal over representation was seen in the below median MPO and below median SCN- 
combination. This would suggest that in this group there was a prevalence towards low levels 
of MPO and low levels of SCN-, the former of which would be expected from controls. 
Under these conditions, we would expect low levels of MPO-derived oxidants, and a lesser 
proportion of these oxidants to be HOSCN. 
For the samples obtained from the subjects with asymptomatic CVD (Figure 5.8 B), 
an over representation was seen in the above median MPO and above median SCN- 
combination, and an approximately equal under representation was seen in the above median 
MPO and below median SCN- combination. This would suggest that in this group there was a 
prevalence towards high levels of MPO and high levels of SCN-. Under these conditions, we 
would expect high levels of MPO-derived oxidants, and a greater proportion of these oxidants 
to be HOSCN at the expense of HOCl. 
For the samples obtained from the subjects with symptomatic CVD (Figure 5.8 C), a 
large over representation was seen in the above median MPO and below median SCN- 
combination, and under representations were seen in the above median MPO and above 
median SCN- combination, as well as the below median MPO and below median SCN- 
combination. This would suggest that in this group there was a prevalence towards high 
levels of MPO and low levels of SCN-. Under these conditions, we would expect high levels 
of MPO-derived oxidants, and a higher proportion of these oxidants to be HOCl rather than 
HOSCN. 
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Figure 5.8-  Percent deviation from expected population proportions (%) based on above and 
below median values for MPO and SCN- in the femoral (A), asymptomatic (B), and 
symptomatic groups (C).  
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5.3.4. Discussion 
The data obtained in this small pilot study indicate that plasma levels of MPO are 
significantly elevated in both asymptomatic and symptomatic CVD, but are also significantly 
elevated in symptomatic CVD when compared to asymptomatic CVD indicating a potential 
association between increasing concentrations of MPO and disease severity. A significant 
decrease in plasma SCN- levels was also observed, which may be due to lifestyle and dietary 
changes made by patients when diagnosed with CVD (such as ceasing cigarette smoking) or 
poor eating habits as SCN- can arise from fruits and vegetables, so low levels may indicate 
poor nutritional status. A significant decrease in plasma thiol levels was also observed in 
symptomatic CVD patients, which is likely due to greater oxidative damage occurring in the 
active disease state. Finally, a significant negative correlation was observed between plasma 
MPO levels and plasma thiol levels, as well as a significant positive correlation between 
SCN- levels and plasma thiol levels. These correlations suggest that elevated MPO levels 
result in greater oxidative damage, and that elevated SCN- is potentially protective against 
this. There are also changes in the profile of above and below median MPO and SCN- with 
disease. The femoral samples indicate a prevalence towards a combination of low levels of 
MPO and low levels of SCN-, the asymptomatic samples indicate a prevalence towards a 
combination of high levels of MPO and high levels of SCN-, and the symptomatic samples 
indicate a prevalence towards a combination of high levels of MPO and low levels of SCN- 
This data is strengthened by the determination that age and total plasma protein levels do not 
appear to be confounding variables. However, it should be noted that the data presented are 
only associations, and considerably more data is required. Further complicating and 
confounding factors, such as smoking status, also need to be identified and either accounted 
for or eliminated.  
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As has been outlined in earlier sections, a number of studies have provided substantial 
evidence that elevated levels of MPO are associated with increased atherosclerosis and 
cardiovascular disease [157,455]. 
 Additionally, several long-term and large scale prospective studies have evaluated 
whether MPO predicts future CVD events in asymptomatic adults. These studies have 
indicated that individuals with increased plasma levels of MPO are at an increased risk of 
future CVD events [456,457]. Our findings of elevated MPO levels in asymptomatic CVD 
patients agree with these previous studies. 
 We have also identified that there is a significant increase in plasma MPO from 
asymptomatic to symptomatic CVD, which suggests (but does not prove) that plasma MPO 
levels may be a useful prognostic and diagnostic marker for CVD. Using MPO as a marker of 
CVD severity and progression has been postulated in the literature previously.  MPO levels 
have been demonstrated to correlate with atherogenesis [458] and the different stages of 
development of CVD [459,460], and has been suggested as a potential indicator for the 
clinical severity of CVDs allowing for the development of more robust cardiac risk 
stratification. However, due to the relatively small sample sizes and lack of further data on 
the subjects, further investigations are needed to determine whether accurate threshold levels 
exist for MPO between the stages of CVD and what these levels are.  
 We have also demonstrated a significant decrease in plasma SCN- levels in both 
asymptomatic and symptomatic CVD patients. This may be due to lifestyle or diet changes, 
such as ceasing to smoke cigarettes under medical recommendation, and therefore may not be 
related to the disease state directly. Unfortunately, the information available on the patients 
examined in this study did not include data on smoking status. Also, due to the limited 
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amount of plasma sample available, no additional analyses could be performed to investigate 
this. If enough plasma had remained, a test to determine the levels of the nicotine metabolite 
cotinine could have been used to determine the smoking status of each individual, and 
therefore determine if the cessation of cigarette smoking could be a confounding factor [461]. 
This would also remove any doubt associated with self-reporting of (cessation of) smoking 
status. 
 The concentration of plasma thiols was also observed to be significantly reduced in 
symptomatic CVD patients. This is not surprising as oxidative stress, and therefore oxidative 
damage, is now generally accepted as being an integral component of the pathogenesis of 
CVDs [462-464]. These data also support the hypothesis that elevated MPO levels in CVDs 
are at least partly responsible for this greater oxidative stress, as we have also shown a 
significant negative correlation between plasma MPO levels and plasma thiol levels. This 
would suggest that a global inflammatory state associated with CVDs results in increased 
circulating MPO levels, and that these elevated levels of MPO are associated with, and 
possibly responsible for, systemic oxidative damage. In addition, the plasma thiol data also 
support our overarching hypothesis that elevated levels of SCN- are protective in the context 
of CVDs as a positive, albeit weak, correlation between plasma SCN- levels and plasma thiols 
levels were also observed. Given the negative correlation between MPO and thiols, this 
would suggest that elevated SCN- levels impact on both the overall concentration and the 
ratio of MPO-derived oxidants generated, and may afford protection by directing MPO away 
from generating HOCl and the resulting oxidative damage. However, further investigation is 
required before this can be definitively proven. 
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Changes in the profile of the combination of above and below median MPO and SCN- 
were also observed with advancing disease state. The femoral samples indicated conditions 
where we would expect low levels of MPO-derived oxidants, and a lesser proportion of these 
oxidants to be HOSCN. The asymptomatic samples indicate conditions where we might 
expect high levels of MPO-derived oxidants, and a greater proportion of these oxidants to be 
HOSCN at the expense of HOCl. Finally, the symptomatic samples indicated conditions 
where we would expect high levels of MPO-derived oxidants, and a higher proportion of 
these oxidants to be HOCl rather than HOSCN. In a study investigating these combinations 
of measures along with long-term survival in subjects following a first MI, it was observed 
that the greatest survivability was seen in patients who had below median levels of MPO and 
above median levels of SCN- [245], which was also seen to be over represented in the 
symptomatic patients of the current study. They also found the worst survivability in patients 
who had above median levels of MPO and below median levels of SCN- [245], which was 
seen to be over represented in the asymptomatic samples of the current study. It is interesting 
to note that the combination of variables that correlated with the greatest survivability in their 
study correlated with the worst CVD state in this study, and that the combination of variables 
that correlated with the worst survivability in their study correlated with the better CVD state 
in this study. The reasons for this could be many and varied, and require considerably more 
data and other confounding factors to be accounted for or eliminated before a fair comparison 
can be drawn. 
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5.4. Sepsis 
5.4.1. Introduction 
Severe sepsis is characterised by a systemic, dysregulated and highly exaggerated 
inflammatory response, accompanied by oxidative stress and mitochondrial dysfunction [465]. 
Due to the inflammatory nature of sepsis, and given that MPO is released at sites of 
inflammation from activated neutrophils, monocytes and some tissue macrophages, it has 
been postulated that MPO may play a dual protective and detrimental role in the pathogenesis 
of sepsis [466,467]. Given that MPO-derived oxidants contribute to protein damage at sites of 
inflammation, they may also contribute to the pathophysiology of sepsis. In this study, 
plasma MPO concentration, SCN- ions, and levels of protein oxidation were analysed in a 
cohort of 38 patients admitted to the intensive care unit (ICU) at Aberdeen Royal Infirmary, 
Scotland, including both sepsis (n=20) and also a control group of non-infected (n=18) but 
critically ill patients. All procedures were approved by the Scotland A Research Ethics 
Committee (REC reference 11/AL/0137). This work was a small sub-project of a larger 
collaborative study conducted by Mertens et al. investigating the effect of sepsis on zinc and 
selenium levels in vitro and clinically [303].   
5.4.2. Methods 
Venous blood samples were drawn from the recruited cohort of patients and processed within 
2 hours for plasma extraction. Samples were then stored at -80 °C and researchers were 
blinded until statistical analysis took place. The same methods that were employed earlier in 
this Chapter (5.3.2) were used again in an identical manner for this current study. Some of the 
data presented in this section was conducted by other members of the study group and is 
stated so, where appropriate. 
  
 
194 
 
 
5.4.3. Results 
The total amount of plasma MPO was observed to be significantly increased in the sepsis 
patients (average of 211 ng/mL) compared to the critically-ill patient controls not suffering 
from sepsis (average of 130 ng/mL), as seen in Figure 5.9. Therefore, it can be concluded that 
under conditions of sepsis, plasma MPO levels are significantly elevated. 
Figure 5.9- Average total plasma MPO concentrations (ng/mL) of critically ill control (n = 
19) and sepsis patients (n = 20) at the time of presentation at the ICU. The data are expressed 
as maximum to minimum box plots. Unpaired two-way t tests with Welch’s correction 
indicated a significant increase in total plasma MPO levels in the sepsis patient group when 
compared to the control group (where ** = p < 0.01).  
  
 
195 
 
 
The concentration of SCN- was observed to be significantly increased in the sepsis 
patients compared to controls (82 µM vs. 60 µM), as seen in Figure 5.10. Therefore, it can be 
concluded that under conditions of sepsis, plasma SCN- levels are significantly higher. The 
extent of the increase in levels of SCN- in sepsis patients was only small, and may be a 
reflection of smoking status or poor nutrition in the control subjects, but the cause is difficult 
to determine without more demographic data. The high levels of SCN- may also indicate that 
MPO-derived oxidant HOSCN may be generated at higher levels during the development of 
sepsis and may therefore play a role in the pathogenesis of sepsis.  
 
 
Figure 5.10- Mean plasma SCN- concentration (µM), as determined by ion-exchange 
chromatography, of critically ill control (n = 19) and sepsis patients (n = 20) at the time of 
presentation at the ICU. The data are expressed as maximum to minimum box plots. 
Unpaired two-way t tests with Welch’s correction indicated a significant increase in plasma 
thiocyanate levels in the sepsis patient group when compared to the control group (where * = 
p < 0.05).  
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The relative plasma thiol levels were observed to be significantly decreased in the 
sepsis patients compared to controls (9.5 vs. 13.7 nM thiols per mg total protein), as seen in 
Figure 5.11. This may be due to a greater level of oxidative stress arising from the elevated 
levels of MPO.  
 
Amino acid analysis was also performed to detect any changes in the amino acid 
composition in the subject plasma samples. This was performed by Dr Jihan Talib, a fellow 
member of our group and contributor to the overall study [303].  Together with cysteine, 
methionine is one of two sulfur-containing proteinogenic amino acids and is known to be 
readily oxidised. As such, methionine is known to be highly susceptible to reaction with 
Figure 5.11- Mean relative thiols levels (nM thiols per mg total protein), as determined by 
DTNB assay, of critically ill control (n = 19) and sepsis patients (n = 20) at the time of 
presentation at the ICU. The data are expressed as maximum to minimum box plots. 
Unpaired two-way t tests with Welch’s correction indicated a significant decrease in plasma 
thiol levels in the sepsis patient group when compared to the control group (where ** = p < 
0.01). 
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MPO-derived oxidants, as seen by the rate constant for its reaction with HOCl of 3 x 107 M-
1s-1 [229], and is therefore a sensitive marker of oxidative damage. As shown in Figure 5.12 
(A), methionine levels were significantly reduced in sepsis patients compared to the critically 
ill controls. Methionine sulfoxide is the major oxidation product of methionine, therefore a 
build-up of this product, along with reduction of the parent amino acid, are indicative of 
increased oxidative damage. It was observed in this study that methionine sulfoxide levels 
were significantly elevated in sepsis patients compared to the critically ill controls, as shown 
in Figure 5.12 (B). No change in other amino acids could be detected by this method. 
 
 
Figure 5.12- Mean plasma methionine (A) and methionine sulfoxide (B) concentrations 
(pmol/Ile/mg ml-1), as determined by HPLC with methanesulfonic acid hydrolysis and 
precolumn o-phthaldialdehyde derivitisation, of critically ill control (n = 19) and sepsis 
patients (n = 20) at the time of presentation at the ICU. The data are expressed as maximum 
to minimum box plots. Unpaired two-way t tests with Welch’s correction indicated a 
significant decrease in plasma methionine levels and an increase in plasma methionine 
sulfoxide levels in the sepsis patient group when compared to the control group (where * = p 
< 0.05). 
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A number of plasma markers of inflammation were also investigated, including 
interleukin-6 (IL-6), interleukin-8 (IL-8), soluble urokinase-type plasminogen activator 
receptor (suPAR), and C-reactive protein (CRP). This analysis was performed by Dr Kathrin 
Mertens, the lead investigator on the overall study [303]. IL-6 and IL-8 are both pro-
inflammatory cytokines, CRP is a classic acute-phase protein elevated in infection, and 
suPAR levels are associated with disease severity regardless of infection type [303]. Each of 
these markers were found to be elevated in the sepsis patients, as summarised in Table 5.1. 
 
 
 
 
Table 5.1- Inflammatory markers in plasma from critically ill control and sepsis patients at 
the time of presentation at the ICU. Using the Wilcoxon-Mann-Whitney test, a statistically 
significant increase in plasma IL-6 and IL-8, suPAR, and CRP was observed between sepsis 
and control patients. 
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5.4.4. Discussion 
The MPO system appears to behave quite differently in sepsis patients when compared to 
other critically ill controls, with plasma levels of MPO and SCN- both significantly elevated. 
This may directly contribute to a greater level of oxidative damage, as indicated by a 
significant decrease in relative plasma thiols and methionine levels in sepsis patients, along 
with a concomitant increase in plasma methionine sulfoxide concentrations. Additionally, 
plasma IL-6, IL-8, CRP and suPAR are all elevated in sepsis patients compared to critically 
ill patients without sepsis. 
MPO is believed to be involved in the pathophysiology of sepsis, with oxidative stress 
and dysregulated inflammation being hallmarks of the disease [303]. However, there is some 
discrepancy in the literature as to whether it is the presence or absence of MPO that promotes 
the progression of the sepsis disease state. It has been suggested that the role of MPO in 
sepsis is protective, as MPO-deficient mice and humans with sepsis have been demonstrated 
to have increased mortality [467,468]. MPO has also been demonstrated to be required to 
suppress and control bacteria growth, and thus aid in survival, in a mouse model [469]. It has 
also been reported that increased MPO enzyme activity in plasma and tissue is an indicator of 
inflammation and the onset of sepsis [466,470]. Therefore, while the exact role of MPO in the 
context of sepsis is still somewhat controversial, it is apparent that MPO levels are increased 
in the disease state, and our findings are in agreement with this. 
 We have also demonstrated that there is an increase in plasma SCN- and a decrease in 
relative plasma thiols in sepsis patients. While the increase in plasma SCN- is difficult to 
rationalise, this change is small and may be related to poor nutrition in the controls rather 
than an increase in the sepsis subjects, as the control subjects are also very ill. The decrease 
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in protein thiol levels is likely to be due to the greater oxidative stress and damage associated 
with the sepsis disease state. The elevated levels of MPO are therefore likely to drive greater 
oxidation of sulfur-containing amino acids, including cysteine, of which thiols make up the 
functional group [142]. Another sulfur-containing amino acid is methionine, and this study 
has shown that in sepsis patients there is a significant decrease in plasma methionine levels 
along with a significant increase in methionine sulfoxide, the major oxidation product of 
methionine [303]. The changes in these amino acids indicate that there is greater oxidative 
stress in sepsis patients compared to other critically ill controls. Given that these markers of 
oxidative damage consistent with the reactions of MPO-derived oxidants, and the elevation 
seen in the inflammatory plasma markers IL-6, IL-8, CRP and suPAR, it is therefore possible 
that the MPO system plays a significant role in propagating and sustaining the heightened 
state of oxidative stress observed in sepsis patients.  
5.5. Conclusion 
Numerous alterations are apparent in the MPO system with increasing CVD severity, and 
also sepsis. Plasma levels of MPO are significantly elevated in both asymptomatic and 
symptomatic CVD, but are also significantly elevated in symptomatic CVD when compared 
to asymptomatic CVD. A significant decrease in plasma SCN- levels was observed in both 
asymptomatic and symptomatic CVD, which is likely to be due to lifestyle changes made by 
patients when diagnosed with CVD (such as ceasing cigarette smoking and dietary changes). 
A significant decrease in plasma thiol levels was also observed in symptomatic CVD patients, 
which is likely due to greater oxidative damage occurring in the more advanced and active 
disease state.  
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Additionally, in the entire cohort of patients from the asymptomatic vs. symptomatic 
CVD study, a significant negative correlation was observed between plasma MPO levels and 
plasma thiol levels, indicating that elevated MPO levels result in greater oxidative damage. 
However, a significant positive correlation between SCN- levels and plasma thiol levels was 
also observed, which would suggest that elevated SCN- is potentially protective, despite the 
detrimental effect shown by high levels of MPO. 
In sepsis patients, plasma levels of MPO were also found to be significantly elevated, 
and sepsis patients were shown to have higher levels of SCN- when compared to other 
critically ill controls. A significant decrease in plasma thiol levels was also observed in sepsis 
patients, which is likely due to a heightened state of oxidative stress associated with the 
disease. Additionally, plasma methionine levels were decreased and plasma methionine 
sulfoxide levels were increased, consistent with increased oxidative damage by MPO-derived 
oxidants. Finally, the inflammatory markers IL-6, IL-8, CRP and suPAR were all shown to be 
elevated in sepsis patients compared to critically ill control subjects without sepsis.  
It should be noted that the data presented in this section are only associations and 
considerably more data is required. Further complicating and confounding factors also need 
to be identified and either accounted for or eliminated. However, the data suggest that further 
studies along these lines may be worthwhile.  
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Chapter 6 
Overall discussion and future directions 
6.1. Overview 
The research undertaken in this project sought to provide insights into the effects of 
manipulating the concentration of the MPO substrate SCN- in vivo, and the impact this had on 
the development and progression of atherosclerosis as well as recovery from myocardial IR 
injury. Two additional studies were also undertaken to assess this system in clinical settings. 
 MPO is released by activated neutrophils, monocytes, and some tissue macrophages 
as part of the inflammatory response at sites of inflammation [99]. SCN- anions are a major 
and preferred substrate for MPO, with oxidation giving rise to increased concentrations of 
HOSCN at the expense of HOCl, which is generated from Cl- [114]. There is considerable 
evidence that these oxidants contribute to damage at sites of inflammation and contribute to 
the pathophysiology of CVDs [99,108]. HOSCN is much less reactive and more selective 
than HOCl, and the damage induced by HOSCN, which occurs primarily at Cys residues is 
generally reversible [141,142]. Therefore, we hypothesised that increased formation of 
HOSCN, at the expense of HOCl, driven by increasing SCN- levels, may be protective 
against inflammation-induced damage in the context of CVD and possibly other pathologies 
associated with elevated MPO levels. 
 Given the degree of controversy in the literature surrounding the role of SCN- in in 
vitro, in vivo, and clinical settings of various human diseases, we have examined the potential 
protective effect of elevated levels of SCN- in two animal models of CVD: an MI/IR injury 
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model (Chapter 3) as well as in an atherosclerosis model (Chapter 4). We also went on to 
look at MPO and SCN- in two pilot studies of clinical samples from asymptomatic and 
symptomatic CVD patients, and sepsis patients (Chapter 5).  
6.2. Thiocyanate and IR injury 
In the wake of an acute MI/IR event, current treatments aim to rapidly maximise the 
restoration of blood flow to the heart. This occurs in 2 main ways; clot-busting medicines and 
percutaneous coronary intervention (PCI). It has been acknowledged for many years that the 
predominant cause of acute MI is occlusion of a coronary artery due to a thrombus, which 
usually forms at the site of intimal disruption over an atherosclerotic plaque [471]. The 
prompt administration of thrombolytic medicines, including tissue-type plasminogen 
activator and streptokinase, is used in the wake of acute MI to promote lysis of the thrombus 
and therefore remove the obstruction and restore blood flow [472]. If the plaque itself has 
grown to such a size that it is occluding the vessel, a PCI is implemented. PCI is a 
nonsurgical procedure that reopens blocked or narrowed coronary arteries. A catheter 
mounted with a balloon is threaded through a blood vessel, usually in the femoral artery, until 
it reaches the site of the occlusion. Once in place, the balloon is inflated to compress the 
plaque and any related thrombus against the artery wall restoring blood flow through the 
artery. During the procedure, a stent may also be deployed as a means to help keep the artery 
open to prevent further blockages in the artery following the procedure [473]. 
 Whilst reperfusion is the absolute treatment for MI, and strategies to minimise 
ischemic injury have been greatly successful, reperfusion also has the potential to exacerbate 
tissue injury in a unique form of myocardial damage, a process termed reperfusion injury 
[317], as discussed in detail in Chapter 3. There are several therapies being investigated for 
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IR injury. Given that the root cause of IR injury is believed to be a surge in generation of 
ROS from reactivated mitochondria, an agent that could prevent or neutralise the ROS 
generated may protect against IR injury [474]. MitoQ is one such agent that was designed in 
the late 1990s as a mitochondria-targeted antioxidant [475]. While conventional antioxidants 
have limited efficacy due to the difficulty of delivering them to mitochondria in situ, MitoQ 
overcomes this problem as it comprises of a lipophilic triphenylphosphonium cation 
covalently attached to a ubiquinol antioxidant. Driven by the large mitochondrial membrane 
potential, the cation concentrates MitoQ several hundred-fold within mitochondria, and thus 
selectively prevents oxidative damage from mitochondria-derived ROS [475,476]. After 
detoxifying a ROS, the ubiquinol moiety is regenerated by the respiratory chain, therefore 
enabling its antioxidant activity to be recycled [475]. MitoQ has been investigated and shown 
to be an effective treatment in a number of disease models where the pathology is underlined 
by mitochondrial dysfunction, including type 2 diabetes [477], pancreatitis [478], 
hepatosteatosis [479], liver cirrhosis [480], and Alzheimer’s disease [481]. In addition, 
MitoQ has been shown to effectively decrease cardiac IR injury in both MI [474] and heart 
transplant models [482]. To date, MitoQ has been used in two phase II human clinical trials, 
and proven to be well tolerated [483,484]. 
The ROS generated in IR injury while damaging in themselves can also act as a 
chemoattractant for neutrophils, as well as damaged species and cellular responses to these, 
which accumulate rapidly in the infarcted myocardium following reperfusion as discussed in 
detail in Chapter 3 [85,87]. Neutrophils may cause damage in several ways, including via 
MPO-mediated damage. Therefore, MPO inhibitors have also been investigated as a means of 
modulating IR injury. PF-1355 is one such novel, orally bioavailable, mechanism-based, 
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irreversible inhibitor of MPO that is currently being investigated in several inflammatory 
conditions, including CVD [485]. PF-1355 has been assessed in a mouse model of MI/IR 
injury, and has shown positive results. Oral treatment with PF-1355 for 7 days following MI 
surgery attenuated both inflammation and cardiac dilation during the early stages of infarct 
healing. Additionally, a 21-day treatment time course was shown to improve ejection fraction. 
A decreased end-diastolic volume and left ventricular mass were also detected compared with 
untreated control subjects. A greater therapeutic effect was also observed when treatment 
began within an hour of the initial ischemic insult [486]. Another novel, selective, suicide 
inhibitor of MPO is AZD3241. This inhibitor has undergone phase II clinical trials in 
Parkinson’s disease patients and shows potential for use in other neurodegenerative disorders 
[487], and could also be potentially therapeutic in IR injury.  One final small-molecule 
inhibitor of MPO is INV-315 which has been shown to decrease plaque burden and improve 
endothelial function in a mouse model of atherosclerosis [488].  
Several other drugs have shown promising results in reducing IR injury in various 
animal models, and in the early stages of clinical trials [489]. These include cyclosporine-A 
which acts to replicate some of the effects exhibited during post-conditioning, specifically by 
inhibiting the opening of the mitochondrial permeability transition pore (MPTP), and thus 
inhibiting ROS generation. Cyclosporine-A has been shown to reduce infarct size [490]. The 
β-blocker metoprolol also shows positive signs in reducing IR injury, which has been 
suggested to be as a result of blocking neutrophil migration [491,492] as well as the anti-
apoptotic properties it possesses in the failing myocardium [493]. Pre-clinical data from a pig 
model of MI demonstrated that IV administration of metoprolol significantly reduced infarct 
size when administered prior to reperfusion [494]. The subsequent METOCARD-CNIC 
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(Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction) trial 
showed that in a 6 month follow up, patients who received pre-reperfusion IV administration 
of metoprolol saw a greater long-term left ventricle ejection fraction, reduced incidence of 
severe left ventricle systolic dysfunction, and fewer heart failure admissions [495]. A clinical 
trial powered for long-term clinical endpoints, including cardiac mortality and congestive 
heart failure, would offer a definitive answer as to whether the improvement of MI/IR injury 
seen by early IV metoprolol translates into a genuine clinical benefit [496]. Glucose 
modulators have also been investigated as a means to protect cardiomyocytes from energy 
depletion during MI. The IMMEDIATE (Immediate Myocardial Metabolic Enhancement 
During Initial Assessment and Treatment in Emergency Care) trial recruited patients with 
suspected acute coronary syndrome and randomised them to either a combined administration 
of glucose/insulin/potassium (GIK) or placebo during hospital transfer. GIK was shown to 
significantly reduce infarct size [497]. The use of glucagon-like peptide 1 (GLP-1) has also 
been investigated and shown to increase myocardial salvage [498,499]. Finally, thrombus 
embolisation and its resulting impaired microvascular perfusion following reperfusion has 
seen the development of glycoprotein IIb/IIIa inhibitors to reduce these thrombotic events. 
The INFUSE-AMI trial recruited patients undergoing PCI to test the effect of a particular 
inhibitor, abciximab, on infarct size. While manual thrombectomy had no effect on infarct 
size, the intracoronary administration of abciximab was demonstrated to significantly reduce 
infarct size [500].  
The study reported in this thesis investigated the impact of a SCN- preconditioning 
protocol on MI/IR injury, and also found potentially positive results. Supplementation with 
10 mM NaSCN for 1 week prior to MI challenge resulted in reduced infarct size and greater 
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LVED and LVES areas over a 4 week recovery period when compared to vehicle controls. 
However, further investigation is required. Further histological examination of the hearts at 
the 4 week time point is planned to assess the impact of SCN- preconditioning on cardiac 
remodelling, and hard endpoints are also necessary to assess greater clinical and therapeutic 
relevance of the regime.   
6.3.  Thiocyanate and atherosclerosis 
Current treatments for atherosclerosis may include lifestyle changes, medicines, and medical 
procedures or surgery. Lifestyle changes are the first port of call when addressing 
atherosclerosis, particularly in individuals who are known to have a history of CVDs or in 
early stages of the disease have been identified. The changes that are encouraged to improve 
cardiovascular health include improving diet, body weight, stress, physical activity, and 
ceasing smoking. Making these lifestyle changes has been definitively proven to reduce, and 
even reverse, coronary artery disease without the use of any drugs. The success of this 
approach was shown in The Lifestyle Heart Trial published in 1990, although in low subject 
numbers for a trial [501]. In this prospective, randomised, controlled trial 28 patients were 
assigned to an experimental group and 20 to a usual-care control group. The experimental 
group was asked to make a number of lifestyle changes for a 1 year period. This included 
being asked to consume a low-fat vegetarian diet, which included fruits, vegetables, grains, 
legumes, and soybean products without caloric restriction. One patient in the experimental 
group was smoking at the time of baseline measurements, and they agreed to stop on 
commencement of the trial. The experimental group was also taught stress management 
techniques, which included stretching exercises, breathing techniques, meditation, 
progressive relaxation, and imagery. Experimental patients were asked to practise these stress 
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management techniques for at least 1 hr per day. Finally, experimental patients were also 
asked to exercise for a minimum of 3 hr per week, and reach a personalised target training 
heart rate for a minimum of 30 min per session. Patients in the control group were not asked 
to make lifestyle changes, although they were free to do so. The study found no significant 
differences at baseline measurements prior to commencement of the study between the 
experimental and control groups in demographic characteristics, diet and lifestyle 
characteristics, functional status, cardiac history, or known risk factors. However, by the end 
of the year, significant reductions in cholesterol and LDL content were observed in the 
experimental group. In addition, experimental patients experienced a significant reduction in 
the frequency, duration, and severity of angina. Control patients in contrast saw their 
symptoms significantly deteriorate, becoming worse over the 1 year period. Upon 
examination of lesions, the experimental group was shown to have reduced stenosis diameter, 
while the control group had greater. Overall, adherence with the lifestyle changes brought 
about regression of atherosclerosis, while not making these changes saw progression of the 
disease [501]. Given the extensive experimental evidence for a central role of oxidative stress 
in atherogenesis, a potential role for antioxidant treatment has been postulated for 
atherosclerosis [502]. However, experimental data has not translated into clinical benefit with 
most antioxidant supplement trials failing to reduce cardiovascular morbidity and mortality 
for a myriad of reasons [503-505]. After over 20 years of clinical trials that have studied the 
effect of supplemental antioxidants on cardiovascular disease, there is no conclusive data to 
suggest that this intervention works [505,506]. It is conceivable that there may be some role 
of antioxidant therapies in the prevention of cardiovascular disease in the future; however, at 
this stage, scavenging oxidants once they have formed appears to be a poor strategy. 
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Increasing SCN- levels can also be achieved through lifestyle changes. As discussed 
in Chapter 1, a wide number of plants contain cyanogenic glycosides which can result in 
elevated levels of plasma SCN- when they are eaten. These include cassava, bitter almonds, 
apples, apricots, cherries, peaches, plums, raspberries, barley, flaxseed, bamboo shoots, and 
lima beans [236]. In addition, broccoli, cabbage, and sprouts contain low levels of cyanide 
derivatives which can also result in an elevation of plasma SCN- levels [236]. When smoking 
is removed as a variable, a vegetarian diet has been shown to increase plasma SCN- levels by 
1.5 fold [507]. Therefore, dietary changes could be used as an efficient and effective means 
of elevating plasma SCN- levels, if it is definitively proven to be protective against 
atherosclerosis. Given the controversy surrounding statins, the primary drug prescribed in the 
case of early CVD to lower cholesterol levels [508], and the invasive nature of surgery in the 
case of advanced atherosclerosis, including procedures such as PCI [509] and coronary artery 
bypass grafting [510], a simple alteration or supplementation in diet presents itself as an 
attractive means of potentially protecting against CVD. 
However, at this stage, the effect of elevated levels of SCN- on atherosclerosis clearly 
need further investigation. This study has shown that elevated levels of SCN- have the 
potential to be protective in terms of reducing plaque size as well as increasing plaque 
stability. However, at higher concentrations with long term exposure a possible decrease in 
plaque stability has been detected. Therefore, while promising signs for elevated levels of 
SCN- on atherosclerosis have been demonstrated in this study, the concentration of SCN- 
employed and the time course of treatment may require greater optimisation before any 
clinical applications may be considered. Given that the previously mentioned MPO inhibitor, 
INV-315, has also been shown to decrease plaque burden and improve endothelial function in 
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a very similar mouse model of atherosclerosis [488], a combination of inhibiting MPO and 
directing oxidant generation in favour of less reactive products could be interesting to 
investigate. 
6.4. Future directions 
The positive signs for SCN- as a potential cardioprotective therapeutic regime in the context 
of both MI/IR injury and atherosclerosis observed in this study gives plenty of scope for 
future studies on the potential actions and activities of this agent.  
With hindsight, several advantageous alterations to the IR injury model could have 
been made, and it would be beneficial to incorporate these modifications in future studies. It 
would have been very useful to take a blood sample immediately prior to surgery, via the tail 
vein. This would have allowed for the measurement of serum SCN- at the time of IR 
challenge, which is the most time critical and important SCN- measurement. This would have 
also been useful in determining the rate at which SCN- is excreted from rat plasma. It would 
also have been valuable to measure the biomarkers of heart failure and inflammation used in 
this study immediately prior to surgery to determine base line levels to better compare and 
contrast any changes in the wake of IR injury. 
There was also an oversight in the initial planning stages of the study in regard to the 
MRI of the 4 week animals. The ligature placed around the LAD artery is required to be 
retightened when the MRI contrast agents are administered. While the ligature could be left 
in situ for the 24 hour recovery rats, this was not the case for the 4 week recovery period 
animals. This was because keeping the suture in place for such a time was deemed to be too 
significant a risk of having further adverse effects on the animal, as it could tangle in the 
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thoracic organs as well as introducing another compounding factor and potential source of 
inflammation. Because the ligature was removed in these animals, the infarct could not be 
replicated. As such, if a new ligature was put in after the 4 week recovery period this would 
give rise to a new ischemic region, not allowing for measurement of the original and how 
well it had recovered. While the original infarct could still be observed with Multihance 
infusion prior to sacrifice at 4 weeks, the iron microparticles to observe the total reperfused 
area could not. As a result, total infarct size could be measured at 4 weeks, but without the 
total reperfused area to normalise against, this value means very little due to the highly 
variable nature of the surgery. As such, total infarct size was measured, but not presented in 
this thesis, as the data was inconsistent and provided no greater understanding of the effect of 
SCN- on myocardial remodelling over time.   
Aside from these improvements that could have been made to the study, there are a 
number of additional studies that could be undertaken with remaining or additional samples 
going forward. In the immediate future, histology of the hearts that underwent MRI may be 
beneficial. As the hearts have been fixed in NBF and then stored in agar, they can be 
extracted after undergoing MRI and prepared for histology. This would be of benefit as the 
major drawback of the study at this stage is the lack of information on potential mechanisms 
by which SCN- is providing its protective effect against IR injury. The reason this has not 
been carried out during the time frame of this thesis is due to delays in getting the hearts 
imaged, a process which has to be completed before the hearts are processed for histology. In 
saying that, a panel of markers has been identified to investigate the effects of SCN-. 
Potentially, the most interesting marker would be the antibody 2D10G9, which has been 
previously shown to react with HOCl-modified proteins [383]. In a similar vein, 3-ClTyr 
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levels could also be investigated as a measure of HOCl-mediated damage [243]. If it was 
shown that SCN- supplementation significantly reduced the level of HOCl-modified proteins 
in the reperfused tissue of the myocardium, this would directly support our hypothesis that 
SCN- exerts its protective effect by manipulating the MPO system to favour HOSCN 
formation at the expense of HOCl as HOSCN does not appear to generate epitopes 
recognised by the 2D10G9 antibody. Along with the 2D10G9 staining, if the NGAL and 
MPO staining protocols, that were utilised in the atherosclerosis study, were also 
implemented this would give much greater insights into the potential protective mechanisms 
of SCN- as it pertains to the MPO system. Additionally, while MRI of the 4 week hearts is 
unsuitable, as previously outlined, histological methods including Evan’s blue staining could 
provide answers as to the size of the infarct and reperfusion zone. In addition, stains such as 
picrosirius red and Milligan’s trichrome could provide insight into the remodelling of the 
reperfused region over the 4 week recovery period, including the levels of fibrosis and 
collagen content. Other possible experiments could include the use of other SCN- salts, such 
as KSCN and LiSCN, to eliminate the potential effects of elevated Na+ levels. Assessing the 
effect of other dosage concentrations and length of dosing period could also be valuable.   
Following on from the studies reported in this thesis, it would be interesting to see if 
SCN- preconditioning can also protect against other models of IR injury besides myocardial 
IR injury, such as renal IR injury. IR injury contributes to the pathological conditions 
associated with acute kidney injury (AKI). AKI is a clinical syndrome which results in rapid 
kidney dysfunction, and has high mortality rates [511]. The pathological pathways involved 
bear a number of similarities to myocardial IR injury, including activation of neutrophils, 
release of ROS, MPO, and other inflammatory mediators. A variety of cytokines are also 
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known to be involved [512]. Therefore, SCN- may potentially be therapeutically relevant in 
the context of IR injury at numerous sites within the body.  
With an eye towards future clinical applications, it would be interesting to determine 
if other methods of SCN- delivery afford protection against myocardial IR injury. One 
potential therapeutic regime to investigate would be an acute intravenous infusion of NaSCN, 
or other SCN- salts, immediately following MI. Another potential regime to investigate would 
be postconditioning with oral NaSCN.  
In terms of the atherosclerosis study, it would be of interest to investigate the effects 
of SCN- supplementation on a different model of atherosclerosis, namely a slow progression 
model, such as using standard C57BL/6 mice and a standard chow diet. Due to the length of 
time this model requires, and the large number of animals already committed to the ApoE-/- 
study, this was not possible as part of this thesis. The high-fat diet ApoE-/- model of 
atherosclerosis represents an aggressive form of atherosclerosis, driven by genetic 
predisposition and environmental factors that combine to heavily favour the onset of the 
disease. Using the chow diet fed C57BL/6 model represents a more passive model, and looks 
at atherosclerosis as more of a disease associated with aging, and thus may present a more 
representative model to what is occurring in the human clinical setting. Another possible 
experiment could be combining SCN- dosing with other therapies, as well as MPO inhibitors 
such as TEMPOL [421]. To further the translation to the human setting, several other models 
would be of interest to explore, including with human transgenic MPO mice on a C57BL/6 
background, as a means of assessing the impact of SCN- on atherosclerosis in the context of 
human MPO levels with either normal or high-fat diet [246]. Exploring the effect of SCN- in 
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a model of plaque rupture would also be beneficial to further assess the impact of SCN- on 
plaque stability [513]. 
It would also be of interest to determine whether SCN- supplementation impacts on 
atherosclerosis once it has already developed; whether it can act as a treatment rather than a 
preventative. In this case, the same protocol implemented in Chapter 4 could be employed, 
but with SCN- dosing commencing at 8 weeks after commencement of the high-fat diet rather 
than at the same time. 
Additionally, various tissue samples were collected but have not been currently used. 
The descending aorta was harvested with the intention of being used for en face Oil red O 
staining, which stains for lipid content within the aortic wall. The aortic tree was also 
collected with the intention of performing PCR, to investigate possible changes in genes 
known to be involved in the pathogenesis of atherosclerosis and inflammation. Changes in 
the HDL/LDL profile could also provide interesting data and could be worth investigating. It 
would also be beneficial to look at other histology markers within the atherosclerotic plaques. 
Of particular interest would be the previously mentioned 3Cl-Tyr analyses and 2D10G9 
antibody staining, both markers for HOCl-mediated damage [243,383]. As there is no marker 
for HOSCN-mediated damage, this would be a critical marker to determine whether the effect 
of SCN- on the plaque is by directing intra-plaque MPO to favour the formation of HOSCN 
rather than HOCl, or by altering the levels of inflammation and hence MPO protein levels. 
Analysis on the mouse livers could also offer some useful insight into changes in metabolism 
that may relate to the disease and/or the function of SCN-. 
The clinical studies examined in this thesis could also be taken further. The main 
limitations of the asymptomatic vs. symptomatic CVD study presented were the limited 
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demographic information and the small volumes of plasma available. In future experiments, 
obtaining as much demographic data from patients could be essential, particularly 
surrounding smoking status and diet as these are the primary contributors to SCN- levels in 
the body. Additionally, supplementing this data with the measurement of the nicotine 
metabolite cotinine could also prove useful. It would also be useful to examine 3Cl-Tyr 
concentration and/or 2D10G9 reactivity with plasma proteins as markers for HOCl-mediated 
damage. Amino acid analysis could also be useful to examine, particularly in identifying 
differences in the sulfur containing amino acid methionine, and its oxidation product 
methionine sulfoxide. It would also be beneficial to examine a range of cytokines to assess 
any differences in other inflammatory markers associated with the disease state. 
In terms of the sepsis study, the main limitation is sample size. Once confounding 
variables begin to be examined, statistical power is lost due to the relatively low numbers. 
With greater numbers, it would be valuable to assess the impact of potentially confounding 
demographic data, including smoking status (as it heavily contributes to SCN- levels) and 
paracetamol administration (given that it is an inhibitor of MPO). It would also be useful to 
examine 3Cl-Tyr concentration and/or 2D10G9 reactivity with plasma proteins as markers 
for HOCl-mediated damage. Also, as the control group in this study are also critically-ill 
subjects, it could be beneficial to introduce a third group of genuine healthy controls against 
which to compare both groups.  
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6.5. Concluding remarks 
The role of SCN- in the context of human CVDs has been quite controversial, with plenty of 
evidence presented in the literature to support both deleterious and protective effects of the 
anion. We chose to examine the effect of SCN- supplementation in two models of human 
CVD: MI/IR injury and atherosclerosis. 
 SCN- preconditioning was examined in a rat model of MI/IR injury. SCN- 
supplementation (as NaSCN) was shown to be protective in terms of reducing the size of the 
infarct area and increasing the size of the salvageable area when compared to vehicle controls. 
The LVED and LVES areas, which were found to be significantly impaired in the MI/IR 
injury vehicle control rats over the 4 week recovery period, were unperturbed in the 
SCN- supplemented rats. Metabolomic analysis also indicated there were far fewer significant 
alterations to the serum metabolome in the SCN- supplemented rats compared to the vehicle 
controls. Altogether, this data suggests that elevated levels of SCN- provide greater protection 
and recovery against the challenge of MI/IR injury.  
SCN- supplementation was also examined in a mouse model of atherosclerosis. SCN- 
supplementation (as NaSCN) was found to have both a time and dose-dependent effect on 
atherosclerosis development. The major effects of SCN- were seen in the plaque size and 
composition. The lower 2.5 mM NaSCN dose was found to significantly reduce plaque size 
during the early stages of the disease. It also appeared to promote the formation of a more 
stable late-stage plaque, with lower levels of MPO and SMCs present in the developing 
plaque and ultimately greater levels of collagen present at later stages. In contrast, the higher 
10 mM NaSCN dose was not found to affect plaque size. It also appeared to promote the 
formation of a more unstable late-stage plaque, with greater levels of MPO and macrophages 
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present in the developing plaque and ultimately greater levels of cholesterol and reduced 
collagen present at later stages. 
Alterations in the MPO system were observed in pilot studies of increasing CVD 
severity and sepsis. Changes in MPO, SCN-, and thiol concentrations was observed in each 
study. However, further investigation is required to draw definitive conclusions on the effect 
of SCN- on these disease states. 
While the effect of SCN- on CVDs is a complex and controversial affair, this thesis 
suggests that there is promise for a protective effect of SCN-. With further investigation and 
optimisation, SCN- supplementation could be adapted as a cost-effective and easily 
administered means of providing protection against human CVDs.  
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